


US 20050026170A1

(19) **United States**(12) **Patent Application Publication**
Patti et al.(10) **Pub. No.: US 2005/0026170 A1**(43) **Pub. Date: Feb. 3, 2005**(54) **EXTRACELLULAR MATRIX-BINDING
PROTEINS FROM STAPHYLOCOCCUS
AUREUS**(76) Inventors: **Joseph M. Patti**, Cumming, GA (US);
Timothy J. Foster, Templeogue (IE);
Elisabet Josefsson, Goteborg (SE);
Deidre Ni Eidhin, The Coombe (IE);
Magnus A.O. Hook, Houston, TX
(US); **Samuel E. Perkins**, Houston, TX
(US)Correspondence Address:
STITES & HARBISON PLLC
1199 NORTH FAIRFAX STREET
SUITE 900
ALEXANDRIA, VA 22314 (US)(21) Appl. No.: **10/744,616**(22) Filed: **Dec. 24, 2003****Related U.S. Application Data**(62) Division of application No. 09/200,650, filed on Nov.
25, 1998, now Pat. No. 6,680,195.(60) Provisional application No. 60/066,815, filed on Nov.
26, 1997. Provisional application No. 60/098,427,
filed on Aug. 31, 1998.**Publication Classification**(51) **Int. Cl.⁷ C12Q 1/68; C07K 16/40**(52) **U.S. Cl. 435/6; 530/388.1; 530/388.26**(57) **ABSTRACT**

Isolated extracellular matrix-binding proteins, designated ClfB, SdrC, SdrD and SdrE, and their corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of *S. aureus* infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of *S. aureus* infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of *S. aureus* to wounds or biomaterials.

ClfB is a cell-wall associated protein having a predicted molecular weight of approximately 88 kDa and an apparent molecular weight of approximately 124 kDa, which binds both soluble and immobilized fibrinogen. ClfB binds both the alpha and beta chains of fibrinogen and acts as a clumping factor. SdrC, SdrD and SdrE are cell-wall associated proteins that exhibit cation-dependent ligand binding to the extracellular matrix. It has been discovered that in the A region of SdrC, SdrD, SdrE, ClfA and ClfB, there is a highly conserved amino acid sequence that can be used to derive a consensus motif of TYTFTDYVD.

ClfA



ClfA

FIG. 1




FIG. 2





FIG. 3






FIG. 4

S>
TAGAAATTGAAATGGAGTAATATTTTTGAAAAAAGAATTGATTATTTGTCGAATAAGCAGAATAAGTATTCGATTAGACGTTTTCAGT
N G V I F L K K R I D Y L S N K Q N K Y S I R R F
T V 22

A>
AGGTACCACATCAGTAATAGTAGGGGCAACTATACTATTTGGGATAGGCAATCATCAAGCACAAGCTTCAGAACAAATCGAACGATCAAC
G T T S V I V G A T I L F G I G N H Q A Q A S E Q S N D
T T 52
GCAATCTTCGAAAAATAATGCAAGTGCAGATTCCGAAAAAACAATATGATAGAAACACCTCAATTAAATACAACGGCTAATGATACATC
Q S S K N N A S A D S E K N N M I E T P Q L N T T A N D
T S 82
TGATATTAGTGCAAACACAAACAGTGCGAATGTAGATAGCACAACAAACCAATGTCTACACAAACGAGCAATACCACTACAACAGAGCC
D I S A N T N S A N V D S T T K P M S T Q T S N T T T T
E P 112
AGCTTCAACAAATGAAACACCTCAACCGACGGCAATTAAAAATCAAGCAACTGCTGCAAAAATGCAAGATCAAACCTGTTCTCTCAAG
A S T N E T P Q P T A I K N Q A T A A K M Q D Q T V P Q
E G 142
AAATTCTCAAGTAGATAATAAAACAACGAATGATGCTAATAGCATAGCAACAAACAGTGAGCTTAAAAATTCTCAAACATTAGATT
N S Q V D N K T T N D A N S I A T N S E L K N S Q T L D
L P 172
ACAATCATCACCACAAACGATTTCCAATGCGCAAGGAAGTAGTAAACCAAGTGTTAGAACGAGAGCTGTACGTAGTTTAGCTGTTGCTGA
Q S S P Q T I S N A Q G T S K P S V R T R A V R S L A V
A E 202
ACCGGTAGTAAATGCTGCTGATGCTAAAGGTACAAATGTAAATGATAAAGTTACGGCAAGTAATTTCAAGTTAGAAAAGACTACATTTGA
P V V N A A D A K G T N V N D K V T A S N F K L E K T T
F D 232
CCCTAATCAAAGTGGTAACACATTTATGGCGGCAAATTTTACAGTGACAGATAAAGTCAAATCAGCGGATTATTTTACAGCGAAGTTACC
P N Q S G N T F M A A N F T V T D K V K S G D Y F T A K
L P 262
AGATAGTTTAACTGGTAATGGAGACGTGATTATTCTAATTCAAATAATACGATGCCAATTGCAGACATTAAAAGTACGAATGGCGATGT
D S L T G N G D V D Y S N S N N T M P I A D I K S T N G
D V 292
TGTAGCTAAAGCAACATATGATATCTTGACTAAGACGTATACATTTGTCTTTACAGATTATGTAAATAATAAGAAAATATTAACG

FIG. 5A

GACA
V A K A T Y D I L T K T Y T F V F T D Y V N N K E N I N
G Q 322
ATTTTCATTACCTTTATTTACAGACCGAGCAAAGGCACCTAAATCAGGAACATATGATGCGAATATTAATATTGCGGATGAAATGT
TTAA
F S L P L F T D R A K A P K S G T Y D A N I N I A D E M
F N 352
TAATAAAATTACTTATAACTATAGTTCGCCAATTGCAGGAATTGATAAACCAATGGCGCGAACATTTCTTCTCAAATTATTGCTC
TAGA
N K I T Y N Y S S P I A G I D K P N G A N I S S Q I I G
V D 382
TACAGCTTCAGGTCAAACACATACAGCAAACAGTATTTGTTAACCCCTAAGCAACGAGTTTTAGGTAATACGTGGGTGTATATTA
AAGG
T A S G Q N T Y K Q T V F V N P K Q R V L G N T W V Y I
K G 412
CTACCAAGATAAAATCGAAGAAAGTAGCGGTAAAGTAAGTGCTACAGATACAAACTCAGAATTTTTGAAGTGAATGATACATCTA
AATT
Y Q D K I E E S S G K V S A T D T K L R I F E V N D T S
K L 442
ATCAGATAGCTACTATCCAGATCCAAATGACTCTAACCTTAAAGAAGTAACAGACCAATTTAAAAATAGAATCTATTATGAGCATC
CAAA
S D S Y Y A D P N D S N L K E V T D Q F K N R I Y Y E H
P N 472
TG TAGCTAGTATTAAATTTGGTGATTTACTAAAACATATGTAGTATTAGTAGAAGGGCATTACGACAATACAGGTAAGAACTTAA
AAAC
V A S I K F G D I T K T Y V V L V E G H Y D N T G K N L
K T 502
TCAGGTTATTCAAGAAAATGTTGATCCTGTAACAAATAGAGACTACAGTATTTTCGGTTGGAATAATGAGAATGTTGTACGTTATG
GTGG
Q V I Q E N V D P V T N R D Y S I F G W N N E N V V R Y
G G 532
P>
TGGAAGTGCTGATGGTGATTACGCAGTAAATCCGAAAGACCCAACTCCAGGGCCGCCGGTTGACCCAGAACCAAGTCCAGACCCAG
AACC
G S A D G D S A V N P K D P T P G P P V D P E P S P D P
E P 562
R>
AGAACCAACGCCAGATCCAGAACCAAGTCCAGACCCAGAACCGGAACCAAGCCCAGACCCGGATCCCGATTCCGATTACAGACAGTG
ACTC
E P T P D P E P S P D P E P E P S P D P D P D S D S D S
D S 592
AGGCTCAGACAGCGACTCAGGTTACATAGCGACTCAGAATCAGATAGCGATTTCGATTACAGACAGTGATTACAGATTACAGACAGCG
ACTC

FIG. 5B

G S D S D S G S D S D S E S D S D S D S D S D S D S D S
 D S 622
 AGAATCAGATAGCGATTGAGAATCAGATAGCGACTCAGATTGAGATAGCGATTGAGATAGCGATTGAGATAGCG
 ATTC
 E S D S D S E S D S D S D S D S D S D S D S D S D S D S
 D S 652
 GGATTGAGACAGTATTCAGATTGAGACAGCGACTCAGAATCAGATAGCGACTCAGAATCAGATAGTGAATCAGATTGAGACAGT
 ACTC
 D S D S D S D S D S D S E S D S D S E S D S E S D S D S
 D S 682
 GGACTGAGACAGTATTCAGACTCAGATAGCGATTGAGACTCAGATAGCGATTGAGATTGAGACAGCGACTCAGATTGAGACAGCG
 ACTC
 D S D S D S D S D S D S D S D S D S D S D S D S D S D S
 D S 712
 AGACTCAGATAGCGACTCAGACTCAGACAGCGACTCAGATTGAGATAGCGATTGAGACTCAGACAGCGACTCAGACTCAGACAGCG
 ACTC
 D S D S D S D S D S D S D S D S D S D S D S D S D S D S
 D S 742
 AGACTCAGATAGCGACTCAGATTGAGATAGCGATTGAGACTCAGACAGCGACTCAGATTGAGATAGCGATTGAGACTCAGACAGCG
 ATTC
 D S D S D S D S D S D S D S D S D S D S D S D S D S D S
 D S 772
 AGATTGAGACAGCGACTCAGACTCGGATAGCGATTGAGATTGAGATAGCGATTGAGATTGAGACAGTGAATCAGATTGAGACAGCG
 ACTC
 D S D S D S D S D S D S D S D S D S D S D S D S D S D S
 D S 802
 AGACTCGGATAGCGACTCAGACTCAGACAGCGATTGAGACTCAGATAGCGACTCAGACTCGGATAGCGACTCGGATTGAGATAGCG
 ACTC
 D S D S D S D S D S D S D S D S D S D S D S D S D S D S
 D S 832
 W>
 AGACTCAGATAGTGAATCCGATTCAAGAGTTACACCACCAAATAATGAACAGAAAGCACCATCAAAATCCTAAAGGTGAAGTAAACC
 ATTC
 D S D S D S D S R V T P P N N E Q K A P S N P K G E V N
 H S 862
 M>
 TAATAAGGTATCAAAACAACACAAACTCATGCTTTACCAGAAACAGCAGATAAGAGCGAAACACAAATGCAACTTTATTTGGTG
 CAAT
 N K V S K Q H K T D A L P E T G D K S E N T N A T L F G
 A M 892
 GATGCGATTATTAGCATCATTACTATTGTTTAGAAAACGCAAGCAAGATCATAAAGAAAAAGCGTAAATACTTTTTTAGGCCGAAT
 ACAT
 M A L L G S L L L F R K R K Q D H K E K A

FIG. 5C

913

TTGTATTCGGTTTTTTTGTTGAAAATGATTTTAAAGTGAATTGATTAAGCGTAAAATGTTGATAAAGTAGAATTAGAAAGGGGTCA
TGAC

GTATGGCTTATATTTTCATTAACTATCATTACCAACAATTGGTATGCATCAAATTTGACAGTCATTTTACCGGAACAACGAGAA
TTC

FIG. 5D

clfB	DVDYNSNNTMPIADIKSTNGDVVAKATYDILTKTYTFVFTDYVNNKENINGQFSLPLFT 329
clfA	-VTSTAKVPPIMAGDQVLANGVIDSDG-----NVIYTFTDYVNTKDDVKATLTMPAYI 339
	* . . * .** *****.*. . . .*

FIG. 6

S>
ATGAATAATAAAAAGACAGCAACAAATAGAAAAGGCATGATACCAATCGATTAAACAAATTTTCGATAAGAAAGTATTCTGTAGG
TACT
M N N K K T A T N R K G M I P N R L N K F S I R K Y S V G
T 30

A>
GCTTCAATTTTAGTAGGGACAACATTGATTTTTCGGTAAAGTGGTCATGAAGCTAAAGCGGCAGAACATACGAATGCAGAATTAAA
TCAA
A S I L V G T T L I F G L S G H E A K A A E H T N G E L N
Q 60
TCAAAAAATGAAACGACAGCCCCAAGTGAAGAATAAAACAACATAAAAAAGTTGATAGTCGTCAACTAAAAGACAATACGCAAACTGC
AACT
S K N E T T A P S E N K T T K K V D S R Q L K D N T Q T A
T 90
GCAGATCAGCCTAAAGTGACAATGAGTGATAGTGCAACAGTTAAAGAACTAGTAGTAACATGCAATCACCACAAAACGCTACAGC
TAAT
A D Q P K V T M S D S A T V K E T S S N M Q S P Q N A T A
N 120
CAATCTACTACAAAAGTAGCAATGTACAACAAATGATAAATCATCAACTACATATAGTAATGAAACTGATAAAAGTAATTTAAC
ACAA
Q S T T K T S N V T T N D K S S T T Y S N E T D K S N L T
Q 150
GCAAAAGATGTTTCAACTACACCTAAACAACGACTATTAAACCAAGAACTTTAAATCGCATGGCAGTGAATACTGTTGCAGCTCC
ACAA
A K D V S T T P K T T T I K P R T L N R M A V N T V A A P
Q 180
CAAGGAACAAATGTTAATGATAAAGTACATTTTTCAAATATTGACATTCCGATTGATAAAGGACATGTTAATCAGACTACTCGTAA
AACT
Q G T N V N D K V H F S N I D I A I D K G H V N Q T T G K
T 210
GAATTTGGGCAACTTCAAGTGATGTTTTAAATTAAGCAAATTACACAATCGATGATTCTGTAAAGAGGGCGATACATTTAC
TTTT
E F W A T S S D V L K L K A N Y T I D D S V K E G D T F T
F 240
AAATATGGTCAATATTTCCGTCCAGGATCAGTAAGATTACCTTCACAACTCAAAATTTATATAATGCCCAAGGTAATATTATTGC
AAAA
K Y G Q Y F R P G S V R L P S Q T Q N L Y N A Q G N I I A
K 270
GGTATTTATGATAGTACAACAAACACACAACATATACTTTTACGAACTATGTAGATCAATATACAAATGTTAGAGGTAGCTTTGA
ACAA
G I Y D S T T N T T T Y T F T N Y V D Q Y T N V R G S F F
Q 300
GTTGCATTTGCCGAAACGTAAAAATGCAACAACGATAAAACAGCTTATAAAATGGAAGTAACTTTAGGTAATGATACATATAGCGA

FIG. 7A

AGAA
V A F A K R K N A T T D K T A Y K M E V T L G N D T Y S E
E 330
ATCATTGTCGATTATGGTAATAAAAAAGCACAACCGCTTATTTCAAGTACAACTATATTAACAATCAAGATTTATCGCGTAATAT
GACT
I I V D Y G N K K A Q P L I S S T N Y I N N E D L S R N M
T 360
GCATATGTAAATCAACCTAAAAATACATATACTAAACAAACGTTTGTACTAATTTAACTGGATATAAATTTAATCCAAATGCAAA
AAAC
A Y V N Q P K N T Y T K Q T F V T N L T G Y K F N P N A K
N 390
TTCAAAATTTACGAAGTGACAGATCAAAATCAATTTGTGGATAGTTTCACCCCTGATACTTCAAACTTAAAGATGTTACTGATCA
ATTC
F K I Y E V T D Q N Q F V D S F T P D T S K L K D V T D Q
F 420
GATGTTATTTATAGTAATGATAATAAACAGCTACAGTCGATTTAATGAAAGGCCAAACAAGCAGCAATAACAATACATCATTCA
ACAA
D V I Y S N D N K T A T V D L M K G Q T S S N K Q Y I I Q
Q 450
GTTGCTTATCCAGATAATAGTTCAACAGATAATGGAAAAATTGATTATACTTTAGACACTGACAAACTAAATATAGTTGGTCAAA
TAGT
V A Y P D N S S T D N G K I D Y T L D T D K T K Y S W S N
S 480

B1>

TATTCAAATGTGAATGCCTCATCAACTGCTAATGGCGACCAAAAGAAATATAATCTAGGTGACTATGTATGGGAAGATACAAATAA
AGAT
Y S N V N G S S T A N G D Q K K Y N L G D Y V W E D T N K
D 510
GGTAAACAAGATGCCAATGAAAAAGCGATTAAAGGTGTTTATGTCATTCTTAAAGATAGTAACGCTAAAGAATTAGATCGTACGAC
AACA
G K Q D A N E K G I K G V Y V I L K D S N G K E L D R T T
T 540
GATGAAAATGGTAAATATCAGTTCACTGGTTTAAGCAATGGAAGTTATAGTGTAGAGTTTCAACACCAGCCGTTATACACCGAC
AACT
D E N G K Y Q F T G L S N G T Y S V E F S T P A G Y T P T
T 570
GCAAATGTAGGTACAGATGATGCTGTAGATTCTGATGGACTAACTACAACAGGTGTCATTAAAGACGCTGACAACATGACATTAGA
TAGT
A N V G T D D A V D S D G L T T T G V I K D A D N M T L D
S 600

B2>

GGATTCTACAAAACACCAAAATATAGTTTAGGTGATTATGTTTGGTACGACAGTAATAAAGATGGTAAACGAGATTCGACTGAAAA
AGGA

FIG. 7B

G F Y K T P K Y S L G D Y V W Y D S N K D G K R D S T E K
G 630
ATTAAAGGTGTTAAAGTTACTTTGCAAACGAAAAGGCGAAGTAATTGGTACAACAGATGAAAATGGTAAATACCGCTT
TGAT
I K G V K V T L Q N E K G E V I G T T E T D E N G K Y R F
D 660
AATTTAGATAGTGGTAAATACAAAGTTATCTTTGAAAACCTGCTGGCTTAACTCAAACAGGTACAAATACAACTGAAGATGATAA
AGAT
N L D S G K Y K V I F E K P A G L T Q T G T N T T E D D K
D 690

R>
GCCGATGGTGGCGAAGTTGATGTAACAATTACGGATCATGATGATTCACACTTGATAATGGCTACTACGAACAAGAAACATCAGA
TAGC
A D G G E V D V T I T D H D D F T L D N G Y Y E E E T S D
S 720
GACTCAGATTCTGACAGCGATTACAGACTCAGATAGCGACTCAGATTCAGATAGCGACTCAGATTCAGACAGCGATTACAGACAGCGA
CTCA
D S D
S 750
GACTCAGATAGCGATTACAGATTACAGACAGCGACTCAGACTCAGACAGCAATTCAGACTCGGATAGCGACTCAGACTCAGATAGCGA
CTCA
D S D S D S D S D S D S D S D S D S D S N S D S D S D S D S D S D S D S D S D S D S D S D S D S D
S 780
GATTCGGATAGCGACTCAGACTCAGATAGCGATTACAGATTACAGATAGCGATTCCGACTCAGACAGTGATTACAGATTACAGACTCAGA
TAGC
D S D
S 810
GACTCAGATTCTGACAGCGATTACAGACTCAGACATCGACTCAGACTCAGACAGTGATTACAGATTACAGACAGCGACTCAGATTACAGA
TAGC
D S D
S 840
GACTCAGACTCAGATAGCGACTCAGACTCAGATAGCGACTCAGACTCGGATAGCGATTACAGATTACAGACAGCGACTCAGATTACAGA
TAGC
D S D
S 870

W>
GATTCGACTCAGACAACGACTCAGATTACAGATAGCGATTACAGATTACAGATGCAGGTAAACATACTCCGGCTAAACCAATGAGTAC
GGTT
D S D S D N D S D S D S D S D S D S D S D A G K H T P A K P M S T
V 900

M>
AAAGATCAGCATAAAACAGCTAAAGCATTACCAGAAACAGGTAGTGAAAATAATAATTCAAATAATGGCACATTATTCGGTCGATT
ATTC

FIG. 7C

K D Q H K T A K A L P E T G S E N N N S N N G T L F G G L
F 930

GCGGCATTAGGATCATTATTGTCATTCGGTCGTCGTAAAAACAAAATAAA

A A L G S L L S F G R R K K Q N K

947

FIG. 7D

S>
 ATGCTAAACAGAGAAAATAAAACGGCAATAACAAGGAAAGGCATGGTATCCAATCGATTAAATAAATTTTCGATTAGAAAGTACAC
 AGTG
 M L N R E N K T A I T R K C M V S N R L N K F S I R K Y T
 V 30

A>
 GGAACAGCATCAATTTTAGTAGGTACAACATTAATTTTGGTCTGGGGAACCAAGAAGCAAAGGCTGCAGAAAGTACTAATAAAGA
 ATTG
 G T A S I L V G T T L I F G L G N Q E A K A A E S T N K E
 L 60
 AACGAAGCGACAACCTTCAGCAAGTGATAATCAATCGAGTGATAAAGTTGATATGCAGCAACTAAATCAAGAAGACAATACTAAAAA
 TGAT
 N E A T T S A S D N Q S S D K V D M Q Q L N Q E D N T K N
 D 90
 AATCAAAAAGAAATGGTATCATCTCAAGGTAATGAAACGACTTCAATGGGAATAAATTAATAGAAAAAGAAAGTGTACAATCTAG
 CACT
 N Q K E M V S S Q G N E T T S N G N K L I E K E S V Q S T
 T 120
 GGAAATAAAGTTGAAGTTTCAACTGCCAAATCAGATGAGCAAGCTTCACCAAAATCTACGAATGAAGATTTAAACACTAAACAAAC
 TATA
 G N K V E V S T A K S D E Q A S P K S T N E D L N T K Q T
 I 150
 AGTAATCAAGAAGCGTTACAACCTGATTTGCAAGAGAATAAATCAGTGGTAAATGTTCAACCAACTAATGAGGAAAACAAAAGGT
 AGAT
 S N Q E A L Q P D L Q E N K S V V N V Q P T N E E N K K V
 D 180
 GCCAAACTGAATCAACTACATTAAATGTTAAAAGTGATGCTATCAAGAGTAATGATCAAACTCTTGTTGATAACAATAGTAATTC
 AAAT
 A K T E S T T L N V K S D A I K S N D E T L V D N N S N S
 N 210
 AATGAAAATAATGCAGATATCATTTTGCCAAAAGTACAGCACCTAAACGTTTGAATACAAGAATGCGTATAGCAGCAGTACAGCC
 ATCA
 N E N N A D I I L P K S T A P K R L N T R M R I A A V Q P
 S 240
 TCAACAGAGGCTAAAAATGTTAATGATTTAATCACATCAAATACAACATTAAGTGTGTTGATGCAGATAAAAACAATAAATCGT
 ACCA
 S T E A K N V N D L I T S N T T L T V V D A D K N N K I V
 P 270
 GCCCAAGATTATTATCATTAAATCACAATTACAGTTGATGACAAAGTTAAATCAGGTGATTATTCACAATTAATACTCAGA
 TACA
 A Q D Y L S L K S Q I T V D D K V K S G D Y F T I K Y S D
 T 300
 GTACAAGTATATGGATTGAATCCGGAAGATATTAATAATATTTGGTGATATTAAAGATCCAAATAATGGTGAAACAATTGCGACTGC

FIG. 8A

AAAA
V Q V Y G L N P E D I K N I G D I K D P N N G E T I A T A
K 330
CATGATACTGCAAATAATTTAATTACATATACATTTACAGATTATGTTGATCGATTTAATTCTGTACAAATGGGAATTAATTATTC
AATT
H D T A N N L I T Y T F T D Y V D R F N S V Q M G I N Y S
I 360
TATATGCATGCTGATACAATTCCTGTTAGTAAAAACGATGTTGAGTTTAATGTTACCATAGGTAATACTACAACAAAAACAACCTGC
TAAC
Y M D A D T I P V S K N D V E F N V T I G N T T T K T T A
N 390
ATTCAATATCCAGATTATGTTGTAAATGAGAAAAATTCAATTGGATCAGCGTTCACTCAAACAGTTTCACATGTTGAAATAAAGA
AAAT
I Q Y P D Y V V N E K N S I G S A F T E T V S H V G N K E
N 420
CCAGGGTACTATAAACAACGATTTATGTAAATCCATCGGAAAATTCCTTAACAAATGCCAACTAAAAGTTCAAGCTTACCACTC
AAGT
P G Y Y K Q T I Y V N P S E N S L T N A K L K V Q A Y H S
S 450
TATCCTAATAATATCGGGCAAATAAATAAAGATGTAAACAGATATAAAAAATATATCAAGTTCCTAAAGGTTATACATTAAATAAAG
ATAC
Y P N N I G Q I N K D V T D I K I Y Q V P K G Y T L N K G
Y 480
GATGTGAATACTAAAGAGCTTACAGATGTAAACAATCAATACTTGCAGAAAATTACATATGGCGACAACAATAGCGCTGTTATTGA
TTTT
D V N T K E L T D V T N Q Y L Q K I T Y G D N N S A V I D
F 510
GGAAATGCAGATTCTGCTTATGTTGTAATGGTTAATACAAAATTCGAATATACAAATAGCGAAAGCCCAACACTTGTTCAAATGGC
TACT
G N A D S A Y V V M V N T K F Q Y T N S E S P T L V Q M A
T 540
TTATCTTCAACAGGTAATAAATCCGTTTCTACTGGCAATGCTTTAGGATTTACTAATAACCAAAGTGGCGGAGCTGGTCAAGAAGT
ATAT
L S S T G N K S V S T G N A L G F T N N Q S G G A G Q E V
Y 570
AAAATTGCTAACTACGTATCGGAAGATACTAATAAAAACGGTGTTCAGAATTAGCAGAAAAAGCGGTTGGCAATGTAAGTGTAACT
TGTA
K I G N Y V W E D T N K N G V Q E L G E K G V G N V T V T
V 600
TTTGATAATAATACAAATACAAAAGTAGGAGAAGCAGTTACTAAAGAAGATGGGTCATACTTGATTCCAACTTACCTAATGCAGA
TTAC
F D N N T N T K V G E A V T K E D G S Y L I P N L P N G D

FIG. 8B

Y 630
 CGTGTAGAATTTTCAAACCTACCAAAGGTTATGAAGTAACCCCTTCAAAACAAGGTAATAACGAAGAATTAGATTCAAACGGCTT
 ATCT
 R V E F S N L P K G Y E V T P S K Q G N N E E L D S N G L
 S 660

B2>
 TCAGTTATTACAGTTAATGGCAAAGATAACTTATCTGCAGACTTAGGTATTTACAAACCTAAATACAACCTAGGTGACTATGCTCTG
 GGAA
 S V I T V N G K D N L S A D L G I Y K P K Y N L G D Y V W
 E 690
 GATACAAATAAAAATCGTATCCAAGACCAAGATGAAAAAGGTATATCTGCCGTAACGTAACATTAAAAGATGAAAACGGTAACGT
 GTTA
D T N K N G I Q D Q D E K G I S G V T V T L K D E N G N V
 L 720
 AAAACAGTTACAACAGACGCTGATGGCAAATATAAATTTACTGATTTAGATAATGGTAATTATAAAGTTGAATTTACTACACCAGA
 AGGC
 K T V T T D A D G K Y K F T D L D N G N Y K V E F T T P E
 G 750
 TATACACCGACTACAGTAACATCTGGTAGCGACATTGAAAAAGACTCTAATGGTTTAACAACAACAGGTGTTATTAATGGTGCTCA
 TAAC
 Y T P T T V T S G S D I E K D S N G L T T T G V I N G A D
 N 780

B3>
 ATGACATTAGATAGTGGATTCTACAAAACACCAAATATAATTTAGGTAATTATGTATGGGAAGATACAAATAAAGATGGTAACCA
 GGAT
 M T L D S G F Y K T P K Y N L G N Y V W E D T N K D G K Q
D 810
 TCAACTGAAAAAGGTATTTTACGCCGTAACAGTTACATTGAAAAATGAAAACGGTGAAGTTTACAAACAACCTAAAACAGATAAAGA
 TGGT
S T E K G I S G V T V T L K N E N G E V L Q T T K T D K D
 G 840
 AAATATCAATTTACTGGATTAGAAAATGGAACCTATAAAGTTGAATTCGAAACACCATCAGGTTACACACCAACACAAGTAGGTTT
 AGGA
 K Y Q F T G L E N G T Y K V E F E T P S G Y T P T Q V G S
 G 870
 ACTGATGAAGGTATAGATTCAAATGGTACATCAACAACAGGTGTCATTAAAGATAAAGATAACGATACTATTGACTCTGGTTTCTA
 CAAA
 T D E G I D S N G T S T T G V I K D K D N D T I D S G F Y
 K 900

B4>
 CCGACTTACAACCTAGGTGACTATGTATGGGAAGATACAAATAAAAACGGTGTTCAGATAAAGATGAAAAGGCCATTTACAGGTGT
 AACA
 P T Y N L G D Y V W E D T N K N G V Q D K D E K G I S G V

FIG. 8C

T 930
GTTACGTTAAAAGATGAAAACGACAAAGTTTAAAAACAGTTACAACAGATGAAAATGGTAAATATCAATTCAGTTTAAACAA
TGGA
V T L K D E N D K V L K T V T T D E N G K Y Q F T D L N N
G 960
ACTTATAAAGTTCAATTCGAGACACCATCAGGTTATACACCAACTTCAGTAACTTCTGGAAATGATACTGAAAAAGATTCTAATGC
TTTA
T Y K V E F E T P S G Y T P T S V T S G N D T E K D S N G
L 990

B5>

ACAACAACAGCTGTCATTAAAGATGCAGATAACATGACATTAGACAGTCGTTTCTATAAAACACCAAAATATAGTTTAGGTGATTA
TGTT
T T T G V I K D A D N M T L D S G F Y K T P K Y S L G D Y
V 1020
TGGTACGACAGTAATAAAGACGGCAACAAGATTCAACTGAAAAAGGTATCAAAGATGTTAAAGTTACTTTATTAAATGAAAAAGC
CGAA
W Y D S N K D G K O D S T E K G I K D V K V T L L N E K G
E 1050
GTAATTGGAACAACATAAACAGATGAAAATGCTAAATACTGCTTTGATAATTTAGATAGCGGTAAATACAAAGTTATTTTTGAAAA
GCCT
V I G T T K T D E N G K Y C F D N L D S G K Y K V I F E K
P 1080
GCTGGCTTAACACAACAGGTACAAATACAACGAAGATGATAAAGATGCAGATGGTGGCGAAGTTGACGTAACAATTACGGATCA
TGAT
A G L T Q T G T N T T E D D K D A D G G E V D V T I T D H
D 1110
R>
GATTTACACTTGATAATGGCTACTACGAAGAAGAAACATCAGATAGCGACTCAGATTCGGACAGCGACTCAGATTCAGACAGAGA
CTCA
D F T L D N G Y Y E E E T S D S D S D S D S D S D S D S D R D
S 1140
GACTCAGATAGTATTCAGACTCGGATAGCGATTCAGATTCAGACAGCGATTCAGATTCAGATAGCGATTCAGATTCAGACAGAGA
CTCA
D S D S D S D S D S D S D S D S D S D S D S D S D S D S D R D
S 1170
GATAGTGATTCAGACTCAGATAGCGACTCAGATTCAGACAGCGACTCAGATTCAGACAGCGACTCAGACTCAGATAGTGATTCAGA
CTCA
D S D S D S D S D S D S D S D S D S D S D S D S D S D S D
S 1200
GATAGCGACTCAGATTCGGATAGCGACTCAGATTCAGACAGCGACTCAGACTCGGATAGTGATTCAGACTCAGATAGCGACTCAGA
CTCA
D S D S D S D S D S D S D S D S D S D S D S D S D S D S D
S 1230

FIG. 8D

W>
GATAGCGATTCAGATTCAGATAGCGACTCAGACTCAGACAGCGATTCAGACTCAGACAGCGACTCAGACTCAGATGCAGGTAAGCA
CACA
D S D S D S D S D S D S D S D S D S D S D S D S D A G K H
T 1260
CCTGTAAACCAATGAGTACTACTAAAGACCATCACAATAAAGCAAAGCATTACCAGAAACAGGTAATGAAAATAGCGGCTCAAA
TAAC
P V K P M S T T K D H H N K A K A L P E T G N E N S G S N
N 1290
M>
GCAACGTTATTTGGCGGATTATTCGCAGCATTAGGATCATTATTGTTATTCGGTCGTCGTAAAAACAAAATAAA
A T L F G G L F A A L G S L L L F G R R K K Q N K
1315

FIG. 8E

S>
 ATGATTAACAGGGATAATAAAAAGGCAATAACAAAAAGGGTATGATTTCAAATCGCTTAAACAAATTTTCGATTAGAAAGTATAC
 TGTA
 M I N R D N K K A I T K K G M I S N R L N K F S I R K Y T
 V 30

A>
 GGAAGTGCATCGATTTTAGTAGGTACGACATTGATTTTGGTCTAGGGAACCAAGAAGCTAAAGCTGCTGAAAACACTAGTACAGA
 AAAT
 G T A S I L V G T T L I F G L G N Q E A K A A E N T S T E
 N 60
 GCAAAACAAGATGATGCAACGACTAGTGATAATAAAGAAGTAGTGTCCGAAACTGAAAATAATTCGACAACAGAAAATAATTCAAC
 AAAT
 A K Q D D A T T S D N K E V V S E T E N N S T T E N N S T
 N 90
 CCAATTAAGAAAGAAACAAATACTGATTCACAACCAGAAGCTAAAAAGAATCAACTTCATCAAGTACTCAAAAACAGCAAAATAA
 CGTT
 P I K K E T N T D S Q P E A K K E S T S S S T Q K Q Q N N
 V 120
 ACAGCTACAAGTAAAGCTCAAAACATTGAAAAAGAAAATGTTAAACCTTCAACTGATAAACTGCGACAGAAGATACATC
 TGTT
 T A T T E T K P Q N I E K E N V K P S T D K T A T E D T S
 V 150
 ATTTTAGAAGAGAAGAAAGCACCAAATAATACAAATAACGATGTAAGTACAAAACCATCTACAAGTGAACCATCTACAAGTGAAT
 TCAA
 I L E E K K A P N N T N N D V T T K P S T S E P S T S E I
 Q 180
 ACAAACCAACTACACCTCAAGAATCTACAAATATTGAAAATTCACAACCGCAACCAACGCCTTCAAAAGTAGACAATCAAGTTAC
 AGAT
 T K P T T P Q E S T N I E N S Q P Q P T P S K V D N Q V T
 D 210
 GCAACTAATCCAAAAGAACCAGTAAATGTGTCAAAGAAGAACTTAAAAATAATCCTGAGAAATTAAAAGAATTGGTTAGAAATGA
 TAGC
 A T N P K E P V N V S K E E L K N N P E K L K E L V R N D
 S 240
 AATACAGATCATTCAACTAAACCAGTTGCTACAGCTCCAACAAGTGTGCACCAAAACGTGTAAACGCAAAAATGCGCTTTGCAGT
 TGCA
 N T D H S T K P V A T A P T S V A P K R V N A K M R F A V
 A 270
 CAACCAGCAGCAGTTGCTTCAAACAATGTAAATGATTTAATTAAAGTGACGAAGCAAACAATCAAAGTTGGCGATGGTAAAGATAA
 TGTG
 Q P A A V A S N N V N D L I K V T K Q T I K V G D G K D N
 V 300
 GCAGCAGCGCATGACGGTAAAGATATTGAATATGATACAGAGTTTACAATTGACAATAAAGTCaAAAAAGGCGATACAATGACGAT

FIG. 9A

TAAT
A A A H D G K D I E Y D T E F T I D N K V K K G D T M T I
N 330
TATGATAAGAATGTAATTCCTTCGGATTTAACAGATAAAAATGATCCTATCGATATTACTGATCCATCAGGAGAGGTCATTGCTAA
AGGA
Y D K N V I P S D L T D K N D P I D I T D P S G E V I A K
G 360
ACATTTGATAAAGCAACTAAGCAAATCACATATACATTTACAGACTATGTAGATAAATATGAAGATATAAAATCACGCTTAACTCT
ATAT
T F D K A T K Q I T Y T F T D Y V D K Y E D I K S R L T L
Y 390
TCGTATATTGATAAAAAACAGTTCCAAATGAGACAAGTTTGAATTTAACATTTGCTACAGCAGGTAAAGAAACAAGCCAAAATGT
CACT
S Y I D K K T V P N E T S L N L T F A T A G K E T S Q N V
T 420
GTTGATTATCAAGATCCAATGGTCCATGGTGATTCAAACATTCAATCTATCTTTACAAAATTAGATGAAGATAAGCAAACCTATTGA
ACAA
V D Y Q D P M V H G D S N I Q S I F T K L D E D K Q T I E
Q 450
CAAATTTATGTTAACCATTGAAAAATCAGCAACCAACACTAAAGTTGATATAGCTGGTAGTCAAGTAGATGATTATGGAAATAT
TAAA
Q I Y V N P L K K S A T N T K V D I A G S Q V D D Y G N I
K 480
CTAGGAAATGGTAGCACCATTATTGACCAAAATACAGAAATAAAGGTTTATAAAGTTAACTCTGATCAACAATTGCCTCAAAGTAA
TAGA
L G N G S T I I D Q N T E I K V Y K V N S D Q Q L P Q S N
R 510
ATCTATGATTTTAGTCAATACGAAGATGTAACAAGTCAATTTGATAATAAAAAATCATTTAGTAATAATGTAGCAACATTGGATTT
TGGT
I Y D F S Q Y E D V T S Q F D N K K S F S N N V A T L D F
G 540
GATATTAATTCAGCCTATATTATCAAAGTTGTTAGTAAATATACACCTACATCAGATGGCGAACTAGATATTGCCCAAGGTACTAG
TATG
D I N S A Y I I K V V S K Y T P T S D G E L D I A Q G T S
M 570
AGAACAACCTGATAAATATGGTTATTATAATTATGCAGGATATTCAAACCTTCATCGTAACTTCTAATGACACTGGCGGTGGCGACGG
TACT
R T T D K Y G Y Y N Y A G Y S N F I V T S N D T G G G D G
T 600
B1>
GTTAAACCTGAAGAAAAGTTATACAAAATTGGTGACTATGTATGGGAAGACGTTGATAAAGACGGTGTTCAAGGTACAGATTCAA
AGAA
V K P E E K L Y K I G D Y V W E D V D K D G V Q G T D S K

FIG. 9B

E 630
AAACCAATGGCAAACGTTTTAGTTACATTAACCTACCCGGACGGTACTACAAAATCAGTAAGAACAGATGCTAATGGTCATTATGA
ATTC
K P M A N V L V T L T Y P D G T T K S V R T D A N G H Y E
F 660
GGTGGTTTGAAGACGGAGAACTTATACAGTTAAATTCGAAACGCCAACTGGATATCTTCCAACAAAAGTAAATCGAACAACCTGA
TGGT
G G L K D G E T Y T V K F E T P T G Y L P T K V N G T T D
G 690
B2>
GAAAAAGACTCAAATGGTAGTTCGGTTACTGTAAAATTAATGGTAAAGATGATATGTCTTTAGATACTGGTTTTTACAAAGAACC
TAAA
E K D S N G S S V T V K I N G K D D M S L D T G F Y K E P
K 720
TACAACTTAGGTGACTATGTATGGGAAGATACTAATAAAGATGGTATCCAAGATGCAAATGAGCCAGGAATCAAAGATGTTAAGGT
TACA
Y N L G D Y V W E D T N K D G I Q D A N E P G I K D V K V
T 750
TTAAAAGATAGTACTGGAAAAGTTATTGGTACAACCTACTACTGATGCCTCGGGTAAATATAAATTTACAGATTTAGATAATGGTAA
CTAT
L K D S T G K V I G T T T T D A S G K Y K F T D L D N G N
Y 780
ACAGTAGAATTTGAAACACCAGCAGGTACACGCCAACGGTTAAAAATACTACAGCTGATGATAAAGATTCTAATGGTTTAAACAAC
AACA
T V E F E T P A G Y T P T V K N T T A D D K D S N G L T T
T 810
B3>
GGTGTCAATTAAGATGCAGATAATATGACATTAGACAGGGGTTTCTATAAACACCAAAAATACAGTTTAGGTGATTATGTTTGGTA
CGAC
G V I K D A D N M T L D R G F Y K T P K Y S L G D Y V W Y
D 840
AGTAATAAAGACGGCAAACAAGATTCAACTGAAAAAGGTATCAAAGATGTGACAGTTACATTGCAAACGAAAAAGGCGAAGTAAT
TGGA
S N K D G K Q D S T E K G I K D V T V T L Q N E K G E V I
G 870
ACAATAAACAGATGAAAATGGTAAATATCGTTTCGATAATTTAGATAGCGGTAAATACAAAGTTATTTTTGAAAAGCCTGCTGG
CTTA
T T K T D E N G K Y R F D N L D S G K Y K V I F E K P A G
L 900
ACACAAACAGTTACAAATACAACCTGAAGATGATAAAGATGCAGATGGTGGCGAAGTTGACGTAACAATTACGGATCATGATGATTT
CACA
T Q T V T N T T E D D K D A D G G E V D V T I T D H D D F
T 930

FIG. 9C

R>

CTTGATAACGGATACTTCGAAGAAGATACATCAGACAGCGATTTCAGACTCAGATAGTGA
 CACTCAGACAGCGACTCAGACTCAGACAG
 CGAC
 L D N G Y F E E D T S D S D S D S D S D S D S D S D S D S D S
 D 960
 TCAGACTCAGACAGTGATTTCAGATTTCAGACAGCGACTCAGATTTCAGATAGCGACTCAGATTTCGACAGCGATTTCAGACTCAGATAG
 CGAC
 S D S D S D S D S D S D S D S D S D S D S D S D S D S D S D S
 D 990
 TCAGATTTCAGATAGCGATTTCAGACTCAGACAGCGACTCAGATTTCAGATAGCGATTTCGACTCAGACAGCGATTTCAGACTCAGATAG
 CGAC
 S D S D S D S D S D S D S D S D S D S D S D S D S D S D S D S
 D 1020
 TCAGACTCAGACAGCGACTCAGATTTCAGATAGCGATTTCGACTCAGATAGCGACTCAGATTTCAGACAGCGATTTCAGACTCAGATAG
 CGAC
 S D S D S D S D S D S D S D S D S D S D S D S D S D S D S D S
 D 1050
 TCAGATTTCAGACAGCGATTTCAGACTCAGATAGCGACTCAGACTCAGACAGTGATTTCAGATTTCAGACAGCGACTCAGACTCAGATAG
 CGAC
 S D S D S D S D S D S D S D S D S D S D S D S D S D S D S D S
 D 1080

W>

TCAGATTTCAGACAGCGACTCAGACTCAGATAGCGACTCAGACTCAGACAGTGATTTCAGACAGCGATTTCAGACTTCGATTCAGGAAA
 ACAT
 S D S D S D S D S D S D S D S D S D S D S D S D S D S D A G K
 H 1110
 ACACCTGTAAACCAATGAGTACTACTAAAGACCATCACAATAAAGCAAAGCATTACCAGAAACAGGTAGTGAAAATAACGGCTC
 AAAT
 T P V K P M S T T K D H H N K A K A L P E T G S E N N G S
 N 1140

M>

AACGCAACGTTATTTGGTGGATTATTTGCAGCATTAGGTTTCATTATTGTTATTCGGTCGTCGCAAAAACAAAACAAA
 N A T L F G G L F A A L G S L L L F G R R K K Q N K
 1166

FIG. 9D




FIG. 10

$\%$	ClfB	SdrC	SdrD	SdrE
ClfA	27	20	24	25
ClfB		24	25	23
SdrC			24	23
SdrD				30

FIG. 11

1.			
SdrD	TVDDKVKSGDYFTIK	296	
SdrE	TIDNKVKKGDTMTIN	330	
ClfB	TVTDKVKSGDYFTAK	269	
SdrC	TIDDSVKEGDTFTFK	241	
ClfA	SVPNSAVKGDTFKIT	278	
	:: :... .** :. .		
2.			
SdrD -	ETIATAKHDTANNLITYTFTDYVD	347	
SdrE	EVIAKGTFDKATKQITYTFTDYVD	378	
ClfB	DVVAKATYDILTKTYTFVFTDYVN	314	
SdrC	NIIAKGIYDSTTNTTTYTFTNYVD	289	
ClfA	QVLANGVIDSDGN-VIYTFTDYVN	324	
	: :*.. * : :. **: **: :		
3.			
SdrD	TDIKIYQVPK	472	
SdrE	TEIKVYKVNS	501	
ClfB	TKLRIFEVND	438	
SdrC	--FKIYEVD	398	
ClfA	TSIKVYKVDN	440	
	: : : : : *		
4.			
SdrD	DVTNQ	493	
SdrE	DVTSQ	523	
ClfB	EVTQ	461	
SdrC	DVTQ	419	
ClfA	DVTNS	461	
	: ** ..		
5.			
SdrCB1	KYNLG DYVWEDTNKDGKQ--DANEKGIKGVYVILKDSNGK-ELDRTTT DENGKYQFTGLS		
SdrCB2	KYSLG DYVWYDSNKGDKR--DSTEKGIKGVKVTLQNEKGE-VIGTTETDENGKYRFDNLD		
SdrDB1	VYKIGNYVWEDTNKNGVQ--ELGEKGVGNVTVTVFDNNTNTKVGEAVTKEDGSYLIPNLP		
SdrDB2	KYNLG DYVWEDTNKNGIQ--DQDEKGISGVTVTLKDENG-NVLKTVTTDADGKYKFTDLN		
SdrDB3	KYNLG NYVWEDTNKDGKQ--DSTEKGISGVTVTLKNENGE-VLQTTKTDKDGKYQFTGLE		
SdrDB4	TYNLG DYVWEDTNKNGVQ--DKDEKGISGVTVTLKDENDK-VLKTVTTDENGKYQFTDLN		
SdrDB5	KYSLG DYVWYDSNKGDKQ--DSTEKGIKDVKVTLLNEKGE-VIGTTKTDENGKYCFDNLD		
SdrEB1	LYKIG DYVWEDVDKDGVOGTD SKEKPMANVLVTLTYPDG--TTKSVRTDANGHYEFGGLK		
SdrEB2	KYNLG DYVWEDTNKDGIO--DANEKGIKDVKVTLKDSTGK-VIGTTTTDASGKYKFTDLN		
SdrEB3	KYSLG DYVWYDSNKGDKQ--DSTEKGIKDVTVTLQNEKGE-VIGTTKTDENGKYRFDNLD		
	.::*** * :*: * : : * : . * * : . * . . * * : . *		

FIG. 12A

SdrCB1	NG-TYSVEFST-PAGYTPTTANVGTDDAVDSGLTTTGVIKDADNMTLDSGFYKTP-
SdrCB2	SG-KYKVIFEK-PAGLTQTGTNTTEDD-KDADGGEVDVTITDHDDFTLDNGYEEET
SdrDB1	NG-DYRVEFSNLPKGYEVTSPKQGNNEELDSNGLSSVITVNGKDNLSADLGIYKP--
SdrDB2	NG-NYKVEFTT-PEGYTPTTVTSGSDIEKDSNGLTTTGVIKADNMTLDSGFYKTP-
SdrDB3	NG-TYKVEFET-PSGYTPTQVSGTDEGIDSNGTSTTGVIKDKDNDTIDSGFYKP--
SdrDB4	NG-TYKVEFET-PSGYTPTSVTSGNDEKDSNGLTTTGVIKDADNMTLDSGFYKTP-
SdrDB5	SG-KYKVIFEK-PAGLTQTGTNTTEDD-KDADGGEVDVTITDHDDFTLDNGYEEET
SdrEB1	DGETYTVKFET-PTGYLPTKVNGTTDGEKDSNGSSVTVKINGKDDMSLDTGFYKEP-
SdrEB2	NG-NYTVEFET-PAGYTPTVKNTTADD-KDSNGLTTTGVIKDADNMTLDRGFYKTP-
SdrEB3	SG-KYKVIFEK-PAGLTQTVTNTTEDD-KDADGGEVDVTITDHDDFTLDNGYFEEDT

. * * * * , * * * : * : * : ... * : : * * :

FIG. 12B




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19

Staphylococcus aureus Consensus and Variable Motif

Protein	Motif									
ClfA	I	Y	T	F	T	D	Y	V	N	
ClfB	T	F	V	F	T	D	Y	V	N	
SdrC	T	Y	T	F	T	D	Y	V	D	
SdrD	T	Y	T	F	T	D	Y	V	D	
SdrE	T	Y	T	F	T	D	Y	V	D	
Consensus	T	Y	T	F	T	D	Y	V	D	
Variable Motif	T/I	Y/F	T/V	F	T	D/N	Y	V	D/N	

FIG. 20




FIG. 21




FIG. 22A

FIG. 22B




FIG. 23

EXTRACELLULAR MATRIX-BINDING PROTEINS FROM STAPHYLOCOCCUS AUREUS

[0001] This application claims priority to U.S. provisional application Nos. 60/098,427, filed Aug. 31, 1998 and 60/066,815, filed Nov. 26, 1997. The U.S. Government has rights in this invention arising out of National Institutes of Health grant number A120624.

FIELD OF THE INVENTION

[0002] The present invention is in the fields of microbiology and molecular biology. The invention includes the isolation and use of extracellular matrix-binding proteins and genes that express the proteins from *Staphylococcus aureus* to inhibit, prevent and diagnose *S. aureus* infection.

BACKGROUND OF THE INVENTION

[0003] In hospitalized patients *Staphylococcus aureus* is a major cause of infections associated with indwelling medical devices, such as catheters and prostheses, and related infections of surgical wounds. A significant increase in *Staphylococcus aureus* isolates that exhibit resistance to most known antibiotics has been observed in hospitals throughout the world. The recent emergence of resistance to vancomycin, the last remaining antibiotic for treating methicillin-resistant *Staphylococcus aureus* (MRSA) infections, has emphasized the need for alternative prophylactic or vaccine strategies to reduce the risk of nosocomial *S. aureus* infections.

[0004] Initial localized infections of wounds or indwelling medical devices can lead to serious invasive infections such as septicemia, osteomyelitis, and endocarditis. In infections associated with medical devices, plastic and metal surfaces become coated with host plasma and extracellular matrix proteins such as fibrinogen and fibronectin shortly after implantation. The ability of *S. aureus* to adhere to these proteins is of crucial importance for initiating infection. Vascular grafts, intravenous catheters, artificial heart valves, and cardiac assist devices are thrombogenic and prone to bacterial colonization. *S. aureus* is the most damaging pathogen to cause such infections.

[0005] Fibrin is the major component of blood clots, and fibrinogen/fibrin is one of the major plasma proteins deposited on implanted biomaterials. Considerable evidence exists to suggest that bacterial adherence to fibrinogen/fibrin is important in the initiation of device-related infection. For example, as shown by Vaudaux et al., *S. aureus* adheres to in vitro plastic that has been coated with fibrinogen in a dose-dependent manner (*J. Infect. Dis.* 160:865-875 (1989)). In addition, in a model that mimics a blood clot or damage to a heart valve, Herrmann et al. demonstrated that *S. aureus* binds avidly via a fibrinogen bridge to platelets adhering to surfaces (*J. Infect. Dis.* 167: 312-322 (1993)). *S. aureus* can adhere directly to fibrinogen in blood clots formed in vitro, and can adhere to cultured endothelial cells via fibrinogen deposited from plasma acting as a bridge (Moreillon et al., *Infect. Immun.* 63:4738-4743 (1995); Cheung et al., *J. Clin. Invest.* 87:2236-2245 (1991)). As shown by Vaudaux et al. and Moreillon et al., mutants defective in the fibrinogen-binding protein clumping factor (ClfA) exhibit reduced adherence to fibrinogen in vitro, to explanted catheters, to blood clots, and to damaged heart valves in the rat model for endocarditis (Vaudaux et al.,

Infect. Immun. 63:585-590 (1995); Moreillon et al., *Infect. Immun.* 63: 4738-4743 (1995)).

[0006] An adhesin for fibrinogen, often referred to as "clumping factor," is located on the surface of *S. aureus* cells. The interaction between the clumping factor on bacteria and fibrinogen in solution results in the instantaneous clumping of bacterial cells. The binding site on fibrinogen is located in the C-terminus of the gamma chain of the dimeric fibrinogen glycoprotein. The affinity is very high and clumping occurs in low concentrations of fibrinogen. Scientists have recently shown that clumping factor also promotes adherence to solid phase fibrinogen, to blood clots, and to damaged heart valves (McDevitt et al., *Mol. Microbiol.* 11: 237-248 (1994); Vaudaux et al., *Infect. Immun.* 63:585-590 (1995); Moreillon et al., *Infect. Immun.* 63: 4738-4743 (1995)).

[0007] The gene for a clumping factor protein, designated ClfA, has been cloned, sequenced and analyzed in detail at the molecular level (McDevitt et al., *Mol. Microbiol.* 11: 237-248 (1994); McDevitt et al., *Mol. Microbiol.* 16:895-907 (1995)). The predicted protein is composed of 933 amino acids. A signal sequence of 39 residues occurs at the N-terminus followed by a 520 residue region (region A), which contains the fibrinogen binding domain. A 308 residue region (region R), composed of 154 repeats of the dipeptide serine-aspartate, follows. The R region sequence is encoded by the 18 basepair repeat GAYTCNGAYT CNGAYAGY (SEQ ID NO: 9) in which Y equals pyrimidines and N equals any base. The C-terminus of ClfA has features present in many surface proteins of Gram-positive bacteria such as an LPDTG (SEQ ID NO: 10) motif, which is responsible for anchoring the protein to the cell wall, a membrane anchor, and positive charged residues at the extreme C-terminus.

[0008] The platelet integrin alpha IIb β 3 recognizes the C-terminus of the gamma chain of fibrinogen. This is a crucial event in the initiation of blood clotting during coagulation. ClfA and alpha IIb β 3 appear to recognize precisely the same sites on fibrinogen gamma chain because ClfA can block platelet aggregation, and a peptide corresponding to the C-terminus of the gamma chain (198-411) can block both the integrin and ClfA interacting with fibrinogen (McDevitt et al., *Eur. J. Biochem.* 247:416-424 (1997)). The fibrinogen binding site of alpha IIb β 3 is close to, or overlaps, a Ca²⁺ binding determinant referred to as an "EF hand". ClfA region A carries several EF hand-like motifs. A concentration of Ca²⁺ in the range of 3-5 mM blocks these ClfA-fibrinogen interactions and changes the secondary structure of the ClfA protein. Mutations affecting the ClfA EF hand reduce or prevent interactions with fibrinogen. Ca²⁺ and the fibrinogen gamma chain seem to bind to the same, or to overlapping, sites in ClfA region A.

[0009] The alpha chain of the leucocyte integrin, alpha MB2, has an insertion of 200 amino acids (A or I domain) which is responsible for ligand binding activities. A novel metal ion-dependent adhesion site (MIDAS) motif in the I domain is required for ligand binding. Among the ligands recognized is fibrinogen. The binding site on fibrinogen is in the gamma chain (residues 190-202). It was recently reported that *Candida albicans* has a surface protein, alpha Intlp, having properties reminiscent of eukaryotic integrins. The surface protein has amino acid sequence homology with

the I domain of alpha MB2, including the MIDAS motif. Furthermore, alpha Intlp binds to fibrinogen.

[0010] ClfA region A also exhibits some degree of sequence homology with alpha Intlp. Examination of the ClfA region A sequence has revealed a potential MIDAS motif. Mutations in supposed cation coordinating residues in the DXSXS portion of the MIDAS motif in ClfA results in a significant reduction in fibrinogen binding. A peptide corresponding to the gamma-chain binding site for alpha MB2 (190-202) has been shown by O'Connell et al. to inhibit ClfA-fibrinogen interactions (O'Connell et al., *J. Biol. Chem.*, in press). Thus it appears that ClfA can bind to the gamma-chain of fibrinogen at two separate sites. The ligand binding sites on ClfA are similar to those employed by eukaryotic integrins and involve divalent cation binding EF-hand and MIDAS motifs.

[0011] Scientists have recently shown that *S. aureus* expresses proteins other than ClfA that may bind fibrinogen (Boden and Flock, *Mol. Microbiol.* 12:599-606 (1994)). One of these proteins is probably the same as the broad spectrum ligand-binding protein reported by Homonylo-McGavin et al., *Infect. Immun.* 61:2479-2485 (1993). Another is coagulase, as reported by Boden and Flock, *Infect. Immun.* 57:2358-2363 (1989), a predominantly extracellular protein that activates the plasma clotting activity of prothrombin. Coagulase binds prothrombin at its N-terminus and also interacts with soluble fibrinogen at its C-terminus. Cheung et al., *Infect. Immun.* 63:1914-1920 (1995) have described a variant of coagulase that binds fibrinogen. There is some evidence that coagulase can contribute, in a minor way, to the ability of *S. aureus* cells to bind fibrinogen. As shown by Wolz et al., *Infect. Immun.* 64:3142-3147 (1996), in an agr regulatory mutant, where coagulase is expressed at a high level, coagulase appears to contribute to the binding of soluble fibrinogen to bacterial cells. Also, as shown by Dickinson et al., *Infect. Immun.* 63:3143-3150 (1995), coagulase contributes in a minor way to the attachment of *S. aureus* to plasma-coated surfaces under flow. However, it is clear that clumping factor ClfA is the major surface-located fibrinogen-binding protein responsible for bacterial attachment to immobilized fibrinogen/fibrin.

[0012] The identification and isolation of additional *S. aureus* extracellular matrix binding proteins would be useful for the development of therapies, diagnosis, prevention strategies and research tools for *S. aureus* infection.

[0013] Accordingly it is an object of the present invention to provide 15 isolated cell-wall associated extracellular matrix-binding proteins of *S. aureus* and active fragments thereof.

[0014] It is a further object of the invention to provide methods for preventing, diagnosing, treating or monitoring the progress of therapy for bacterial infections caused by *S. aureus*.

[0015] It is a further object of the present invention to provide isolated *S. aureus* surface proteins that are related in amino acid sequence to ClfA and are able to promote adhesion to the extracellular matrix or host cells.

[0016] It is another object of the present invention to generate antisera and antibodies to cell-wall associated extracellular matrix-binding proteins of *S. aureus*, or active fragments thereof.

[0017] It is a further object of the present invention to provide *S. aureus* vaccines, including a DNA vaccine.

[0018] It is a further object of the present invention to provide improved materials and methods for detecting and differentiating *S. aureus* organisms in clinical and laboratory settings.

[0019] It is a further object of the invention to provide nucleic acid probes and primers specific for *S. aureus*.

[0020] It is a further object of the invention to provide isolated extracellular matrix-binding proteins or peptides of *S. aureus*.

SUMMARY OF THE INVENTION

[0021] Isolated extracellular matrix-binding proteins, designated ClfB, SdrC, SdrD and SdrE, and their corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of *S. aureus* infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of *S. aureus* infection. The proteins, peptides, peptide fragments, antibodies, or antibody fragments can be administered in an effective amount to a patient in need thereof in any appropriate manner, preferably intravenously or otherwise by injection, to impart active or passive immunity. In an alternative embodiment, the proteins or antibodies thereof can be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of *S. aureus* to wounds or biomaterials.

[0022] Specifically, extracellular matrix-binding proteins from *S. aureus* designated as ClfB, SdrC, SdrD, and SdrE are provided.

[0023] ClfB is a fibrinogen binding protein. The nucleic acid and amino acid sequences of ClfB are provided in FIG. 5. The amino acid sequence of ClfB is SEQ ID NO: 1, and the nucleic acid sequence of ClfB is SEQ ID NO:2.

[0024] SdrC has been discovered to bind to several extracellular matrix proteins of the host, including for example, bone sialoprotein (BSP), decorin, plasmin, fibrinogen and vitronectin. The amino acid and nucleic acid sequences of SdrC are SEQ ID NOS:3 and 4 respectively and are provided in FIG. 7.

[0025] Another of the discovered proteins, SdrD, binds at least vitronectin. The amino acid and nucleic acid sequences of SdrD are SEQ ID NOS:5 and 6 respectively and are provided in FIG. 8.

[0026] SdrE binds to extracellular matrix proteins, for example, bone sialoprotein (BSP). The amino acid and nucleic acid sequences of SdrE are SEQ ID NOS:7 and 8 respectively and are provided in FIG. 9.

[0027] ClfB has a predicted molecular weight of approximately 88 kDa and an apparent molecular weight of approximately 124 kDa. ClfB is a cell-wall associated protein and binds both soluble and immobilized fibrinogen. In addition, ClfB binds both the alpha and beta chains of fibrinogen and acts as a clumping factor. SdrC, SdrD and SdrE are cell-wall

associated proteins that exhibit cation-dependent ligand binding of extracellular matrix proteins such as decorin, plasmin, fibrinogen, vitronectin and BSP.

[0028] It has been discovered that in the A region of SdrC, SdrD, SdrE, ClfA, and ClfB, there is highly conserved amino acid sequence that can be used to derive a consensus TYTFTDYVD (SEQ ID NO: 18) motif (see **FIG. 20**). The motif can be used in vaccines to impart broad spectrum immunity against bacterial infections. The motif can also be used as an antigen in the production of monoclonal or polyclonal antibodies to impart broad spectrum passive immunity. In an alternative embodiment, any combination of the variable sequence motif (T/I) (Y/F) (T/V) (F) (T) (D/N) (Y) (V) (D/N) can be used as an immunogen or antigen, or in the preparation of antibodies.

[0029] The ClfB, SdrC, SdrD and SdrE proteins or the consensus or variable motifs thereof are useful as scientific research tools to identify *S. aureus* binding sites on the extracellular matrix. They are further useful as research tools to promote an understanding of the mechanisms of bacterial pathology and the development of antibacterial therapies.

[0030] The ClfB, SdrC, SdrD and SdrE nucleic acid sequences or selected fragments thereof, including the sequences encoding the consensus or variable motifs, are useful as nucleic acid probes for the identification of other *S. aureus* extracellular matrix-binding proteins. Alternatively, the amino acid sequences of the proteins, or selected fragments thereof, can be used as probes to identify the corresponding nucleic acid sequences.

[0031] The ClfB, SdrC, SdrD and SdrE nucleic acid sequences or the sequences encoding the consensus or variable motifs are further useful as polynucleotides which comprise contiguous nucleic acid sequences capable of being expressed. The nucleic acid sequences may be inserted into a vector and placed in a microorganism for the production of recombinant ClfB, SdrC, SdrD and SdrE proteins or the variable or consensus amino acid motifs. This allows for the production of the gene product upon introduction of said polynucleotide into eukaryotic tissues in vivo. The encoded gene product preferably either acts as an immunostimulant or as an antigen capable of generating an immune response. Thus, the nucleic acid sequences in this embodiment encode an MSCRAMM (Microbial Surface Components Recognising Adhesive Matrix Molecules) immunogenic epitope, and optionally a cytokine or a T-cell costimulatory element, such as a member of the B7 family of proteins.

[0032] There are several advantages of immunization with a gene rather than its gene product. The first is the relative simplicity with which native or nearly native antigen can be presented to the immune system. A second advantage of DNA immunization is the potential for the immunogen to enter the MHC class I pathway and evoke a cytotoxic T cell response. Cell-mediated immunity is important in controlling infection. Since DNA immunization can evoke both humoral and cell-mediated immune responses, its greatest advantage may be that it provides a relatively simple method to survey a large number of *S. aureus* genes for their vaccine potential.

[0033] Antibodies immunoreactive with ClfB, SdrC, SdrD and SdrE proteins, or their active fragments, including with the consensus or variable amino acid motifs, are provided

herein. Vaccines or other pharmaceutical compositions containing the proteins or amino acid motifs are additionally provided herein.

[0034] Antibodies and antisera to the consensus TYTFTDYVD sequence epitope or the variable (T/I) (Y/F) (T/V) (F) (T) (D/N) (Y) (V) (D/N) sequence, specifically TYTFTNYVD (SEQ ID NO: 19) in SdrC, TYTFTDYVD (SEQ ID NO: 18) in SdrD and SdrE, TFVFTDYVN (SEQ ID NO: 20) in ClfB or IYTFTDYVN (SEQ ID NO: 21) in ClfA are provided herein. Vaccines or other pharmaceutical compositions containing the epitopes are also provided herein.

[0035] In addition, diagnostic kits containing nucleic acid molecules, the proteins, antibodies or antisera to ClfB, SdrC, SdrD, SdrE or their active fragments, including the consensus or variable amino acid motifs and the appropriate reagents for reaction with a sample are also provided.

[0036] In one embodiment of the invention, the diagnostic kit is used to identify patients or animals that have levels of antibodies to ClfB, ClfA, SdrC, SdrD, or SdrE that are above a population norm. The plasma of the patients or animals can be obtained, processed, and administered to a host in need of passive immunity to *S. aureus* infection.

BRIEF DESCRIPTION OF THE FIGURES

[0037] **FIG. 1** is a schematic representation comparing features of unprocessed ClfA and ClfB proteins. S indicates the signal sequence. A indicates the conserved region (region A). P indicates the proline-rich region (repeats are indicated by gray boxes). R indicates the SD repeat region (region R). W indicates the wall-spanning region. M indicates the membrane spanning and anchoring regions. EF hand I of ClfA and its partial homologue on ClfB are indicated by black vertical bars. The MIDAS motifs are indicated by hatched (DXSXS) and narrow vertical lines (downstream T and D residues) connected by dashed lines.

[0038] **FIG. 2** is a schematic representation of general plasmid and probe constructions for sequencing clfB. A repeat-carrying EcoRI fragment was cloned from phage clone A1-1 into pGEM 7Z (f)+ to give pA1-1E (top), and subsequently reduced by deletion of an XbaI fragment to give pA1-1EX, which contains the entire clfB gene. A SmaI fragment containing clfB and 500 bp of upstream DNA was cloned into pCU1 for overexpression and complementation work (pA1-1EA). The HpaI probe used to screen mutants, and the hybridizing BamHI fragment are also indicated.

[0039] **FIG. 3** is a schematic representation showing construction of a cassette for allele replacement. clfB was interrupted by blunt-end cloning the Tc determinant from pT181 into the HpaI site in the middle of the gene in pA1-1EX. pTS2 was then cloned into the SmaI site of the cassette to enable temperature sensitive propagation in *S. aureus*.

[0040] **FIG. 4** is a schematic representation of a physical map of the sdrC sdrD sdrE locus in *S. aureus* strain Newman. The extents of the plasmid clones are delineated. A6-2 is a LambdaGEM®-12 clone. pEJ1, pEJ2 and pEJ3 are A6-2 fragments subcloned in the pGEM 7Z (f)+(pEJ 1 and pEJ2) and the pBluescript KS+vector (pEJ3). pC1 is a HindIII fragment directly cloned from strain Newman in the pBluescript KS+vector. Arrows indicate the direction of transcription of sdrC, sdrD and sdrE.

[0041] FIG. 5 is the nucleic acid sequence of ClfB and flanking DNA, and amino acid translation of the ORF. The likely start codon is double underlined, and the principal regions indicated using the abbreviations of FIG. 1. Two salient features of region A, the DYSNS (SEQ ID NO: 11) of the putative MIDAS motif, and the sequence FTDYVN (SEQ ID NO: 12), the longest region of identity with ClfB, are underlined. Vertical bars indicate the repeats in the proline-rich region. An inverted repeat specifying a possible transcription termination signal is underlined.

[0042] FIG. 6 is an amino acid sequence alignment of part of region A of the ClfB and ClfA proteins in the region of strongest similarity. EF hand I of ClfA is underlined. Identical residues are denoted by an asterisk; conservative substitutions are denoted by a period. The DXSXS (SEQ ID NO: 13) portion of the MIDAS motif of ClfB is double underlined.

[0043] FIG. 7 is the nucleic acid sequence and amino acid translation of the sdrC gene. The consensus TYTFTDYVD motif, expressed in SdrC as TYTFTNYVD, the EF hands in the B repeats, and the LPXTG (SEQ ID NO: 14) motif are underlined. Major regions, such as the signal sequence (S), region A (A), B repeats (B) region R (R), the wall-spanning domain (W), and the membrane-anchoring domain (M), are indicated.

[0044] FIG. 8 is the nucleic acid sequence and amino acid translation of the sdrD gene. The consensus TYTFTDYVD motif, the EF hands in the B repeats, and the LPXTG motif are underlined. Major regions, such as the signal sequence (S), region A (A), B repeats (B) region R (R), the wall-spanning domain (W), and the membrane-anchoring domain (M), are indicated.

[0045] FIG. 9 is the nucleic acid sequence and amino acid translation of the sdrE gene. The consensus TYTFTDYVD motif, the EF hands in the B repeats, and the LPXTG motif are underlined. Major regions, such as the signal sequence (S), region A (A), B repeats (B) region R (R), the wall-spanning domain (W), and the membrane-anchoring domain (M), are indicated.

[0046] FIG. 10 is a schematic diagram of the region R-containing proteins. Numerals over the proteins denote numbers of amino acids in the regions, numerals under the proteins denote the location on the amino acid sequence of the motifs counted from the beginning of the signal peptide. Abbreviations: S: Signal peptide; A: Region A; B: B repeat; R: Region R; W.M: Wall and membrane spanning regions.

[0047] FIG. 11 is a chart showing similarities between A regions ClfA, ClfB, SdrC, SdrD and SdrE. Each sequence was aligned in pairwise combinations and the percent identical residues given.

[0048] FIG. 12 indicates Clustal™ multiple sequence alignments of areas of similarity of the A and B regions of the region R containing genes of strain Newman. An asterisk denotes identity of amino acids, and a colon represents increasing similarity of polarity and hydrophobicity/hydrophilicity of side chains of amino acids. Alignments 1-4 show areas from region A. Alignments 1,3 and 4 show the common motifs. Alignment 2 shows homology in the vicinity of the ClfA EF-hand (underlined), with the consensus TYTFTDYVD sequence conserved in all five genes. Alignment 5

shows the B repeats of proteins SdrC, SdrD and SdrE with possible EF hands underlined.

[0049] FIG. 13 is a time-course graph of ClfB expression in *S. aureus* Newman versus time, monitored by Western blotting. Shake flask cultures were sampled at specific time intervals. A standard number of cells was used to prepare lysates.

[0050] FIG. 14 is a graph of absorbance versus concentration of ClfA/ClfB comparing the binding of increasing concentrations of biotinylated recombinant region A from ClfA and ClfB to fibrinogen coated plates. Binding to BSA-coated plates is shown as a control. The closed square symbol represents fibrinogen-ClfA; the closed circle symbol represents fibrinogen-ClfB; the open square symbol represents BSA-ClfA; the open circle symbol represents BSA-ClfB.

[0051] FIG. 15 is a graph of cells bound versus fibrinogen concentration showing adherence of *S. aureus* Newman and mutants to fibrinogen immobilized on ELISA plates. Increasing amounts of fibrinogen were used to coat the plates, and a fixed concentration of cells from exponential phase cultures were added. The square symbol represents wild-type; the diamond symbol represents ClfA; the circle symbol represents clfB; the triangle symbol represents clfA-clfB; the x symbol represents clfAclfB,clfB⁺.

[0052] FIG. 16 is a graph of cells bound versus fibrinogen concentration showing adherence of *S. aureus* Newman and mutants to fibrinogen immobilized on ELISA plates. Increasing amounts of fibrinogen were used to coat the plates, and a fixed concentration of cells from stationary phase cultures added. The square symbol represents wild-type; the diamond symbol represents clfA; the circle symbol represents clfB; the triangle symbol represents clfAclfB; the x symbol represents clfAclfB,clfB⁺.

[0053] FIG. 17 is a graph of cells bound versus IgG concentration showing effects of preincubation with anti-ClfB IgG on adherence of *S. aureus* Newman and mutants to immobilized fibrinogen. The square symbol represents wild-type; the diamond symbol represents ClfA; the circle symbol represents clfB; the x symbol represents clfAclfB,clfB⁺.

[0054] FIG. 18 is a bar graph showing adherence of *S. aureus* Newman and mutants to explanted hemodialysis tubing. Cells from two hour shake-flask cultures were used. The graph provides the means and SEM of three experiments.

[0055] FIG. 19 is a bar graph showing adherence of *S. aureus* Newman and mutants to fibrinogen immobilized on PMMA (polymethylmethacrylate) coverslips. Cells from two hour shake-flask cultures were used. The graph provides the means and SEM of three experiments.

[0056] FIG. 20 is a table which shows the highly conserved amino acid sequences in the A region of ClfA, ClfB, SdrC, SdrD and SdrE, which are used to provide consensus and variable motifs.

[0057] FIG. 21 is a graph of absorbance versus concentration of anti-TYTFTDYVD antibodies, demonstrating the binding of increasing concentrations of the antibodies to ClfA, ClfB or BSA coated plates. BSA-coated plates are used as a control, and no significant binding is observed. The

closed square symbol represents antibody bound to ClfB; the open diamond symbol represents antibody bound to ClfA; the open circle symbol represents BSA.

[0058] **FIG. 22** is a Western Blot which illustrates the differing specificities of ClfA and ClfB in the binding of human fibrinogen. The Western Blot was created by the separation of human fibrinogen, and later, the incubation of the nitrocellulose membrane with the A region of either biotinylated ClfA or ClfB. Biotinylated ClfA region A binds the γ chain of fibrinogen, as is seen in lane A2. Biotinylated ClfB region A binds to both the α and β chains of fibrinogen, as seen in lane B2.

[0059] **FIG. 23** is a bar graph showing adherence of recombinant SdrC region A (SdrCA) to ten different extracellular matrix proteins, BSA, BSP, two forms of collagen, decorin, fibrinogen, fibronectin, laminin, plasmin and vitronectin. The extracellular matrix proteins were immobilized on microtiter wells. Absorbance tests revealed reactivity of SdrCA with fibrinogen, BSP, decorin, plasmin and vitronectin.

DETAILED DESCRIPTION OF THE INVENTION

[0060] Isolated extracellular matrix-binding proteins, designated ClfB, SdrC, SdrD and SdrE, and their corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of *S. aureus* infection and as scientific research tools. Further, antibody or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of *S. aureus* infection. In particular, the proteins or antibodies, or active fragments thereof may be administered as vaccines to induce either passive or cellular immunity.

[0061] ClfB binds to at least fibrinogen.

[0062] SdrC has been discovered to bind to extracellular matrix proteins of the host, including for example, BSP, decorin, plasmin, vitronectin and fibrinogen. SdrD binds to at least vitronectin. SdrE binds to extracellular matrix proteins, for example, bone sialoprotein (BSP).

[0063] The amino acid sequence of ClfB is SEQ ID NO: 1. The nucleic acid sequence encoding ClfB is SEQ ID NO:2. The nucleic acid and amino acid sequences of ClfB are also provided in **FIG. 5**. The amino acid and nucleic acid sequences of SdrC are SEQ ID NOS:3 and 4 respectively and are provided in **FIG. 7**. The amino acid and nucleic acid sequences of SdrD are SEQ ID NOS:5 and 6 respectively and are provided in **FIG. 8**. The amino acid and nucleic acid sequences of SdrE are SEQ ID NOS:7 and 8 respectively and are provided in **FIG. 9**. The term "isolated" is defined herein as free from at least some of the components with which it naturally occurs. In a preferred embodiment, an isolated component is at least 90% pure, and more preferably 95% .

[0064] ClfB has a predicted molecular weight of approximately 88 kDa and an apparent molecular weight of approximately 124 kDa. ClfB is a cell-wall associated protein and binds both soluble and immobilized fibrinogen. In addition, ClfB binds both the alpha and beta chains of fibrinogen and

acts as a clumping factor. Despite the low level of identity between ClfA and ClfB, both proteins bind fibrinogen (on different chains) by a mechanism that is susceptible to inhibition by divalent cations, despite not sharing obvious metal binding motifs. The ClfB protein has been demonstrated to be a virulence factor in experimental endocarditis.

[0065] The SdrC, SdrD and SdrE proteins are related in primary sequence and structural organization to the ClfA and ClfB proteins and are localized on the cell surface. The SdrC, SdrD and SdrE proteins are cell wall-associated proteins, having a signal sequence at the N-terminus and an LPXTG motif, hydrophobic domain and positively charged residues at the C-terminus. Each also has an SD repeat containing region R of sufficient length to allow, along with the B motifs, efficient expression of the ligand binding domain region A on the cell surface. With the A region of the SdrC, SdrD and SdrE proteins located on the cell surface, the proteins can interact with proteins in plasma, the extracellular matrix or with molecules on the surface of host cells. The Sdr proteins share some limited amino acid sequence similarity with ClfA and ClfB. Like ClfA and ClfB, SdrC, SdrD and SdrE also exhibit cation-dependent ligand binding of extracellular matrix proteins.

[0066] It was surprising to learn that the disclosed extracellular matrix-binding proteins share a unique dipeptide repeat region (region R) including predominately aspartate and serine residues. It had been reported by McDevitt et al., *Mol. Microbiol.* 11: 237-248 (1994); McDevitt et al., *Mol. Microbiol.* 16:895-907 (1995) that ClfA also has this R repeat region. He reported that there were genes in *S. epidermidis* that hybridized to the gene encoding the R domain containing protein. However, McDevitt et al did not know the function of the R region and had not discovered that other cell surface proteins from *S. aureus*, *S. hemolyticus*, *S. lugdenensis*, *S. schleriferi* share this unusual motif. Therefore, in one aspect of this invention, a method is provided for the identification of genes and encoding proteins from *S. aureus* (other than ClfA), *S. hemolyticus*, *S. lugdenensis*, *S. schleriferi* useful for the prevention, treatment, and diagnosis of bacterial infection that includes using the R repeat region as an identifying probe.

[0067] The DS repeat is encoded by 18 nucleotide repeats with the consensus (where Y equals pyrimidines and N equals any base) GAYTCNGAYT CNGAYAGY, with TCN as the first and second serine codons and AGY as the third serine codon. The R region is near the C-terminus of the proteins and typically contains between 40 and 300 DS residues, or more particularly, greater than 40, 60, 80, 100, 125, 150, 200 or 250 repeating units, of which greater than 90, 95 or even 98% of the amino acids are D or S. The R region DS repeat varies in length between proteins, and while the R region itself does not bind extracellular matrix proteins, the R region enables the presentation of the binding regions of the protein on the cell surface of *S. aureus*. Thus, probes to the consensus DNA encoding the DS repeat (see above) can be used to identify other genes encoding different binding proteins essential to the attachment of *S. aureus* to host tissues. Antibodies to an R region can be used to discover such additional binding proteins as well.

[0068] The sdr genes are closely linked and tandemly arrayed. The Sdr proteins have both organizational and sequence similarity to ClfA and ClfB. At the N-terminus

secretory signal sequences precede A regions which are approximately 500 residues in length. The A regions of the Sdr and Clf proteins exhibit only 20-30% residue identity when aligned with any other member of the family.

[0069] It has been discovered that in the A region of SdrC, SdrD, SdrE, ClfA, and ClfB, there is highly conserved amino acid sequence that can be used to derive a consensus TYTFTDYVD motif. The motif exhibits slight variation between the different proteins. This variation, along with the consensus sequence of the motif is depicted in FIG. 20. In the Clf-Sdr proteins, this motif is highly conserved. The motif can be used in vaccines to impart broad spectrum cellular immunity to bacterial infections, and also can be used as an antigen in the production of monoclonal or polyclonal antibodies. Such an antibody can be used to impart broad spectrum passive immunity.

[0070] The Sdr proteins differ from ClfA and ClfB by having two to five additional 110-113 residue repeated sequences (B-motifs) located between region A and the R-region. Each B-motif contains a consensus Ca^{2+} -binding EF-hand loop normally found in eukaryotic proteins. The structural integrity of a recombinant protein comprising the five B-repeats of SdrD was shown by bisANS fluorescence analysis to be Ca^{2+} -dependent, suggesting that the EF-hands are functional. When Ca^{2+} was removed the structure collapsed to an unfolded conformation. The original structure was restored by addition of Ca^{2+} . The C-terminal R-domains of the Sdr proteins contain 132-170 SD residues. These are followed by conserved wall-anchoring regions characteristic of many surface proteins of Gram positive bacteria. The sdr locus was present in all 31 *S. aureus* strains from human and bovine sources tested by Southern hybridization, although in a few strains it contained two rather than three genes.

[0071] In the Sdr and Clf proteins this B motif is highly conserved while a degenerate version occurs in fibronectin binding MSCRAMMS, as well as the collagen binding protein Cna. The B motifs, in conjunction with the R regions, are necessary for displaying the ligand-binding domain at some distance from the cell surface.

[0072] The repeated B motifs are one common denominator of the sub-group of SD repeat proteins described herein. These motifs are found in different numbers in the three Sdr proteins from strain Newman. There are clear distinctions between the individual B motifs. The most conserved units are those located adjacent to the R regions (SdrC B2, SdrD B5 and SdrE B3). They differ from the rest at several sites, especially in the C-terminal half. A noteworthy structural detail is that adjacent B repeats are always separated by a proline residue present in the C-terminal region, but a proline never occurs between the last B repeats and the R region. Instead this linker is characterized by a short acidic stretch. These differences are evidence that the end units have a different structural or functional role compared to the other B motifs. The N-terminal B motifs of SdrD and SdrE have drifted apart from the others, and there are numerous amino acid alterations, including small insertions and deletions whereas the remaining internal B motifs are more highly conserved. Note that each of the three Sdr proteins has at least one B motif of each kind.

[0073] The C-terminal R-domains of the Sdr proteins contain 132-170 SD residues. These are followed by conserved wall-anchoring regions characteristic of many surface proteins of Gram positive bacteria.

[0074] ClfB, SdrC, SdrD and SdrE subdomains are shown in FIG. 10 and, depending on the protein, include subdomains A and B1-B5.

[0075] The terms ClfB protein, SdrC protein, SdrD protein and SdrE protein are defined herein to include ClfB, SdrC, SdrD and SdrE subdomains, and active or antigenic fragments of ClfB, SdrC, SdrD and SdrE proteins, such as consensus or variable sequence amino acid motifs. Active fragments of ClfB, SdrC, SdrD, SdrE and consensus or variable sequence amino acid motifs peptides or proteins are defined herein as peptides or polypeptides capable of blocking the binding of *S. aureus* to extracellular matrix proteins. Antigenic fragments of ClfB, SdrC, SdrD, SdrE proteins or the consensus or variable amino acid motifs are defined herein as peptides or polypeptides capable of producing an immunological response.

[0076] Nucleic Acid Sequences

[0077] The nucleic acid sequences encoding ClfB, SdrC, SdrD, SdrE and the consensus or variable sequence amino acid motifs are useful for the production of recombinant extracellular matrix-binding proteins. They are further useful as nucleic acid probes for the detection of *S. aureus*-binding proteins in a sample or specimen with high sensitivity and specificity. The probes can be used to detect the presence of *S. aureus* in the sample, diagnose infection with the disease, quantify the amount of *S. aureus* in the sample, or monitor the progress of therapies used to treat the infection. The nucleic acid and amino acid sequences are also useful as laboratory research tools to study the organism and the disease, thus furthering the development of therapies and treatments for the disease.

[0078] It will be understood by those skilled in the art that ClfB, SdrC, SdrD, SdrE and the consensus or variable sequence amino acid motifs are also encoded by sequences substantially similar to the nucleic acid sequences provided in the sequence listing. By "substantially similar" is meant a DNA sequence which, by virtue of the degeneracy of the genetic code, is not identical with that shown in any of SEQ ID NOS:2, 4, 6, and 8, but which still encodes the same amino acid sequence; or a DNA sequence which encodes a different amino acid sequence but retains the activities of the proteins, either because one amino acid is replaced with another similar amino acid, or because the change (whether it be substitution, deletion or insertion) does not affect the active site of the protein. In the latter case, the sequence has substantial homology to the disclosed sequence if it encodes a protein with at least 70% 80%, 90%, 95% or even 98% of the same amino acids.

[0079] Also provided herein are sequences of nucleic acid molecules that selectively hybridize with nucleic acid molecules encoding the extracellular matrix-binding proteins from *S. aureus* described herein or complementary sequences thereof. By "selective" or "selectively" is meant a sequence which does not hybridize with other nucleic acids to prevent adequate detection of ClfB, SdrC, SdrD, SdrE or the consensus or variable sequence amino acid motifs. Therefore, in the design of hybridizing nucleic acids, selectivity will depend upon the other components present in a sample. The hybridizing nucleic acid should have at least 70% complementarity with the segment of the nucleic acid to which it hybridizes. As used herein to describe nucleic acids, the term "selectively hybridizes" excludes the occasional randomly

hybridizing nucleic acids, and thus, has the same meaning as “specifically hybridizing”. The selectively hybridizing nucleic acids of the invention can have at least 70%, 80%, 85%, 90%, 95%, 97%, 98%, and 99% complementarity with the segment of the sequence to which it hybridizes.

[0080] The invention contemplates sequences, probes and primers which selectively hybridize to the encoding DNA or the complementary, or opposite, strand of DNA as those specifically provided herein. Specific hybridization with nucleic acid can occur with minor modifications or substitutions in the nucleic acid, so long as functional species-specific hybridization capability is maintained. By “probe” is meant nucleic acid sequences that can be used as probes or primers for selective hybridization with complementary nucleic acid sequences for their detection or amplification, which probes can vary in length from about 5 to 100 nucleotides, or preferably from about 10 to 50 nucleotides, or most preferably about 18-24 nucleotides. Therefore, the terms “probe” or “probes” as used herein are defined to include “primers”. Isolated nucleic acids are provided herein that selectively hybridize with the species-specific nucleic acids under stringent conditions and should have at least 5 nucleotides complementary to the sequence of interest as described by Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. *MOLECULAR CLONING: A LABORATORY MANUAL*, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.

[0081] If used as primers, the composition preferably includes at least two nucleic acid molecules which hybridize to different regions of the target molecule so as to amplify a desired region. Depending on the length of the probe or primer, the target region can range between 70% complementary bases and full complementarity and still hybridize under stringent conditions. For example, for the purpose of diagnosing the presence of the *S. aureus*, the degree of complementarity between the hybridizing nucleic acid (probe or primer) and the sequence to which it hybridizes (e.g., *S. aureus* DNA from a sample) is at least enough to distinguish hybridization with a nucleic acid from other bacteria.

[0082] The nucleic acid sequences encoding ClfB, SdrC, SdrD, SdrE active fragments thereof or consensus or variable sequence amino acid motifs can be inserted into a vector, such as a plasmid, and recombinantly expressed in a living organism to produce recombinant ClfB, SdrC, SdrD and SdrE proteins or fragments thereof, such as consensus or variable sequence amino acid motifs. For example, DNA molecules producing recombinant ClfB, SdrC, and both SdrD and SdrE were deposited in plasmids pA1-1EX, pC1 and lambda phage A6-2, respectively, at the NCIMB under the Accession Nos. 40903, 40902 and 40904, respectively on Oct. 13, 1997.

[0083] Methods for the Detection and Identification of *S. aureus*

[0084] Methods of using the nucleic acids described herein to detect and identify the presence of *S. aureus* are provided. The methods are useful for diagnosing *S. aureus* infections and disease such as upper respiratory tract infections (such as otitis media, bacterial tracheitis, acute epiglottitis, thyroiditis), lower respiratory infections (such as emphysema, lung abscess), cardiac (such as infective endocarditis), gastrointestinal (such as secretory diarrhea,

splenic abscess, retroperitoneal abscess), central nervous system (such as cerebral abscess), ocular (such as blepharitis, conjunctivitis, keratitis, endophthalmitis, preseptal and orbital cellulitis, dacryocystitis), kidney and urinary tract (such as epididymitis, intrarenal and perinephric abscess, toxic shock syndrome), skin (such as impetigo, folliculitis, cutaneous abscesses, cellulitis, wound infection, bacterial myositis, bone and joint (such as septic arthritis, osteomyelitis).

[0085] The method involves the steps of obtaining a sample suspected of containing *S. aureus*. The sample may be taken from an individual, such as a wound, blood, saliva, tissues, bone, muscle, cartilage, or skin. The cells can then be lysed, and the DNA extracted, precipitated and amplified. Detection of *S. aureus* DNA is achieved by hybridizing the amplified DNA with a *S. aureus* probe that selectively hybridizes with the DNA as described above. Detection of hybridization is indicative of the presence of *S. aureus*.

[0086] Preferably, detection of nucleic acid (e.g. probes or primers) hybridization can be facilitated by the use of detectable moieties. For example, the probes can be labeled with biotin and used in a streptavidin-coated microtiter plate assay. Other detectable moieties include radioactive labeling, enzyme labeling, and fluorescent labeling, for example.

[0087] DNA may be detected directly or may be amplified enzymatically using polymerase chain reaction (PCR) or other amplification techniques prior to analysis. RNA or cDNA can be similarly detected. Increased or decreased expression of ClfB, SdrC, SdrD, SdrE and consensus or variable sequence amino acid motifs can be measured using any of the methods well known in the art for the quantitation of nucleic acid molecules, such as, amplification, PCR, RT-PCR, RNase protection, Northern blotting, and other hybridization methods.

[0088] Diagnostic assays which test for the presence of the ClfB or SdrC, SdrD or SdrE proteins, peptides, motifs, fragments thereof or antibodies to any of these may also be used to detect the presence of an infection. Assay techniques for determining protein or antibody levels in a sample are well known to those skilled in the art and include methods such as radioimmunoassay, Western blot analysis and ELISA (Enzyme-Linked Immunosorbant Assay) assays.

[0089] Amino Acid Sequences

[0090] It will be understood by those skilled in the art that minor amino acid substitutions or deletions may be present in functional ClfB, SdrC, SdrD, SdrE and consensus or variable sequence amino acid motifs, peptides, proteins, or fragments thereof. The amino acid sequences set forth herein and substantially similar amino acid sequences can be used to produce synthetic ClfB, SdrC, SdrD, SdrE and consensus or variable sequence amino acid motifs, peptides, proteins or active fragments thereof. Active ClfB, SdrC, SdrD, SdrE or consensus or variable sequence amino acid motifs, peptide or protein fragments are defined herein as ClfB, SdrC, SdrD, SdrE or consensus or variable sequence amino acid motifs, portions or peptides that bind to extracellular matrix proteins or compete with or prevent *S. aureus* organisms from binding to extracellular matrix proteins such as decorin, plasmin, fibrinogen, vitronectin or bone sialoprotein.

[0091] When used in conjunction with amino acid sequences, the term “substantially similar” means an amino

acid sequence which is not identical to SEQ ID NOS:1, 3, 5, or 7, but which produces a protein having the same functionality and retaining the activities of ClfB, SdrC, SdrD, SdrE and consensus or variable sequence amino acid motifs, either because one amino acid is replaced with another similar amino acid, or because the change (whether it be substitution, deletion or insertion) does not affect the active site of the protein or peptide. Two amino acid sequences are “substantially homologous” when at least about 70%, (preferably at least about 80%, and most preferably at least about 90% or 95%) of the amino acids match over the defined length of the sequences.

[0092] Extracellular Matrix-Binding Protein Antibodies

[0093] The isolated, recombinant or synthetic ClfB, SdrC, SdrD, SdrE or consensus or variable sequence amino acid motifs, or peptides or active fragments thereof or fusion proteins thereof, are useful as scientific research tools to identify *S. aureus* binding sites on the extracellular matrix. This will promote an understanding of the mechanisms of bacterial pathology and the development of antibacterial therapies. Furthermore, the isolated, recombinant or synthetic protein, or antigenic portions thereof (including epitope-bearing fragments), or fusion proteins thereof can be administered to humans or animals as immunogens or antigens. It can be administered alone or in combination with an adjuvant, for the production of antisera reactive with ClfB, SdrC, SdrD, SdrE or motifs or peptides thereof. In addition, the peptides or proteins can be used to screen antisera for hyperimmune patients from whom can be derived antibodies having a very high affinity for the proteins.

[0094] Antibodies isolated from the antisera are useful for the specific detection of *S. aureus* or *S. aureus* extracellular matrix-binding proteins or as research tools. The term “antibodies” as used herein includes monoclonal antibodies, polyclonal, chimeric, single chain, bispecific, simianized, and humanized antibodies as well as Fab fragments, including the products of an Fab immunoglobulin expression library.

[0095] Monoclonal antibodies are generated by methods well known to those skilled in the art. The preferred method is a modified version of the method of Kearney, et al., *J. Immunol.* 123:1548-1558 (1979), which is incorporated by reference herein. Briefly, animals such as mice or rabbits are inoculated with the immunogen in adjuvant, and spleen cells are harvested and mixed with a myeloma cell line, such as P3X63Ag8,653. The cells are induced to fuse by the addition of polyethylene glycol. Hybridomas are chemically selected by plating the cells in a selection medium containing hypoxanthine, aminopterin and thymidine (HAT). Hybridomas producing the preferred antibodies are cloned, expanded and stored frozen for future production.

[0096] Techniques for the production of single chain antibodies are known to those skilled in the art and described in U.S. Pat. No. 4,946,778 and can be used to produce single chain antibodies to the proteins described herein. Phage display technology may be used to select antibody genes having binding activities for ClfB, SdrC, SdrD, SdrE, and consensus or variable sequence amino acid motifs, or antigenic portions thereof, from PCR-amplified v genes of lymphocytes from humans screened for having antibodies to ClfB, SdrC, SdrD, SdrE or consensus or variable sequence

amino acid motifs or naive libraries. Bispecific antibodies have two antigen binding domains wherein each domain is directed against a different epitope.

[0097] The antibody may be labeled directly with a detectable label for identification and quantitation of *S. aureus*. Labels for use in immunoassays are generally known to those skilled in the art and include enzymes, radioisotopes, and fluorescent, luminescent and chromogenic substances including colored particles such as colloidal gold and latex beads. Suitable immunoassays include enzyme-linked immunosorbent assays (ELISA).

[0098] Alternatively, the antibody may be labeled indirectly by reaction with labeled substances that have an affinity for immunoglobulin, such as protein A or G or second antibodies. The antibody may be conjugated with a second substance and detected with a labeled third substance having an affinity for the second substance conjugated to the antibody. For example, the antibody may be conjugated to biotin and the antibody-biotin conjugate detected using labeled avidin or streptavidin. Similarly, the antibody may be conjugated to a hapten and the antibody-hapten conjugate detected using labeled anti-hapten antibody. These and other methods of labeling antibodies and assay conjugates are well known to those skilled in the art.

[0099] Antibodies to the disclosed proteins may also be used in production facilities or laboratories to isolate additional quantities of the protein, such as by affinity chromatography.

[0100] The proteins, or antigenic portions thereof, are useful in the diagnosis of *S. aureus* bacterial infections and in the development of anti-*S. aureus* vaccines for active or passive immunization. When administered to a wound or used to coat polymeric biomaterials in vitro and in vivo, both the proteins and antibodies thereof are useful as blocking agents to prevent or inhibit the initial binding of *S. aureus* to the wound site or biomaterials. Preferably, the antibody is modified so that it is less immunogenic in the patient to whom it is administered. For example, if the patient is a human, the antibody may be “humanized” by transplanting the complementarily determining regions of the hybridoma-derived antibody into a human monoclonal antibody as described by Jones et al., *Nature* 321:522-525 (1986) or Tempest et al. *Biotechnology* 9:266-273 (1991).

[0101] Medical devices or polymeric biomaterials to be coated with the antibodies, proteins and active fragments described herein include, but are not limited to, staples, sutures, replacement heart valves, cardiac assist devices, hard and soft contact lenses, intraocular lens implants (anterior chamber, posterior chamber or phakic), other implants such as corneal inlays, kerato-prostheses, vascular stents, epikeratophalia devices, glaucoma shunts, retinal staples, scleral buckles, dental prostheses, thyroplastic devices, laryngoplastic devices, vascular grafts, soft and hard tissue prostheses including, but not limited to, pumps, electrical devices including stimulators and recorders, auditory prostheses, pacemakers, artificial larynx, dental implants, mammary implants, penile implants, cranio/facial tendons, artificial joints, tendons, ligaments, menisci, and disks, artificial bones, artificial organs including artificial pancreas, artificial hearts, artificial limbs, and heart valves; stents, wires, guide wires, intravenous and central venous catheters, laser and balloon angioplasty devices, vascular and heart devices

(tubes, catheters, balloons), ventricular assists, blood dialysis components, blood oxygenators, urethral/ureteral/urinary devices (Foley catheters, stents, tubes and balloons), airway catheters (endotracheal and tracheostomy tubes and cuffs), enteral feeding tubes (including nasogastric, intragastric and jejunal tubes), wound drainage tubes, tubes used to drain the body cavities such as the pleural, peritoneal, cranial, and pericardial cavities, blood bags, test tubes, blood collection tubes, vacutainers, syringes, needles, pipettes, pipette tips, and blood tubing.

[0102] It will be understood by those skilled in the art that the term “coated” or “coating”, as used herein, means to apply the protein, antibody, or active fragment to a surface of the device, preferably an outer surface that would be exposed to *S. aureus* infection. The surface of the device need not be entirely covered by the protein, antibody or active fragment.

[0103] Immunological and Pharmaceutical Compositions

[0104] Immunological compositions, including vaccine, and other pharmaceutical compositions containing the ClfB, SdrC, SdrD, SdrE or consensus or variable sequence amino acid motif, peptides or proteins are included within the scope of the present invention. One or more of the ClfB, SdrC, SdrD, SdrE or consensus or variable sequence amino acid motif, peptides, proteins, or active or antigenic fragments thereof, or fusion proteins thereof can be formulated and packaged, alone or in combination with other antigens, using methods and materials known to those skilled in the art for vaccines. The immunological response may be used therapeutically or prophylactically and may provide antibody immunity or cellular immunity such as that produced by T lymphocytes such as cytotoxic T lymphocytes or CD4⁺ T lymphocytes.

[0105] The immunological compositions, such as vaccines, and other pharmaceutical compositions can be used alone or in combination with other blocking agents to protect against human and animal infections caused by *S. aureus*. In particular, the compositions can be used to protect humans against endocarditis or to protect humans or ruminants against mastitis caused by *S. aureus* infections. The vaccine can also be used to protect canine and equine animals against similar *S. aureus* infections.

[0106] To enhance immunogenicity, the proteins may be conjugated to a carrier molecule. Suitable immunogenic carriers include proteins, polypeptides or peptides such as albumin, hemocyanin, thyroglobulin and derivatives thereof, particularly bovine serum albumin (BSA) and keyhole limpet hemocyanin (KLH), polysaccharides, carbohydrates, polymers, and solid phases. Other protein derived or non-protein derived substances are known to those skilled in the art. An immunogenic carrier typically has a molecular weight of at least 1,000 daltons, preferably greater than 10,000 daltons. Carrier molecules often contain a reactive group to facilitate covalent conjugation to the hapten. The carboxylic acid group or amine group of amino acids or the sugar groups of glycoproteins are often used in this manner. Carriers lacking such groups can often be reacted with an appropriate chemical to produce them. Preferably, an immune response is produced when the immunogen is injected into animals such as mice, rabbits, rats, goats, sheep, guinea pigs, chickens, and other animals, most preferably mice and rabbits. Alternatively, a multiple antigenic

peptide comprising multiple copies of the protein or polypeptide, or an antigenically or immunologically equivalent polypeptide may be sufficiently antigenic to improve immunogenicity without the use of a carrier.

[0107] The ClfB, SdrC, SdrD, SdrE or consensus or variable sequence amino acid motif, peptide, protein or proteins may be administered with an adjuvant in an amount effective to enhance the immunogenic response against the conjugate. At this time, the only adjuvant widely used in humans has been alum (aluminum phosphate or aluminum hydroxide). Saponin and its purified component Quil A, Freund's complete adjuvant and other adjuvants used in research and veterinary applications have toxicities which limit their potential use in human vaccines. However, chemically defined preparations such as muramyl dipeptide, monophosphoryl lipid A, phospholipid conjugates such as those described by Goodman-Snitkoff et al. *J. Immunol.* 147:410-415 (1991) and incorporated by reference herein, encapsulation of the conjugate within a proteoliposome as described by Miller et al., *J. Exp. Med.* 176:1739-1744 (1992) and incorporated by reference herein, and encapsulation of the protein in lipid vesicles such as NovasomeTM lipid vesicles (Micro Vesicular Systems, Inc., Nashua, N.H.) may also be useful.

[0108] The term “vaccine” as used herein includes DNA vaccines in which the nucleic acid molecule encoding ClfB, SdrC, SdrD, SdrE and consensus or variable sequence amino acid motifs, or nucleic acid molecules which are not identical to the disclosed sequences, but which are substantially homologous thereto and encode peptides or proteins which have the same functionality and activities, or antigenic portions thereof in a pharmaceutical composition is administered to a patient. For genetic immunization, suitable delivery methods known to those skilled in the art include direct injection of plasmid DNA into muscles (Wolff et al., *Hum. Mol. Genet.* 1:363 (1992)), delivery of DNA complexed with specific protein carriers (Wu et al., *J. Biol. Chem.* 264:16985 (1989), coprecipitation of DNA with calcium phosphate (Benvenisty and Reshef, *Proc. Natl. Acad. Sci.* 83:9551 (1986)), encapsulation of DNA in liposomes (Kaneda et al., *Science* 243:375 (1989)), particle bombardment (Tang et al., *Nature* 356:152 (1992) and Eisenbraun et al., *DNA Cell Biol.* 12:791 (1993)), and in vivo infection using cloned retroviral vectors (Seeger et al., *Proc. Natl. Acad. Sci.* 81:5849, 1984).

[0109] Methods of Administration and Dose of Pharmaceutical Compositions

[0110] Pharmaceutical compositions containing the ClfB, SdrC, SdrD or SdrE proteins, nucleic acid molecules, antibodies, or fragments thereof may be formulated in combination with a pharmaceutical carrier such as saline, dextrose, water, glycerol, ethanol, other therapeutic compounds, and combinations thereof. The formulation should be appropriate for the mode of administration. The compositions are useful for interfering with, modulating, or inhibiting *S. aureus* host cell binding interactions with the extracellular matrix.

[0111] Suitable methods of administration include, but are not limited to, topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal and intradermal administration.

[0112] For topical administration, the composition is formulated in the form of an ointment, cream, gel, lotion, drops

(such as eye drops and ear drops), or solution (such as mouthwash). Wound or surgical dressings, sutures and aerosols may be impregnated with the composition. The composition may contain conventional additives, such as preservatives, solvents to promote penetration, and emollients. Topical formulations may also contain conventional carriers such as cream or ointment bases, ethanol, or oleyl alcohol.

[0113] In a preferred embodiment, a vaccine is packaged in a single dosage for immunization by parenteral (i.e., intramuscular, intradermal or subcutaneous) administration or nasopharyngeal (i.e., intranasal) administration. The vaccine is most preferably injected intramuscularly into the deltoid muscle. The vaccine is preferably combined with a pharmaceutically acceptable carrier to facilitate administration. The carrier is usually water or a buffered saline, with or without a preservative. The vaccine may be lyophilized for resuspension at the time of administration or in solution.

[0114] The carrier to which the protein may be conjugated may also be a polymeric delayed release system. Synthetic polymers are particularly useful in the formulation of a vaccine to effect the controlled release of antigens. For example, the polymerization of methyl methacrylate into spheres having diameters less than one micron has been reported by Kreuter, J., MICROCAPSULES AND NANOPARTICLES IN MEDICINE AND PHARMACOLOGY, M. Donbrow (Ed). CRC Press, p. 125-148.

[0115] Microencapsulation of the protein will also give a controlled release. A number of factors contribute to the selection of a particular polymer for microencapsulation. The reproducibility of polymer synthesis and the microencapsulation process, the cost of the microencapsulation materials and process, the toxicological profile, the requirements for variable release kinetics and the physicochemical compatibility of the polymer and the antigens are all factors that must be considered. Examples of useful polymers are polycarbonates, polyesters, polyurethanes, polyorthoesters, polyamides, poly (d,l-lactide-co-glycolide) (PLGA) and other biodegradable polymers. The use of PLGA for the controlled release of antigen is reviewed by Eldridge, J. H., et al. CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, 146:59-66 (1989).

[0116] One typical dose for human administration is from 0.01 mg/kg to 10 mg/kg. Based on this range, equivalent dosages for heavier body weights can be determined. The dose should be adjusted to suit the individual to whom the composition is administered and will vary with age, weight and metabolism of the individual. The vaccine may additionally contain stabilizers such as thimerosal (ethyl(2-mercaptobenzoate-S)mercury sodium salt) (Sigma Chemical Company, St. Louis, Mo.) or physiologically acceptable preservatives.

[0117] Protein-Label Conjugates

[0118] When labeled with a detectable biomolecule or chemical, the extracellular matrix-binding proteins described herein are useful for purposes such as in vivo and in vitro diagnostics and laboratory research. Various types of labels and methods of conjugating the labels to the proteins are well known to those skilled in the art. Several specific labels are set forth below. The labels are particularly useful when conjugated to a protein such as an antibody or receptor.

[0119] For example, the protein can be conjugated to a radiolabel such as, but not restricted to, ^{32}P , ^3H , ^{14}C , ^{35}S , ^{125}I , or ^{131}I . Detection of a label can be by methods such as scintillation counting, gamma ray spectrometry or autoradiography.

[0120] Bioluminescent labels, such as derivatives of firefly luciferin, are also useful. The bioluminescent substance is covalently bound to the protein by conventional methods, and the labeled protein is detected when an enzyme, such as luciferase, catalyzes a reaction with ATP causing the bioluminescent molecule to emit photons of light.

[0121] Fluorogens may also be used to label proteins. Examples of fluorogens include fluorescein and derivatives, phycoerythrin, allo-phycoyanin, phycoyanin, rhodamine, and Texas Red. The fluorogens are generally detected by a fluorescence detector.

[0122] The protein can alternatively be labeled with a chromogen to provide an enzyme or affinity label. For example, the protein can be biotinylated so that it can be utilized in a biotin-avidin reaction, which may also be coupled to a label such as an enzyme or fluorogen. For example, the protein can be labeled with peroxidase, alkaline phosphatase or other enzymes giving a chromogenic or fluorogenic reaction upon addition of substrate. Additives such as 5-amino-2,3-dihydro-1,4-phthalazinedione (also known as LuminolTM) (Sigma Chemical Company, St. Louis, Mo.) and rate enhancers such as p-hydroxybiphenyl (also known as p-phenylphenol) (Sigma Chemical Company, St. Louis, Mo.) can be used to amplify enzymes such as horseradish peroxidase through a luminescent reaction; and luminogenic or fluorogenic dioxetane derivatives of enzyme substrates can also be used. Such labels can be detected using enzyme-linked immunoassays (ELISA) or by detecting a color change with the aid of a spectrophotometer. In addition, proteins may be labeled with colloidal gold for use in immunoelectron microscopy in accordance with methods well known to those skilled in the art.

[0123] The location of a ligand in cells can be determined by labeling an antibody as described above and detecting the label in accordance with methods well known to those skilled in the art, such as immunofluorescence microscopy using procedures such as those described by Warren and Nelson, *Mol. Cell. Biol.* 7: 1326-1337 (1987).

[0124] Screening Methods

[0125] The ClfB, SdrC, SdrD and SdrE proteins, or fragments thereof, such as consensus or variable amino acid motifs, are useful in a method for screening materials to identify substances that inhibit *S. aureus* host cell binding interactions with the extracellular matrix. In accordance with the method for screening, the substance of interest is combined with one or more of the ClfB, SdrC, SdrD, or SdrE proteins, or fragments thereof, such as consensus or variable sequence amino acid motif peptides, and the degree of binding of the molecule to the extracellular matrix is measured or observed. If the presence of the substance results in the inhibition of binding, then the substance may be useful for inhibiting *S. aureus* in vivo or in vitro. The method could similarly be used to identify substances that promote *S. aureus* interactions with the extracellular matrix.

[0126] The method is particularly useful for identifying substances having bacteriostatic or bacteriocidal properties.

[0127] For example, to screen for *S. aureus* agonists or antagonists, a synthetic reaction mixture, a cellular compartment (such as a membrane, cell envelope or cell wall) containing one or more of the ClfB, SdrC, SdrD, SdrE proteins, or fragments thereof, such as consensus or variable sequence amino acid motifs, and a labeled substrate or ligand of the protein is incubated in the presence of a substance under investigation. The ability of the substance to agonize or antagonize the protein is shown by a decrease in the binding of the labeled ligand or decreased formation of substrate product. Substances that bind well and increase the rate of product formation from substrate are agonists. Detection of the rate or level of formation of product from substrate may be enhanced by use of a reporter system, such as a calorimetric labeled substrate converted to product, a reporter gene that is responsive to changes in ClfB, SdrC, SdrD, SdrE or consensus or variable amino acid sequence motifs' nucleic acid or protein activity, and binding assays known to those skilled in the art. Competitive inhibition assays can also be used.

[0128] Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to ClfB, SdrC, SdrD, SdrE or consensus or variable sequence amino acid motifs' nucleic acid molecules or proteins and thereby inhibit their activity or bind to a binding molecule (such as fibrinogen) to prevent the binding of the ClfB, SdrC, SdrD, SdrE or consensus or variable sequence amino acid motifs' nucleic acid molecules or proteins to the binding molecule. For example, a compound that inhibits ClfB, SdrC, SdrD, SdrE or consensus or variable sequence amino acid motifs' activity may be a small molecule that binds to and occupies the binding site of the ClfB, SdrC, SdrD, SdrE or consensus or variable sequence amino acid motif peptide or protein, thereby preventing binding to cellular binding molecules. Examples of small molecules include, but are not limited to, small organic molecules, peptides or peptide-like molecules. Other potential antagonists include antisense molecules. Preferred antagonists include compounds related to and variants or derivatives of ClfB, SdrC, SdrD, SdrE or consensus or variable sequence amino acid motif peptides or proteins.

[0129] The nucleic acid molecules described herein may also be used to screen compounds for antibacterial activity.

[0130] Therapeutic Applications

[0131] In addition to the therapeutic compositions and methods described above, the ClfB, SdrC, SdrD, SdrE or consensus or variable amino acid motifs, peptides or proteins, nucleic acid molecules or antibodies are useful for interfering with the initial physical interaction between a pathogen and mammalian host responsible for infection, to mammalian extracellular matrix proteins on indwelling devices or to extracellular matrix proteins in wounds they are further useful to block ClfB, SdrC, SdrD, SdrE, or active fragments thereof, including consensus or variable amino acid motifs, peptide or protein-mediated mammalian cell invasion. In addition, these molecules are useful to mediate tissue damage and to block the normal progression of pathogenesis in infections.

[0132] *S. aureus* Detection Kit

[0133] The invention further contemplates a kit containing one or more ClfB, SdrC, SdrD, SdrE proteins, peptides, or

active fragments thereof, including consensus or variable amino acid motif-encoding nucleic acid probes. These probes can be used for the detection of *S. aureus* or *S. aureus* extracellular matrix-binding proteins in a sample. Such a kit can also contain the appropriate reagents for hybridizing the probe to the sample and detecting bound probe.

[0134] In an alternative embodiment, the kit contains one or more ClfB, SdrC, SdrD, or SdrE proteins, peptides or consensus or variable amino acid motif-specific antibodies, which can be used for the detection of *S. aureus* organisms or *S. aureus* extracellular matrix-binding proteins in a sample.

[0135] In yet another embodiment, the kit contains one or more ClfB, SdrC, SdrD or SdrE-proteins, or active fragments thereof, such as the consensus or variable sequence amino acid motifs, which can be used for the detection of *S. aureus* organisms or *S. aureus* extracellular matrix-binding antibodies in a sample.

[0136] The kits described herein may additionally contain equipment for safely obtaining the sample, a vessel for containing the reagents, a timing means, a buffer for diluting the sample, and a calorimeter, reflectometer, or standard against which a color change may be measured.

[0137] In a preferred embodiment, the reagents, including the protein or antibody, are lyophilized, most preferably in a single vessel. Addition of aqueous sample to the vessel results in solubilization of the lyophilized reagents, causing them to react. Most preferably, the reagents are sequentially lyophilized in a single container, in accordance with methods well known to those skilled in the art that minimize reaction by the reagents prior to addition of the sample.

EXAMPLES

[0138] The present invention is further illustrated by the following non-limiting examples, which are not to be construed in any way as imposing limitations upon the scope thereof. On the contrary, it is to be clearly understood that resort may be had to various other embodiments, modifications, and equivalents thereof which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the spirit of the present invention.

Example 1

Gene Cloning, Sequencing and Expression

[0139] A fibrinogen-binding protein gene, designated clfB, was isolated, cloned and sequenced as follows:

[0140] Bacterial Strains and Growth Conditions

[0141] The *E. coli* and *S. aureus* strains used for the cloning and sequencing of clfB are listed in Table 1, below. *Escherichia coli* was routinely grown on L-broth or agar. *S. aureus* was routinely grown on trypticase soy broth (Oxoid) or agar. The following antibiotics were incorporated into media where appropriate: ampicillin (Ap), 100 μ g/ml; tetracycline (Tc), 2 μ g/ml; chloramphenicol (Cm), 5 μ g/ml; erythromycin (Em) 10 μ g/ml.

TABLE 1

Bacterial strains used in the present study			
Bacterial strain	Genotype	Relevant properties/ Use in present study	Source/reference
<i>E. coli</i>			
C600	F ⁻ , lacY1, leuB6, supE44, thi-1, thr-1, tonA21	Propagation of lambda recombinants	Appleyard, Genetics 39: 440–452 (1954)
DH5α	F ⁻ , ø80dLacZM15, deoR, endA1, gyrA96, hsdR17, (r _k ⁻ , m _k ⁺), (lacZYA-argF)U169, recA1, relA1, supE44, thi-1	Recombination deficient, host strain for plasmids and for DNA sequencing	Hanahan et al., J. Mol. Biol. 166: 557–580 (1983)
JM101	supE, thi-1, (lac-proAB), [F' traD36, proAB, lacI ^q ZM15]	Host strain for plasmid bank and for sequencing	Stratagene (La Jolla, CA)
LE392	F ⁻ , (r _k ⁻ , m _k ⁺), galK2, galT22, hsdR574, lacY1 or (lacIZY)6, metB1, supE44, supF58, trpR55	Propagation of lambda recombinants	Promega Corp. (Madison, WI)
XL-1 Blue		[F' proAB, lacI ^q ZM15, Tn10(tc ^r), endA1, gyrA96, hsdR17, lac, recA1, relA1, supE44, thi-1	Propagation of plasmidsStratagene
<i>S. aureus</i>			
Newman		Strong adherence to fibrinogen	NCTC 8178; Duthie and Lorenz, J. Gen. Microbiol. 6: 95–107 (1952)
DU5876		clfA2::Tn917, Em _r	McDevitt et al., Mol. Microbiol. 11: 237–248 (1994)
DU5943		clfB::Tc _r , Tc _r	described herein
DU5944		clfAclfB, Em _r , Tc _r	described herein
DU5874		spa::Tc _r	Protein A-defective mutant of NewmanMcDevitt et al., Mol. Microbiol. 16: 895–907 (1995)
Δ map			McDevitt, unpublished
8325-4		NCTC 8325 cured of prophages	Novick, Virology 33: 155–166 (1967)
ISP546		agr::Tn551	8325-4 agrBrown and Pattee, Infect. Immun. 30: 36–42 (1980)
RN4220		Restriction deficient derivative of 8325-4	Kreiswirth et al., Nature 305: 709–712 (1983)
V8		Classic V8 protease producer, produces PV leukocidin	ATCC 27733
Cowan 1		Classic protein A producer, adheres well to fibrinogen and fibronectin	ATCC 12598
RN4282		TSST-1 producer	Kreiswirth et al., 1983 (as 3–14)
Phillips		Collagen binding strain	Patti et al., Infect. Immun. 62: 152–161 (1994)
V13		Septicaemia isolate	O'Reilly et al., Mol. Microbiol. 4: 1947–1955 (1990)
GH13		Methicillin resistant	Poston and Li Saw Hee, J. Med. Microbiol. 34: 193–201 (1991)

TABLE 1-continued

Bacterial strains used in the present study			
Bacterial strain	Genotype	Relevant properties/ Use in present study	Source/reference
P1		Rabbit virulent strain	Sherertz et al., J. Infect. Dis. 167: 98-106 (1993)
M60		Bovine mastitis isolate	Anderson, Zentralbl Bakteriell Parasitenkd Infektionskr Hyg Abt. 1 Orig Reihe A 5(Suppl.): 783-790 (1976)

[0142] DNA Manipulation

[0143] Unless otherwise specified, DNA manipulations were done according to standard methods as described by Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY. New York, John Wiley and Sons (1987) and Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd ed. Cold Spring Harbour, N.Y., Cold Spring Harbour Laboratory Press (1989). Enzymes for DNA manipulation were obtained from New England Biolabs (Beverly, Mass.) and Promega (Madison, Wis.), and used as directed by the manufacturer. Genomic DNA from *S. aureus* Newman was prepared according to methods of Muller et al., *Infect. Immun.* 61:551-558 (1993). Smaller scale preparations were made by lysing cells in phosphate buffered saline (PBS) containing 12 µg/ml lysostaphin and 20 mM EDTA (ethylenediaminetetraacetic acid), followed by protease K treatment (500 µg/ml in 1% SDS) for 1 hour at 60° C., extraction with phenol and chloroform, and dialysis against 10 mM Tris HCl, pH 8.0, 1 mM EDTA. Plasmid DNA was prepared from *S. aureus* according to the method of Vriesema et al., *Appl. Environ. Microbiol.* 62:3527-3529 (1996). *E. coli* plasmid DNA for use in polymerase chain reaction (PCR) and sequencing was routinely made by the modified alkaline lysis method of Feliciello and Chinali, *Anal. Biochem.* 212:394-401 (1993), and occasionally by large scale isolation and dye-buoyant density centrifugation. Screening of *E. coli* transformants for chimeric plasmids was routinely done by the rapid colony lysis procedure of Le Gouill and Dery, *Nucl. Acids Res.* 19:6655 (1994).

[0144] Cloning of Repeat-Containing Loci

[0145] A genomic library of *S. aureus* Newman was constructed in the LambdaGEM-12 replacement vector (obtained as prepared XhoI half-site arms from Promega Madison, Wis.) according to the manufacturer's instructions. Oligonucleotide probes specific for regions A and R of *S. aureus* Newman were made by polymerase chain amplification of these regions from the cloned gene on pCF14, as described by McDevitt and Foster, *Microbiology* 141:937-943 (1995), and random-primer labeled with [alpha-³²P] dATP using the Promega Prime-a-Gene™ kit (Promega). The bank was screened by Southern blotting, using an overnight hybridization temperature of 65° C. Selected clones were single plaque purified twice, and plate-lysate stocks made for storage and for inoculation of liquid cultures for the large-scale preparation of phage for DNA isolation.

[0146] A 3.87-kb HindIII fragment containing homology to region R DNA was cloned from the genome of *S. aureus*. HindIII-cleaved genomic DNA in the range of 34 kb was excised from an agarose gel, purified, and ligated to the pBluescript cloning vector. Plasmids were transformed into *E. coli* JM101 and identification of a recombinant *E. coli* containing a region R DNA insert was identified by PCR screening. PCR products were generated using primers specific for region R DNA. Individual colonies within a pool producing a positive PCR reaction were then analyzed for their potential to generate a PCR product. One transformant, pC1, was identified and found to contain the 3.87-kb fragment with homology to region R.

[0147] DNA Sequencing

[0148] The DNA sequence of *clfB* was obtained from pA1-1EX, a plasmid containing a fragment subcloned from recombinant phage A1-1 into pGEM 7Z (f)+. Nested deletions were made using the Erase-a-Base™ Kit (Promega). The Flash Dye Primer Sequencing Kit (Genpak) was used for sequencing in a Model 373A sequencing system (Applied Biosystems, Foster City, Calif.). Confirmatory sequencing in the forward direction was carried out. Double stranded sequencing of *sdrD* and *sdrE* was done on the subclones pEJ1, pEJ2 and pEJ3, containing fragments subcloned from recombinant phage A6-2 in pGEM 7Z (f)+, by nested deletions and primer walking. Automated sequence analysis of *sdrC* and the 5' end of *sdrD* on plasmid clone pC1 was performed. Sequence analysis was performed on both strands by primer extension to known sequences.

[0149] Screening of *S. aureus* Strains for *clfB* Homologues

[0150] A probe specific for the region A-encoding portion of *clfB* was made by excising a 614 bp internal *AccI* fragment from pA1-1EX, purifying from an agarose gel using the GENECLAN II™ kit (BIO 101 Inc., La Jolla, Calif.), and labeling with [alpha-³²P]dATP as described in **FIG. 2**. A probe was similarly made to distal regions of the gene (encoding region R, the wall and membrane-spanning regions, and about 100 bp of downstream DNA), using a 1.2 kb *BamHI* fragment from pA1-1EX. HindIII digests of genomic DNA from a panel of strains were Southern blotted and screened using these probes.

[0151] Expression of ClfB Region A

[0152] Region A (encoding residues S45 to N542) of *clfB* was amplified from pA1-1EX by PCR using the following primers:

Forward:

5' CGAGGATCCTCAGGACAATCGAACGATACAACG (SEQ ID NO:15)
3'

Reverse:

5' CGAGGTACCATTTACTGCTGAATCACC 3'. (SEQ ID NO:16)

[0153] Cleavage sites for BamHI and KpnI (underlined) were appended to the 5' ends of the respective primers to introduce these sites into the product and facilitate its cloning into expression vectors. The forward primer was subsequently found to include a single base mismatch (G, underlined), changing an E codon to a G codon. Reaction mixtures (50 μ l) contained 2 mM dNTPs, 1.5 mM MgCl₂, 1 ng pA1-1EX, 50 nM primers and 1.25 U Taq polymerase in standard Promega (Madison, Wis.) Taq reaction buffer. Amplification proceeded in a Perkin Elmer Cetus (Foster City, Calif.) thermocycler with an initial denaturation at 94° C. for 4 minutes, followed by 30 cycles with denaturation at 94° C. for 1 minute, annealing at 50° C., and extension at 72° C. for 1.5 minutes, with minimum heating and cooling between steps. The final extension was for 10 minutes. A single product was obtained, which was purified using the WizardTM PCR purification kit (Promega). The product was initially cloned into the His-tag expression vector pQE30. However, because high-level expression was not obtained in this system, the product was re-cloned into an alternative vector, the GST fusion vector pGEX-KG, between the BamHI and HindIII sites. The recombinant protein was recovered from lysates by affinity chromatography on glutathione-sepharose (GST Gene Fusion SystemTM, Pharmacia, Piscataway, N.J.) and from the glutathione-S-transferase fusion partner by thrombin cleavage.

[0154] Cloning of Repeat Carrying Loci

[0155] A library of *S. aureus* Newman genomic DNA was made using the replacement lambda vector LambdaGEMTM-12. About 10 000 plaques were screened using the region R-specific probe. Of the 60 positive plaques retained, 26 were purified and counter-screened with a *clfA* region A-specific probe. One plaque hybridized with the latter, indicating that it contained the *clfA* gene; of the remaining, non-hybridizing plaques, three were selected at random, and the DNA isolated. The DNA was cut with several restriction enzymes and analyzed by Southern blotting using the region R probe. Clones A1-1 and A2-3 appeared to contain overlapping sequences. Restriction mapping and Southern blotting indicated that these clones contained a single region R homologue. Clone A6-2 was found to contain three region R homologues, since cleavage with EcoRV yielded three fragments hybridizing to the region R probe.

[0156] Clone A1-1 was chosen for more detailed study, as the hybridizing fragment was slightly longer than in clone A2-3. A 7.4 kb EcoRI fragment containing the repeat region was subcloned from lambda clone A1-1 into plasmid pGEM 7Z f(+) to generate plasmid pA1-1E. This insert was reduced to approximately 3 kb by excision of a 4.4 kb XbaI segment to form pA1-1EX as shown in **FIGS. 2 and 3**.

[0157] Clone A6-2 was restriction mapped and fragments subcloned into plasmid vectors for sequencing as shown in **FIG. 4**. Southern blotting with the region R probe and preliminary sequencing suggested that there were three tandemly arrayed genes carrying region R encoding sequences. On A6-2 there were two complete ORFs, *sdrD* and *sdrE*, and one incomplete ORF, *sdrC*.

[0158] The two complete ORFs were sequenced on fragments subcloned from lambda A6-2 into plasmid vectors pGEM7Z f(+) (subclones pEJ1 and pEJ2) and pBluescript KS+(subclone pEJ3). *sdrC* was cloned separately from *S. aureus* genomic DNA. A 3.87-kb HindIII fragment of strain Newman was cloned directly into plasmid pBluescript KS+, generating clone pC1 (**FIG. 4**). This clone, containing a region R DNA insert, was identified by PCR screening. The sequence of *sdrC* and the 162 bp at the 5' end of *sdrD* were determined from pC1.

[0159] Plasmid pA1-1EX, carrying the *ClfB* gene, was deposited at the National Collections of Industrial and Marine Bacteria on Oct. 13, 1997 under the Accession No. 40903. Plasmid pC1, carrying the gene for *sdrC*, was deposited at the National Collections of Industrial and Marine Bacteria under the Accession No. NCIMB 40902 on Oct. 13, 1997 and a recombinant lambda phage A6-2, carrying the *sdrD* and *sdrE* genes, was deposited at the NCIMB on Oct. 13, 1997 under the Accession No. NCIMB 40904. All deposits comply with the terms of the Budapest Treaty.

[0160] Features of *ClfB*

[0161] The translated open reading frame (ORF) contained within pA1-1EX is shown in **FIG. 5**. The ORF shows features reminiscent of secreted proteins of Gram positive cocci. Although the entire ORF is shown in **FIG. 5**, the start codon is unlikely to be the N codon. There is no ATG codon at the 5' end of the ORF. However, GTG and TTG are occasionally used as translational start codons in *S. aureus*, although methionine is the actual amino acid residue inserted, e.g., the fibronectin binding proteins (GTG), and protein A (TTG). The first TTG codon (L) may well be the initiation codon, as a possible ribosome binding site, GGAG, is suitably located upstream, starting at position-12. The N-terminal 44 amino acid residue region thus predicted has properties similar to signal sequences of secreted proteins of Gram positive cocci, i.e., an initial stretch of 19 mostly polar residues, with an overall positive charge, followed by 18 neutral residues with a high content of hydrophobic residues, and finally a short stretch of mainly polar residues with a good consensus cleavage site, AQA-S.

[0162] If the above prediction of the signal sequence is correct, region A of *ClfB* is 498 residues long, and shows 26.3% residue identity with the equivalent region in *ClfA*, or 44.4% homology when conservative substitutions are included. The most marked stretch of amino acid similarity between *ClfA* and *ClfB* occurs between residues 314-329 (*ClfA*) and 304-319 (*ClfB*), with 7 identical and 5 conserved residues. In *ClfA*, the stretch overlaps the C-terminal half of a putative Ca²⁺ binding loop, EF hand I, required for fibrinogen binding as shown in **FIG. 6**. The sequence DYSNS, which obeys the consensus for the N-terminal moiety of a MIDAS motif, occurs a short distance upstream. Accordingly, the downstream sequence was inspected for D and T residues to complete the motif. D and T occur frequently throughout the protein, and T 339 is suitably

located, 63 residues downstream. However, the consensus would require a D residue 14-23 residues downstream from the T, and in the present case, the nearest D residues are 9 or 28 residues away (D 348 and D 367).

[0163] At the C-terminal end of region A, a prominent proline-rich region occurs (21/42 residues are P; as shown in FIG. 5). There is a 14-residue repeat within this sequence. The DNA encoding the P-rich repeats is highly conserved. Of the three base substitutions, only one results in an amino acid replacement, a conservative substitution of S for T.

[0164] Region R is somewhat shorter in clfB than in clfA (272 residues instead of 308). The region R encoding sequence comprises the 18-bp consensus repeat observed in the equivalent part of clfA.

[0165] Following region R is a short stretch of predominantly hydrophilic residues, containing the distinctive LPETG motif near its C-terminal end, presumably the cell sorting signal. The C-terminal region of the predicted protein shows strong homology with the corresponding region in ClfA, with an initial stretch of mostly hydrophobic residues and a final stretch rich in positively charged residues, reminiscent of membrane spanning and anchoring domains, respectively. The general organization of ClfA and ClfB is compared in FIG. 1.

[0166] A putative transcription termination signal occurs 3' to ClfB. No open reading frames occur within 260 bp 5' or 200 bp 3', suggesting that the gene is not part of an operon.

[0167] Features of SdrC, SdrD and SdrE

[0168] The DNA sequences and the translated amino acid sequences of sdrC, sdrD and sdrE are shown in FIGS. 7, 8 and 9. Each predicted protein has a putative signal sequence, an approximately 500 residue "region A" with limited homology to region A of ClfA (see FIG. 10), variable numbers of B repeats, an SD repeat containing region R, an LPXTG cell wall sorting motif, a hydrophilic membrane anchor, and positively charged residues at the extreme C terminus.

[0169] The organization of the five region R containing proteins is shown in FIG. 10. The A regions of SdrC, SdrD and SdrE have limited sequence similarity to each other and to those of ClfA and ClfB as shown in FIG. 11. Alignments of those sequences more strongly conserved between all five proteins are shown in FIG. 12. The consensus motif TYT-FTDYVD overlaps the EF hand 1 motif of ClfA (alignment 2, FIG. 12). This region of ClfA has been shown to be of crucial significance in its ligand (fibrinogen) binding activity as described by O'Connell et al., *J. Biol. Chem.*, 273:6821-6829 (1998), and may also be of importance in the biological activity of the new proteins.

[0170] The three proteins SdrC, SdrD and SdrE form a separate subgroup of region R containing proteins: in addition to regions R and A they contain variable numbers of B repeats, located between region A and region R. The B repeats are 110-113 amino acids long and show considerable similarity (alignment 5, FIG. 12). The repeats SdrC B2, SdrD B5 and SdrE B3 adjacent to region R are 93-95% identical. There is a strongly conserved EF hand near the N-terminal end of each repeat.

[0171] clfB Homologues in other *S. aureus* Strains

[0172] Nine strains of *S. aureus* were screened for the ClfB gene by Southern blotting. Genomic DNA was cut to completion with HindIII, and probed with an internal 0.6 kb AccI fragment of the region A coding sequence of clfB, shown in FIG. 2. The probe recognized a single HindIII fragment varying from 2 to 3 kb in length in all nine strains, indicating that each possesses a single clfB allele. A probe made from the region R and distal regions of clfB recognized an identical band in all strains, indicating that the cUB homologues in other strains also contain region R.

[0173] Expression of clfB

[0174] The portion of clfB encoding region A was amplified by PCR using primers incorporating suitable 5' restriction sites, and cloned into the *E. coli* expression vector pGEX-KG. A protein of 94.3 kDa was detected in lysates of induced bacteria. The GST-ClfB fusion protein was immobilized on a glutathione sepharose affinity column, cleaved with thrombin, and examined by SDS-PAGE. The predominant band was 42 kDa, whereas the calculated molecular weight of region A is 54 kDa. This protein was used to raise antibody in rabbits, to probe Western blots of cell lysates made from strain Newman grown under a variety of conditions, as described below. The antibody failed to detect any antigens in lysates made from plate cultures, statically grown broth cultures, or shake-flask cultures grown to stationary phase. A single 124-kDa band was detected in lysates made from exponential phase shake-flask cultures of strain Newman and derivatives. If it is assumed that processing removes the signal sequence and the C-terminal portion of the protein from the last G of the LPETG, the predicted molecular weight of ClfB is 88.3 kDa. In a time-course of ClfB production by a shake-flask culture of strain Newman, the ClfB protein was most abundant in the early exponential phase and showed a sharp decline toward the end of exponential phase, after which levels became undetectable. The results of the time-course study are shown in FIG. 13.

Example 2

Production of Anti-ClfB Serum

[0175] Antibodies to recombinant region A were raised in two young New Zealand white rabbits (2 kg) showing no prior reaction with *E. coli* or *S. aureus* antigens in Western blots. Injections, given subcutaneously, contained 25 μ g of the antigen, diluted to 500 ml in phosphate buffered saline (PBS) emulsified with an equal volume of adjuvant. The initial injection contained Freund's complete adjuvant; the two to three subsequent injections, given at two-week intervals, contained Freund's incomplete adjuvant. When the response to the recombinant protein was judged adequate, the rabbits were bled, serum recovered, and total IgG purified by affinity chromatography on protein A sepharose (Sigma Chemical Co., St. Louis, Mo.).

[0176] SDS-PAGE and Western Blotting

[0177] Samples were analyzed by SDS-PAGE in 10 or 12% acrylamide gels. Isolated proteins and *E. coli* cell lysates were prepared for electrophoresis by boiling for five minutes in denaturation buffer. For *S. aureus*, cells were suspended to an OD₆₀₀ of 40 units in 100 mM PBS con-

taining 10 mM EDTA. To each 500 μ l sample, 40 μ l protease inhibitors (Complete™ cocktail, Boehringer Mannheim, Indianapolis, Ind.), 5 μ l each of DNase and RNase (from 10 mg/ml stocks, Sigma Chemical Co.), and 60 μ l of a 2 mg/ml lysostaphin stock (Ambicin L™ recombinant lysostaphin, Applied Microbiology Inc., Tarrytown, N.Y.) were then added and the suspension incubated in a 37° C. water bath until it cleared. The samples were then processed as usual. Gels were stained with Coomassie blue or transferred to Nytran™ membrane by Western blotting in the Bio-Rad Semidry™ system (Bio-Rad Laboratories, Richmond, Calif.). For detection of native ClfB in *S. aureus*, blots were processed using the BM Chemiluminescence Detection System™ (POD) of Boehringer Mannheim, according to the manufacturer's instructions. Primary anti-ClfB antibody was used at a 1/1000 dilution, for a two hour incubation at room temperature. Protein A conjugated with horse radish peroxidase (Sigma Chemical Co.) was used to detect bound antibody, diluted 1/2000 for a one hour incubation at room temperature. Blots requiring less sensitivity were treated in a similar way, except that 5% skim milk was used as a blocking agent, and the blots were developed using chloronaphthol and hydrogen peroxide.

[0178] To determine whether ClfB is cell wall-associated, whole cells from an exponential phase culture were treated with lysostaphin in buffer supplemented with 30% raffinose to stabilize the protoplasts. The protoplasts were harvested, and the protoplasts and supernatant analyzed separately by Western blotting. ClfB protein was detected only in the supernatant, indicating that all ClfB was cross-linked to the peptidoglycan, and could be released by lysostaphin without disruption of the protoplast.

[0179] ClfB expression was enhanced by growth in rich media, such as tryptone soy broth or brain heart infusion.

[0180] Several *S. aureus* strains known to contain clfB alleles were screened for ClfB production by Western blotting. Cultures were harvested in early exponential phase to maximize expression. Of the nine strains examined, 83254, RN4282, and V13 expressed immunoreactive antigens of similar size and intensity to that of Newman, whereas strains GH13 and P1 had very weak bands of this size. Strains P1, Cowan and M60 expressed smaller immunoreactive antigens which may be degradation products. Strains V8 and Phillips expressed no detectable ClfB protein. Strain RN4220, which was derived from 8325-4, expressed exceptionally high levels of ClfB.

Example 3

Immunoassay for ClfB using Biotinylated Recombinant ClfB Region A

[0181] The DNA encoding region A of clfB (encoding residues S45 to N542) was amplified from genomic DNA of *S. aureus* Newman using the following primers:

Forward:
5' CGAAAGCTTGTCTCAGAACATCGAACGATACAAC (SEQ ID NO:17)
G 3'

Reverse:
5' CGAGGATCCATTCTACTGCTGAATCACC 3' (SEQ ID NO:16)

[0182] Cleavage sites for HindIII and BamHI (underlined) were appended to the 5' ends of the respective primers to facilitate cloning of the product into the His-tag expression vector pV4. Cloning employed *E. coli* JM101 as a host strain. The recombinant region A was purified by nickel affinity chromatography.

[0183] Enzyme Linked Immunosorbent Assay (ELISA)

[0184] Immulon 1™ plates (Dynatech™, Dynal, Inc., Great Neck, N.Y.) were coated overnight with 100 μ l of 10 μ g/ml human fibrinogen (Chromogenix). They were then blocked with 200 μ l of 5 mg/ml bovine serum albumin (BSA) for one hour. The plates were then incubated for three hours with 100 μ l biotinylated ClfB (His-tag recombinant region A) diluted to 0.1-10 μ g/ml. They were then given three five-minute washes with PBS containing 0.02% Tween 20 and 1 mg/ml BSA. The plates were then incubated for one hour with 100 μ l of a 1/10 000 dilution of streptavidin conjugated with alkaline phosphatase (Boehringer Mannheim, Indianapolis, Ind.), and washed as before. The plates were then developed for 30 minutes at 37° C. with 100 μ l of 1 M diethanolamine, pH 9.8, containing 1 mg/ml p-nitrophenyl phosphate (Sigma Chemical Co.). Plates coated with BSA only were used as negative controls. The absorbance was measured at 405 nm.

[0185] Western Affinity Blotting

[0186] A 20 μ g quantity of human fibrinogen (Chromogenix) was subjected to SDS-PAGE on a 15% acrylamide gel for two hours. Proteins were transferred to nitrocellulose at 100 V for two hours. The membrane was blocked overnight in PBS containing 10% nonfat dry milk. The blot was then incubated with 2.5 μ g/ml biotinylated ClfB (His-tag recombinant region A) for one hour with shaking, the biotinylation being performed with EZ link-sulfo-NHS-LC-Biotin™ (Pierce, Rockford, Ill.). The blot was then given three five-minute washes in PBS containing 0.1% Tween 20. The blot was then incubated for one hour with avidin conjugated with horseradish peroxidase (Boehringer Mannheim) at a 1/200,000 dilution. The blot was then washed as before, and developed using the enhanced chemiluminescence system of Amersham (Little Chalfont, Bucks, UK). The band profile was compared with that obtained by subjecting fibrinogen to SDS-PAGE and Coomassie Blue staining.

[0187] In a Western affinity blot, in which biotinylated purified ClfB region A was used to probe blotted fibrinogen, a comparison with a lane of stained fibrinogen indicated that ClfB bound the alpha and beta-chains of fibrinogen. No bands were seen when ClfB was omitted. This experiment shows an important difference with ClfA, which is known to bind to the gamma-chain of fibrinogen.

Example 4

Mutagenesis of clfB

[0188] An insertion mutation in clfB was created by introducing a fragment containing a Tc resistance marker into the middle of the gene on pA1-1EX as shown in FIG. 3. The 2.35-kb HindIII fragment from pT181 was filled in with Klenow enzyme, and blunt-end ligated into the HpaI site of pA1-1EX. Plasmid pTS2, with temperature sensitive replication and a Cm^r marker, was cloned into this construct at the SmaI site by cleaving with AvaI. This cloning step was

carried out in *E. coli*, and transformants were selected on Ap and incubated at 30° C. to avoid selection of revertants to temperature independence. The plasmid was then purified and transformed into *S. aureus* RN4220 by electroporation and Tc^r transformants selected at 30° C. Five independent broth cultures grown at 30° C. were diluted 1/100 in fresh medium without antibiotics, and grown at 42° C. for six hours or 18 hours. The cultures were then diluted 1/100 and incubated at 42° C. for another time period. Six such dilutions and incubations were made, by which time Tc resistance had declined to approximately 1/1000 colony forming units (CFU). The cultures were then diluted to give approximately 100 CFU per plate on medium containing Tc, and incubated overnight at 37° C. Colonies which were Tc^r but Cm^s were presumed to have undergone a double cross-over event between the plasmid and host genome, leading to replacement of the wild-type gene with the mutated one, with subsequent loss of the plasmid. Five hundred colonies were screened per culture. Eleven presumptive mutants were isolated from four of the five cultures. Four representative mutants were selected and genomic DNA isolated. Mutant DU5944, deficient in both *clfA* and *ClfB*, was constructed by transducing *clfA2::Tn917* from strain DU5876 into *clfB* mutant DU5943, selecting for Em^r.

[0189] To determine whether mutations known to affect exoprotein expression influenced *ClfB*, strain 8325-4 and the *agr* mutant ISP546 were compared. No significant differences in the level or dynamics of *ClfB* expression were noted.

[0190] To determine the role of *ClfB* in bacteria-fibrinogen interactions, a *clfB* mutant of strain Newman was constructed by allele replacement as shown in FIG. 2. Genomic DNA of the mutant was digested with BamHI and subjected to Southern blotting with a labeled 1.3 kb HpaI fragment from plasmid pA1-1E containing the 5' half of *clfB* and about 150 bp of upstream sequence. A single band hybridized in each case, but as expected, the band was 2.35 kb longer in the mutant than in the wild-type. The mutation was initially isolated in RN4220 and then transduced into strain Newman, forming strain DU5943.

[0191] Overexpression of *ClfB* and Complementation of *clfB* Mutation

[0192] Overproduction of *ClfB* was enabled by subcloning a SmaI fragment containing the *clfB* gene and 500 bp of upstream DNA from pA1-1E into the high copy number shuttle plasmid pCU1. The construct was then transformed into strain RN4220 and transduced into strain Newman. Transductants were selected on Cm. Southern and Western blotting confirmed that the high copy number was maintained in strain Newman, and that *ClfB* was produced at higher than wild-type levels, indicating that the upstream DNA contained the promoter necessary for expression of the *clfB* gene. Transduction of the construct into *clfB* mutants restored *clfB* synthesis to higher than wild-type levels. The construct was also transduced into *clfAclfB* double mutants for use in complementation studies.

[0193] To create a *clfAclfB* double mutant, a *clfA::Tn917* mutation was transferred by transduction from strain DU5876 into the *clfB::Tc^r* mutant DU5943, forming DU5944. The wild-type *clfB⁺* gene was cloned into shuttle plasmid pCU1 to give plasmid pA1-1EA, which was introduced into the *clfAclfB* mutant by transduction to test

complementation. Western blotting with anti-*ClfB* serum showed that the *ClfB* protein was missing in mutant DU5943. It was expressed at a higher level than the wild-type in mutants carrying the complementing plasmid PA1-1EA, indicating overexpression of the protein due to gene dosage effect.

Example 5

ClfB Binding Assays

[0194] Clumping Assays

[0195] The role of *ClfB* in binding of *S. aureus* cells to soluble fibrinogen was investigated in clumping assays. Clumping assays were carried out in Sarstedt™ flat-bottomed multiwell test plates, using 50-μl volumes of human fibrinogen (Calbiochem Corp. (San Diego, Calif.) plasmidogen free, >95% pure), diluted serially two-fold in PBS from a starting concentration of 1 mg/ml. *S. aureus* cultures were washed once in PBS, resuspended to a final OD₆₀₀ of 6, and 20 μl added to each well. Control wells contained PBS 30 only. The plates were agitated briskly for five minutes and visually examined for clumping. The clumping titer was the lowest concentration of fibrinogen at which clumping occurred. The results are set forth in Table 2, below. Results are the mean of concurrent duplicate assays.

TABLE 2

Clumping titres of <i>S. aureus</i> Newman and mutants from different culture phases		
Strain	Clumping titer, μg/ml fibrinogen	
	Exponential phase	Stationary phase
Wild-type	0.98	0.98
<i>clfA</i>	3.91	>1000.00
<i>clfB</i>	1.95	0.98
<i>clfA clfB</i>	>1000.00	>1000.00
<i>clfA clfB</i> (pA1-1EA; <i>clfB⁺</i>)	2.93	250.00

[0196] The clumping titers of *ClfA* and *clfB* single mutants were very similar to wild-type when exponential phase cultures were used. However, the double *clfAclfB* mutant failed to form clumps, even at the highest fibrinogen concentration. In contrast, the double mutant carrying the wild-type *clfB* gene on pA1-1EA formed clumps with almost the same avidity as the wild-type. These data show unambiguously that *ClfB* is a clumping factor.

[0197] The difference in clumping titer between the single mutants was much greater when stationary phase cultures were used, where only *ClfA* is present on cells. The wild-type strain and single *clfB* mutant had identical titers. The single *clfA* mutant failed to clump, and was thus indistinguishable from the double mutant. Interestingly, there was a slight restoration of clumping when the double mutant was complemented with the overexpressed *ClfB⁺* gene. This probably reflects over expression of the protein.

[0198] Plate Adherence Assays

[0199] To determine whether *ClfB* can promote bacterial attachment to immobilized fibrinogen, strains were tested for fibrinogen binding in a microtiter plate adherence assay.

Binding of cells to fibrinogen immobilized on plates was measured by the assay of Wolz et al., *Infect. Immun.* 64:3142-3147 (1996). Fibrinogen was diluted in carbonate buffer (15 mM Na₂CO₃, 35 mM NaHCO₃, 3.2 μM NaN₃, pH 9.6) and 100 μl used to coat 96-well flat-bottomed ELISA plates (Immulon 4™, Dynatech) overnight at 4° C. Control wells contained carbonate buffer only. After washing in 150 mM NaCl, 0.05% Tween 20™ surfactant, the plates were blocked for one hour at 37° C. in 1% BSA, 0.05% Tween in PBS. After washing as before, 100 μl of a cell suspension (OD₆₀₀ of 0.4 in PBS) was added, and the plates incubated for two hours at 37° C. After gentle washing by hand, adherent cells were fixed by adding 100 μl of 25% aqueous formaldehyde, and incubating at room temperature for at least 30 minutes. The plates were then washed gently once more, stained with crystal violet, washed again, and the plates read by ELISA reader at 570 nm. To avoid inter-assay variation, experiments were designed so that a single plate provided a complete set of results.

[0200] The pattern of adherence strongly reflected that obtained in clumping assays (FIG. 15). Assays in which the concentration of cells was varied indicated that binding was approximately half the maximum value at a cell density of 0.4 OD (except for the double mutant), and this cell density was subsequently used routinely. Wild-type, *clfA*, *clfB* mutants and *clfAclfB* (pA1-1EA) showed a fibrinogen concentration-dependent increase in binding (FIG. 16). This increase was less marked for the *clfB* mutant (expressing ClfA) than for the *clfA* mutant (expressing ClfB), suggesting that ClfB may be a less avid and/or abundant receptor. With stationary phase cells, the *clfB* mutant continued to behave like the wild-type strain, whereas the *clfA* mutant bound much less avidly. As with clumping, adherence was slightly higher with the complemented double mutant, presumably due to a gene dosage effect.

[0201] The clumping and adherence assays show that ClfB mediates binding both to soluble and immobilized fibrinogen, closely resembling the activity of ClfA.

[0202] The binding of increasing concentrations of biotinylated purified region A from ClfA and ClfB to solid phase fibrinogen was compared in a direct ELISA. The results are shown in FIG. 14. The adherence profiles of the two proteins were very similar, especially at the lower concentrations. At the highest concentration, binding of ClfA was approximately 50% greater than that of ClfB. Neither protein bound to BSA.

[0203] Effect of Anti-ClfB Antibody on Bacterial Adherence to Immobilized Fibrinogen

[0204] To study inhibition of fibrinogen binding by IgG, the cells used for the assay were preincubated with serial two-fold dilutions of purified IgG in PBS, starting with a concentration of 500 μg/ml. Preincubation was for two hours at 37° C. in Sarstedt™ multiwell test plates, and the cells were then transferred to ELISA plates coated with fibrinogen (2.5 μg/ml) and blocked as before. The rest of the assay was as before.

[0205] Cells from exponential phase cultures of wild-type and mutant Newman strains were preincubated with increasing concentrations of purified anti-ClfB IgG, and adherence

to plastic surfaces coated with 2.5 μg/ml fibrinogen examined. The results are shown in FIG. 17. Binding of the *clfB* mutant was not inhibited, and binding of wild-type cells was almost unaffected, even at the highest antibody concentration. However, binding of the *clfA* mutant showed an IgG concentration-dependent decrease, with an IC₅₀ of 16 μg/ml. The double mutant carrying *clfB*⁺ on a complementing plasmid was also inhibited by the antibody, although the IC₅₀ was higher (50 μg/ml), presumably because more ClfB was being expressed on the cell surface.

[0206] Effect of Divalent Cations on Bacterial Adherence to Immobilized Fibrinogen

[0207] The effect of metal ions on fibrinogen binding was studied in a similar manner, preincubating the cells with serial two-fold dilutions of MgCl₂, MnCl₂ or MgCl₂ in TBS (50 mM Tris HCl, pH 7.5, 150 mM NaCl), starting with a concentration of 50 mM. TBS was used instead of PBS, which causes precipitation of both calcium and manganese. Since the cells bound less well under these conditions, the starting cell concentration was doubled.

[0208] It is known that the interaction of ClfA and fibrinogen is inhibited by Ca²⁺ and Mn²⁺, but not Mg²⁺ ions. The effect of divalent cations on ClfB-promoted adherence to fibrinogen was thus tested. Preincubation of exponential phase cells of the wild-type strain and the *clf* mutants with CaCl₂ inhibited binding to fibrinogen. Those strains expressing ClfB alone showed greater sensitivity than the mutant expressing ClfA alone (*clfB*). The IC₅₀ for the wild-type strain and the *clfB* mutant were 17 and 14 mM, respectively, whereas for the *clfA* mutant and the *clfB*⁺ complemented double mutant the IC₅₀ was 1.05 and 0.60 mM, respectively. MnCl₂ also inhibited attachment of the wild-type strain and mutants, with a stronger effect on strains expressing only *clfB*. The IC₅₀ for the wild-type and the *clfB* mutant was 3.3 and 6.4 mM, respectively, whereas for the *clfA* mutant and the double mutant carrying *clfB*⁺ on a complementing plasmid the IC₅₀ was 0.35 and 1.26 mM respectively. MgCl₂ had no effect on binding below 12.5 mM.

[0209] Thus, *clfB* promoted adherence of bacteria to immobilized fibrinogen is inhibited by Ca²⁺ and Mn²⁺ at similar concentrations to ClfA-promoted adherence. However, the mechanisms are likely to be different since ClfB does not contain a homologue of EF hand I implicated in Ca²⁺ promoted modulation of ClfA-fibrinogen interactions.

[0210] Platelet-Fibrin Clot Adherence Assay

[0211] Adherence to platelet-fibrin clots was measured using a modification of an assay employed by Moreillon et al., *Infect. Immun.* 63: 4738-4743 (1995). Fresh canine blood was collected on 10% sodium citrate buffer (Sigma Chemical Co.), and centrifuged at 3000×g for 10 minutes at room temperature. The plasma fraction was removed and placed in a clean tube. Platelet-fibrin clots were made by mixing 0.5 ml volumes of plasma with 0.1 ml volumes of 0.2 mM CaCl₂ in 35 mm petri dishes. Thrombin (0.1 ml of 500 U/ml Sigma bovine thrombin) was then added, mixed in quickly, and the clots allowed to form. To measure bacterial adherence, 2 ml of PBS containing 5×10³ cfu/ml of bacteria (from a BHI-grown exponential phase culture) was added to

each dish, and the dishes shaken for three minutes on an orbital shaker. The inoculum was drained off and the clots washed twice for five minutes each with 2 ml of PBS. The clots were then overlaid with 3 ml of molten TSA, incubated for 15 hours at 37° C., and the colonies counted. The bacterial suspension used as an inoculum was spread on TSA plates to obtain a total viable count, and the percentage of bound inoculum calculated. Results represent means of 6-10 plates per strain, and were analyzed statistically using the student's T test.

[0212] The ClfB mutation reduced adherence when compared to the wild-type strain Newman, as did the *clfA* mutation which was previously shown by Moreillon et al. to have significantly reduced adherence in this model. Assay for adherence to haemodialysis tubing In order to demonstrate that ClfB could serve as an adhesin for *S. aureus* in biomaterial-related infections, explanted human haemodialysis tubing was tested for promotion of bacterial adherence in vitro. The tubing was coated with a complex mixture of host plasma proteins including fibrinogen and fibronectin.

[0213] These experiments employed sections of haemodialysis tubing removed from patients 3 to 3.5 hours after implantation. Cultures were grown for two hours with shaking. Results, showing means with SEM of three experiments, are shown in **FIG. 19**.

[0214] Assay for Adherence to Fibrinogen-Coated PMMA Coverslips

[0215] Adherence of *S. aureus* Newman and mutants to fibrinogen-coated polymethylmethacrylate (PMMA) coverslips was measured as described by Greene et al., *Mol. Microbiol.* 17:1143-1152 (1995), except that the coverslips were coated with pure fibrinogen (1 µg/ml). Cultures for the assay were grown for two hours with shaking. Results, showing the means and SEM of triplicate experiments, are shown in **FIG. 18**.

[0216] The pattern of adherence to the tubing segments resembled the pattern of binding seen for immobilized fibrinogen in a parallel assay for adherence to fibrinogen immobilized on PMMA coverslips. The single *clfA* mutants had slightly lower levels of adherence compared to the wild-type whereas the double *clfAclfB* mutant was reduced to approximately 30% of wild-type level. Complementation of the single *clfB* mutant with the *clfB* gene on pA1-1EA restored binding to greater than wild-type levels, whereas complementation of the double mutant with the same plasmid restored binding only to the same level as the single *clfA* mutant.

Example 6

ClfB as a Virulence Factor in Experimental Endocarditis

[0217] Clumping factor A was shown to be a virulence factor promoting adherence to damaged heart valves in the rat model of experimental endocarditis of Moreillon et al., *Infect. Immun.* 63:4738-4743 (1995). Therefore, the role of ClfB in this infection was tested by comparing the infection rate of a *clfB* mutant and the mutant carrying the complementing *clfB*⁺ plasmid. Rats were infected intravenously at an ID₆₀ with 5×10³ cfu. 61% of the wild-type control

animals' valves were infected (n=13), whereas only 30% of the *clfB* mutant infected animals were colonized (n=20). In contrast 77% (n=9) of the complemented mutant became infected. This clearly shows that ClfB is an adhesin and potential virulence factor in the endocarditis model.

Example 7

Generation of TYTFTDYVD Peptide Antibodies

[0218] The nanopeptide, TYTFTDYVD, was synthesized in multiple antigen peptide format (MAP; Research Genetics, Inc., Huntsville, Ala.). The peptide was conjugated to KLH according to manufacturers' directions (Pierce). Two female New Zealand White rabbits were immunized subcutaneously with the KLH-TYTFTDYVD conjugate emulsified with Freund's Complete Adjuvant. The rabbits were boosted 3 weeks later by subcutaneous injection of KLH-TYTFTDYVD adjuvanted with Freund's Incomplete. A third boost was administered subcutaneously with KLH-TYTFTDYVD in PBS. The animals were analyzed for TYTFTDYVD specific antibodies 21 days after the final boost. For purification of antibodies, antisera was diluted 1:1 with Tris-HCl pH 8.0 and passed over a Protein A-Sepharose® column. After sequential washes with Tris-HCl pH 8.0, 0.5 M sodium chloride, the bound antibodies were eluted in 3.5 M MgCl₂, and dialyzed into PBS.

[0219] Immulon-2 microtiter plates (Dynex Technologies, Chantilly, Va.) were coated for 2 hr at room temperature with 1 µg ClfA, ClfB, or BSA. The protein coated plates were washed three times with PBS, 0.05% Tween 20 and then blocked with PBS, 1% BSA. The blocked plates were washed three times with PBS, 0.05% Tween 20. Fifty µl of the purified rabbit KLH-TYTFTDYVD antibodies were serially diluted in PBS and added to the microtiter plate and incubated at 25° C. on a rocker platform. The wells were washed three times with PBS, 0.05% Tween 20 and the secondary antibody was added to the wells and incubated for 1 hr at room temperature. The secondary antibody was alkaline phosphatase-conjugated goat anti-rabbit IgG (Bio-Rad), diluted 3000-fold in PBS. ELISA plates were developed for 1 hr at 37° C. with 1 mg/ml p-nitrophenyl phosphate (Sigma) in 1 M diethanolamine, 0.5 mM MgCl₂, pH 9.8, and quantified at 405 nm on a Perkin Elmer HTS 7000 Bio-Assay reader.

[0220] The data is shown in **FIG. 21**. These data indicate that the anti-consensus sequence TYTFTDYVD antibodies significantly bind to ClfA and ClfB proteins, but not to the control protein, BSA.

Example 8

Passive Immunization with Rabbit CUB IgG

[0221] The DNA encoding region A of *clfB* (encoding residues S45 to N542) was amplified from genomic DNA of *S. aureus* Newman using the following primers:

Forward:
5' CGAAAGCTTGTTCAGAACAAATCGAACGATACAAC (SEQ ID NO:17)
G 3'

Reverse:
5' CGAGGATCCATTTACTGCTGAATCACC 3' (SEQ ID NO:16)

[0222] Cleavage sites for HindII and BamHI (underlined) were appended to the 5' ends of the respective primers to facilitate cloning of the product into the His-tag expression vector pV4. Cloning employed *E. coli* JM101 as a host strain. The recombinant region A was purified by nickel affinity chromatography. Antibodies were raised in rabbits with the purified recombinant A region according to standard procedures. Anti-ClfB A region IgG was purified by affinity chromatography on a Protein A sepharose column.

[0223] Twenty Swiss Webster mice (23-28 g) were used to determine if passive immunization with purified rabbit anti-ClfB A region IgG could prevent infection mediated by a methicillin resistant *S. aureus*.

[0224] Methicillin resistant *S. aureus* strain 601 was cultured on blood agar plates. A single colony was then inoculated into 10 mls of BHI broth and incubated at 37° C. overnight. The culture was diluted to a 1:100 dilution, placed into 10 ml of fresh BHI and grown to an optical density (O.D.) of 1.5-2.0. The culture was then centrifuged and washed in 1xPBS. The culture was re-suspended in 1xPBS containing 5% BSA and 10% dimethyl sulfoxide (DMSO) and kept frozen at -20° C. The bacterial solution was thawed, washed, diluted in PBS, and adjusted to the appropriate concentrations before dosing the mice.

[0225] The mice were divided into four treatment groups (5 mice per treatment group). Mice were assigned to treatment groups as follows:

Antibody/Bacteria	Dose CFU/mouse	No. of Mice
1 Normal rabbit IgG/ <i>S. aureus</i>	3.81×10^7	5
2 Normal rabbit IgG/ <i>S. aureus</i>	7.62×10^7	5
3 Rabbit anti-ClfB IgG/ <i>S. aureus</i>	3.81×10^7	5
4 Rabbit anti-ClfB IgG/ <i>S. aureus</i>	7.62×10^7	5

[0226] On day -1, ten mice were administered 10 mg rabbit anti-ClfB region A IgG and 10 mice were given 10 mg normal rabbit IgG. Both antibodies were given via intraperitoneal (i.p.) injection. On day 0, all mice were infected intravenously (i.v.) with either 3.81×10^7 CFU *S. aureus* or 7.62×10^7 CFU *S. aureus*.

[0227] Systemic infection was measured by evaluation of body weight loss. Body weight loss is one of the primary parameters that is evaluated when cases of illness and injury are being assessed in mice. The body weight of each animal was recorded on Day -1 and every other day thereafter, including terminal sacrifice. The animals were weighed to the nearest 0.1 gram.

[0228] Mice injected with normal rabbit IgG displayed a significantly larger weight loss at the end of the experiment compared to mice passively immunized with rabbit anti-ClfB region A IgG (see table below). In addition, pathological evaluation of the mice at necropsy revealed a greater number of lesions and foci of infection in the kidneys from the mice receiving normal rabbit IgG compared to the

kidneys from mice that were immunized with anti-ClfB region A IgG.

Day of Study	% Change in body weight (mean)			
	Normal IgG/ <i>S. aureus</i>	Anti-ClfB IgG/ <i>S. aureus</i>	Normal IgG/ <i>S. aureus</i>	Anti-ClfB IgG/ <i>S. aureus</i>
	3.81×10^7	3.81×10^7	7.62×10^7	7.62×10^7
-1	0	0	0	0
1	2.9	3.6	3.9	5.8
3	10	5.1	8.5	8.2
5	8.3	1.5	8.0	6.6

Example 9

ClfB Region A Binds α and β chains of Human Fibrinogen

[0229] Human fibrinogen (20 μ g; Chromogenix) was separated by SDS-PAGE on a 15% acrylamide gel for 2 hours. Proteins were transferred to nitrocellulose at 100 V for 2h. The membranes were blocked overnight in PBS containing 10% non-fat dry milk and then incubated with 2.5 μ g/ml biotinylated ClfB or ClfA region A protein for 1 h with shaking. They were then given 3x5 mm washes with PBS containing 0.1% Tween 20 and incubated for 1 hr with avidin conjugated horseradish peroxidase (Boehringer Mannheim: 1:100,000 dilution). The filters were washed as before and developed using enhanced chemilluminescence (Amersham). The Western Blot (FIG. 22) illustrates the binding of biotinylated ClfA to the γ chain of fibrinogen and the binding of biotinylated ClfB to the α and β chains of fibrinogen.

Example 10

ClfB Region A binds 75 kD and 50 kD Proteins from Human Rhabdomyosarcoma Cell Line

[0230] Human Rhabdomyosarcoma Cells were lysed with the SDS-PAGE running buffer and varying amounts (2-10 μ l) of the protein lysate were separated by SDS-PAGE on a 15% acrylamide gel for 2h. Proteins were transferred to nitrocellulose at 100 V for 2h. The membranes were blocked overnight in PBS containing 10% non-fat dry milk and then incubated with 2.5 μ g/ml biotinylated ClfB or ClfA region A protein for 1 hr with constant shaking. They were then given 3x5 min washes with PBS containing 0.1% Tween 20 and incubated for 1 hr with avidin conjugated horseradish peroxidase (Boehringer Mannheim; 1:100,000 dilution). The filters were washed as before and developed using enhanced chemilluminescence (Amersham). Two major bands were seen at 50 kD and 75kD that reacted with the biotinylated ClfB region A protein.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 23

<210> SEQ ID NO 1

<211> LENGTH: 918

<212> TYPE: PRT

<213> ORGANISM: *Staphylococcus aureus*

<400> SEQUENCE: 1

Asn Gly Val Ile Phe Leu Lys Lys Arg Ile Asp Tyr Leu Ser Asn Lys
1 5 10 15
Gln Asn Lys Tyr Ser Ile Arg Arg Phe Thr Val Gly Thr Thr Ser Val
20 25 30
Ile Val Gly Ala Thr Ile Leu Phe Gly Ile Gly Asn His Gln Ala Gln
35 40 45
Ala Ser Glu Gln Ser Asn Asp Thr Thr Gln Ser Ser Lys Asn Asn Ala
50 55 60
Ser Ala Asp Ser Glu Lys Asn Asn Met Ile Glu Thr Pro Gln Leu Asn
65 70 75 80
Thr Thr Ala Asn Asp Thr Ser Asp Ile Ser Ala Asn Thr Asn Ser Ala
85 90 95
Asn Val Asp Ser Thr Thr Lys Pro Met Ser Thr Gln Thr Ser Asn Thr
100 105 110
Thr Thr Thr Glu Pro Ala Ser Thr Asn Glu Thr Pro Gln Pro Thr Ala
115 120 125
Ile Lys Asn Gln Ala Thr Ala Ala Lys Met Gln Asp Gln Thr Val Pro
130 135 140
Gln Glu Gly Asn Ser Gln Val Asp Asn Lys Thr Thr Asn Asp Ala Asn
145 150 155 160
Ser Ile Ala Thr Asn Ser Glu Leu Lys Asn Ser Gln Thr Leu Asp Leu
165 170 175
Pro Gln Ser Ser Pro Gln Thr Ile Ser Asn Ala Gln Gly Thr Ser Lys
180 185 190
Pro Ser Val Arg Thr Arg Ala Val Arg Ser Leu Ala Val Ala Glu Pro
195 200 205
Val Val Asn Ala Ala Asp Ala Lys Gly Thr Asn Val Asn Asp Lys Val
210 215 220
Thr Ala Ser Asn Phe Lys Leu Glu Lys Thr Thr Phe Asp Pro Asn Gln
225 230 235 240
Ser Gly Asn Thr Phe Met Ala Ala Asn Phe Thr Val Thr Asp Lys Val
245 250 255
Lys Ser Gly Asp Tyr Phe Thr Ala Lys Leu Pro Asp Ser Leu Thr Gly
260 265 270
Asn Gly Asp Val Asp Tyr Ser Asn Ser Asn Asn Thr Met Pro Ile Ala
275 280 285
Asp Ile Lys Ser Thr Asn Gly Asp Val Val Ala Lys Ala Thr Tyr Asp
290 295 300
Ile Leu Thr Lys Thr Tyr Thr Phe Val Phe Thr Asp Tyr Val Asn Asn
305 310 315 320
Lys Glu Asn Ile Asn Gly Gln Phe Ser Leu Pro Leu Phe Thr Asp Arg
325 330 335
Ala Lys Ala Pro Lys Ser Gly Thr Tyr Asp Ala Asn Ile Asn Ile Ala

-continued

340					345					350					
Asp	Glu	Met	Phe	Asn	Asn	Lys	Ile	Thr	Tyr	Asn	Tyr	Ser	Ser	Pro	Ile
		355					360					365			
Ala	Gly	Ile	Asp	Lys	Pro	Asn	Gly	Ala	Asn	Ile	Ser	Ser	Gln	Ile	Ile
	370					375					380				
Gly	Val	Asp	Thr	Ala	Ser	Gly	Gln	Asn	Thr	Tyr	Lys	Gln	Thr	Val	Phe
385					390					395					400
Val	Asn	Pro	Lys	Gln	Arg	Val	Leu	Gly	Asn	Thr	Trp	Val	Tyr	Ile	Lys
				405					410					415	
Gly	Tyr	Gln	Asp	Lys	Ile	Glu	Glu	Ser	Ser	Gly	Lys	Val	Ser	Ala	Thr
			420					425					430		
Asp	Thr	Lys	Leu	Arg	Ile	Phe	Glu	Val	Asn	Asp	Thr	Ser	Lys	Leu	Ser
		435					440					445			
Asp	Ser	Tyr	Tyr	Ala	Asp	Pro	Asn	Asp	Ser	Asn	Leu	Lys	Glu	Val	Thr
	450					455					460				
Asp	Gln	Phe	Lys	Asn	Arg	Ile	Tyr	Tyr	Glu	His	Pro	Asn	Val	Ala	Ser
465					470					475					480
Ile	Lys	Phe	Gly	Asp	Ile	Thr	Lys	Thr	Tyr	Val	Val	Leu	Val	Glu	Gly
			485						490					495	
His	Tyr	Asp	Asn	Thr	Gly	Lys	Asn	Leu	Lys	Thr	Gln	Val	Ile	Gln	Glu
			500					505					510		
Asn	Val	Asp	Pro	Val	Thr	Asn	Arg	Asp	Tyr	Ser	Ile	Phe	Gly	Trp	Asn
		515					520					525			
Asn	Glu	Asn	Val	Val	Arg	Tyr	Gly	Gly	Gly	Ser	Ala	Asp	Gly	Asp	Ser
	530					535					540				
Ala	Val	Asn	Pro	Lys	Asp	Pro	Thr	Pro	Gly	Pro	Pro	Val	Asp	Pro	Glu
545					550					555					560
Pro	Ser	Pro	Asp	Pro	Glu	Pro	Glu	Pro	Thr	Pro	Asp	Pro	Glu	Pro	Ser
			565						570					575	
Pro	Asp	Pro	Glu	Pro	Glu	Pro	Ser	Pro	Asp	Pro	Asp	Pro	Asp	Ser	Asp
			580					585					590		
Ser	Asp	Ser	Asp	Ser	Gly	Ser	Asp	Ser	Asp	Ser	Gly	Ser	Asp	Ser	Asp
		595					600					605			
Ser	Glu	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp
	610					615					620				
Ser	Asp	Ser	Glu	Ser	Asp	Ser	Asp	Ser	Glu	Ser	Asp	Ser	Asp	Ser	Asp
625					630					635					640
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp
			645						650					655	
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Glu	Ser	Asp
			660					665					670		
Ser	Asp	Ser	Glu	Ser	Asp	Ser	Glu	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp
			675				680					685			
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp
	690					695					700				
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp
705					710					715					720
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp
			725						730					735	
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp
			740					745					750		

```
<210> SEQ ID NO 2
<211> LENGTH: 2969
<212> TYPE: DNA
<213> ORGANISM: Staphylococcus aureus
```

<400> SEQUENCE: 2

tagaaattga	aatggagtaa	tatttttgaa	aaaagaatt	gattatttgt	cgaataagca	60		
gaataagtat	tcgattagac	gttttacagt	aggtagcaca	tcagtaatag	taggggcaac	120		
tatactattt	gggataggca	atcatcaagc	acaagcttca	gaacaatcga	acgatacaac	180		
gcaatcttcg	aaaaataatg	caagtgcaga	ttccgaaaaa	aacaatatga	tagaaacacc	240		
tcaattaaat	acaacggcta	atgatacatc	tgatattagt	gcaaacacaa	acagtgcgaa	300		
tgtagatagc	acaacaaaac	caatgtctac	acaaacgagc	aataccacta	caacagagcc	360		
agcttcaaca	aatgaaacac	ctcaaccgac	ggcaattaaa	aatcaagcaa	ctgctgcaaa	420		
aatgcaagat	caaactgttc	ctcaagaagg	aaattctcaa	gtagataata	aaacaacgaa	480		
tgatgcta	at	agcatagcaa	caaacagtga	gcttaaaaat	tctcaaacat	tagatttacc	540	
acaatcatca	ccacaaacga	tttccaatgc	gcaaggaact	agtaaacc	aa	gtgttagaac	600	
gagagctgta	cgtagtttag	ctgttgctga	accggtagta	aatgctgctg	atgctaaagg		660	
tacaaatgta	aatgataaag	ttacggcaag	taattttcaag	ttagaaaaga	ctacatttga		720	
ccctaatacaa	agtggtaaca	cattttatggc	ggcaaatttt	acagtgacag	ataaagtgaa		780	
atcaggggat	tatttttacag	cgaagttacc	agatagttta	actggtaatg	gagacgtgga		840	
ttatttcta	at	tcaaataata	cgatgccaat	tg	cagacatt	aaaagtacga	atggcgatgt	900
tgtagctaaa	gcaacatatg	atatcttgac	taagacgtat	acatttgtct	ttacagatta		960	
tgtaaataat	aaagaaaata	ttaacggaca	attttccatta	cctttattta	cagaccgagc		1020	

-continued

aaaggcacct	aatcaggaa	catatgatgc	gaatattaat	attgcggatg	aatgttttaa	1080
taataaaatt	acttataact	atagttcgcc	aattgcagga	attgataaac	caaatggcgc	1140
gaacatttct	tctcaaatta	ttggtgtaga	tacagcttca	ggtcaaaaca	catacaagca	1200
aacagtattt	gttaacccta	agcaacgagt	tttaggtaat	acgtgggtgt	atattaaagg	1260
ctaccaagat	aaaatcgaag	aaagtagcgg	taaagtaagt	gctacagata	caaaactgag	1320
aatttttgaa	gtgaatgata	catctaaatt	atcagatagc	tactatgcag	atccaaatga	1380
ctctaacctt	aaagaagtaa	cagaccaatt	taaaaataga	atctattatg	agcatccaaa	1440
tgtagctagt	attaaatttg	gtgatattac	taaaacatat	gtagtattag	tagaagggca	1500
ttacgacaat	acaggtaa	acttaaaaac	tcaggttatt	caagaaaatg	ttgatcctgt	1560
aacaaataga	gactacagta	ttttcggttg	gaataatgag	aatgttgtac	gttatgggtg	1620
tggaagtgct	gatggtgatt	cagcagtaaa	tccgaaagac	ccaactccag	ggccgccggt	1680
tgacccagaa	ccaagtccag	accagaacc	agaaccaacg	ccagatccag	aaccaagtcc	1740
agacccagaa	cgggaacc	gccagaccc	ggatccggat	tcggattcag	acagtgactc	1800
aggctcagac	agcgactcag	gttcagatag	cgactcagaa	tcagatagcg	attcggattc	1860
agacagtgat	tcagattcag	acagcgactc	agaatcagat	agcgattcag	aatcagatag	1920
cgactcagat	tcagatagcg	attcagattc	agatagcgat	tcagattcag	atagcgattc	1980
ggattcagac	agtgattcag	attcagacag	cgactcagaa	tcagatagcg	actcagaatc	2040
agatagttag	tcagattcag	acagtgactc	ggactcagac	agtgattcag	actcagatag	2100
cgattcagac	tcagatagcg	attcagattc	agacagcgac	tcagattcag	acagcgactc	2160
agactcagat	agcgactcag	actcagacag	cgactcagat	tcagatagcg	attcagactc	2220
agacagcgac	tcagactcag	acagcgactc	agactcagat	agcgactcag	attcagatag	2280
cgattcagac	tcagacagcg	actcagattc	agatagcgat	tcggactcag	acagcgattc	2340
agattcagac	agcgactcag	actcggatag	cgattcagat	tcagatagcg	attcggattc	2400
agacagtgat	tcagattcag	acagcgactc	agactcggat	agcgactcag	actcagacag	2460
cgattcagac	tcagatagcg	actcagactc	ggatagcgac	tcggattcag	atagcgactc	2520
agactcagat	agtgactccg	attcaagagt	tacaccacca	aataatgaac	agaaagcacc	2580
atcaaatacct	aaaggtgaag	taaaccattc	taataaggta	tcaaaacaac	acaaaactga	2640
tgctttacca	gaaacaggag	ataagagcga	aaacacaaat	gcaactttat	ttggtgcaat	2700
gatggcatta	ttaggatcat	tactattgtt	tagaaaacgc	aagcaagatc	ataaagaaaa	2760
agcgtaaata	cttttttagg	ccgaatacat	ttgtattcgg	tttttttgtt	gaaaatgatt	2820
ttaaagttaa	ttgattaagc	gtaaaatgtt	gataaagtag	aattagaaag	gggtcatgac	2880
gtatggctta	tatttcatta	aactatcatt	caccaacaat	tggtatgcat	caaaatttga	2940
cagtcatttt	accggaagaa	cgagaattc				2969

<210> SEQ ID NO 3
<211> LENGTH: 930
<212> TYPE: PRT
<213> ORGANISM: Staphylococcus aureus

<400> SEQUENCE: 3

Met Asn Asn Lys Lys Thr Ala Thr Asn Arg Lys Gly Met Ile Pro Asn
1 5 10 15

-continued

Arg	Leu	Asn	Lys	Phe	Ser	Ile	Arg	Lys	Tyr	Ser	Val	Gly	Thr	Ala	Ser	
		20						25					30			
Ile	Leu	Val	Gly	Thr	Thr	Leu	Ile	Phe	Gly	Leu	Ser	Gly	His	Glu	Ala	
		35					40					45				
Lys	Ala	Ala	Glu	His	Thr	Asn	Gly	Glu	Leu	Asn	Gln	Ser	Lys	Asn	Glu	
	50					55					60					
Thr	Thr	Ala	Pro	Ser	Glu	Asn	Lys	Thr	Thr	Lys	Lys	Val	Asp	Ser	Arg	
65					70					75					80	
Gln	Leu	Lys	Asp	Asn	Thr	Gln	Thr	Ala	Thr	Ala	Asp	Gln	Pro	Lys	Val	
				85					90					95		
Thr	Met	Ser	Asp	Ser	Ala	Thr	Val	Lys	Glu	Thr	Ser	Ser	Asn	Met	Gln	
			100					105					110			
Ser	Pro	Gln	Asn	Ala	Thr	Ala	Asn	Gln	Ser	Thr	Thr	Lys	Thr	Ser	Asn	
		115					120					125				
Val	Thr	Thr	Asn	Asp	Lys	Ser	Ser	Thr	Thr	Tyr	Ser	Asn	Glu	Thr	Asp	
	130					135					140					
Lys	Ser	Asn	Leu	Thr	Gln	Ala	Lys	Asp	Val	Ser	Thr	Thr	Pro	Lys	Thr	
145					150					155					160	
Thr	Thr	Ile	Lys	Pro	Arg	Thr	Leu	Asn	Arg	Met	Ala	Val	Asn	Thr	Val	
			165						170					175		
Ala	Ala	Pro	Gln	Gln	Gly	Thr	Asn	Val	Asn	Asp	Lys	Val	His	Phe	Ser	
			180					185					190			
Asn	Ile	Asp	Ile	Ala	Ile	Asp	Lys	Gly	His	Val	Asn	Gln	Thr	Thr	Gly	
		195					200					205				
Lys	Thr	Glu	Phe	Trp	Ala	Thr	Ser	Ser	Asp	Val	Leu	Lys	Leu	Lys	Ala	
	210					215					220					
Asn	Tyr	Thr	Ile	Asp	Asp	Ser	Val	Lys	Glu	Gly	Asp	Thr	Phe	Thr	Phe	
225				230						235					240	
Lys	Tyr	Gly	Gln	Tyr	Phe	Arg	Pro	Gly	Ser	Val	Arg	Leu	Pro	Ser	Gln	
			245						250					255		
Thr	Gln	Asn	Leu	Tyr	Asn	Ala	Gln	Gly	Asn	Ile	Ile	Ala	Lys	Gly	Ile	
		260						265					270			
Tyr	Asp	Ser	Thr	Thr	Asn	Thr	Thr	Thr	Tyr	Thr	Phe	Thr	Asn	Tyr	Val	
	275					280						285				
Asp	Gln	Tyr	Thr	Asn	Val	Arg	Gly	Ser	Phe	Glu	Gln	Val	Ala	Phe	Ala	
	290					295					300					
Lys	Arg	Lys	Asn	Ala	Thr	Thr	Asp	Lys	Thr	Ala	Tyr	Lys	Met	Glu	Val	
305					310					315				320		
Thr	Leu	Gly	Asn	Asp	Thr	Tyr	Ser	Glu	Glu	Ile	Ile	Val	Asp	Tyr	Gly	
			325						330					335		
Asn	Lys	Lys	Ala	Gln	Pro	Leu	Ile	Ser	Ser	Thr	Asn	Tyr	Ile	Asn	Asn	
			340					345					350			
Glu	Asp	Leu	Ser	Arg	Asn	Met	Thr	Ala	Tyr	Val	Asn	Gln	Pro	Lys	Asn	
	355					360						365				
Thr	Tyr	Thr	Lys	Gln	Thr	Phe	Val	Thr	Asn	Leu	Thr	Gly	Tyr	Lys	Phe	
	370					375					380					
Asn	Pro	Asn	Ala	Lys	Asn	Phe	Lys	Ile	Tyr	Glu	Val	Thr	Asp	Gln	Asn	
385					390					395					400	
Gln	Phe	Val	Asp	Ser	Phe	Thr	Pro	Asp	Thr	Ser	Lys	Leu	Lys	Asp	Val	
			405						410					415		

Thr	Asp	Gln	Phe	Asp	Val	Ile	Tyr	Ser	Asn	Asp	Asn	Lys	Thr	Ala	Thr	
			420					425					430			
Val	Asp	Leu	Met	Lys	Gly	Gln	Thr	Ser	Ser	Asn	Lys	Gln	Tyr	Ile	Ile	
		435					440					445				
Gln	Gln	Val	Ala	Tyr	Pro	Asp	Asn	Ser	Ser	Thr	Asp	Asn	Gly	Lys	Ile	
	450					455					460					
Asp	Tyr	Thr	Leu	Asp	Thr	Asp	Lys	Thr	Lys	Tyr	Ser	Trp	Ser	Asn	Ser	
465					470					475					480	
Tyr	Ser	Asn	Val	Asn	Gly	Ser	Ser	Thr	Ala	Asn	Gly	Asp	Gln	Lys	Lys	
				485					490					495		
Tyr	Asn	Leu	Gly	Asp	Tyr	Val	Trp	Glu	Asp	Thr	Asn	Lys	Asp	Gly	Lys	
		500						505					510			
Gln	Asp	Ala	Asn	Glu	Lys	Gly	Ile	Lys	Gly	Val	Tyr	Val	Ile	Leu	Lys	
		515					520					525				
Asp	Ser	Asn	Gly	Lys	Glu	Leu	Asp	Arg	Thr	Thr	Thr	Asp	Glu	Asn	Gly	
	530					535						540				
Lys	Tyr	Gln	Phe	Thr	Gly	Leu	Ser	Asn	Gly	Thr	Tyr	Ser	Val	Glu	Phe	
545					550					555					560	
Ser	Thr	Pro	Ala	Gly	Tyr	Thr	Pro	Thr	Thr	Ala	Asn	Val	Gly	Thr	Asp	
				565					570					575		
Asp	Ala	Val	Asp	Ser	Asp	Gly	Leu	Thr	Thr	Thr	Gly	Val	Ile	Lys	Asp	
		580						585					590			
Ala	Asp	Asn	Met	Thr	Leu	Asp	Ser	Gly	Phe	Tyr	Lys	Thr	Pro	Lys	Tyr	
		595					600					605				
Ser	Leu	Gly	Asp	Tyr	Val	Trp	Tyr	Asp	Ser	Asn	Lys	Asp	Gly	Lys	Arg	
	610					615					620					
Asp	Ser	Thr	Glu	Lys	Gly	Ile	Lys	Gly	Val	Lys	Val	Thr	Leu	Gln	Asn	
625					630					635					640	
Glu	Lys	Gly	Glu	Val	Ile	Gly	Thr	Thr	Glu	Thr	Asp	Glu	Asn	Gly	Lys	
				645					650					655		
Tyr	Arg	Phe	Asp	Asn	Leu	Asp	Ser	Gly	Lys	Tyr	Lys	Val	Ile	Phe	Glu	
			660					665					670			
Lys	Pro	Ala	Gly	Leu	Thr	Gln	Thr	Gly	Thr	Asn	Thr	Thr	Glu	Asp	Asp	
		675					680						685			
Lys	Asp	Ala	Asp	Gly	Gly	Glu	Val	Asp	Val	Thr	Ile	Thr	Asp	His	Asp	
	690					695					700					
Asp	Phe	Thr	Leu	Asp	Asn	Gly	Tyr	Tyr	Glu	Glu	Glu	Thr	Ser	Asp	Ser	
705					710					715					720	
Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	
				725					730					735		
Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	
				740					745				750			
Asp	Ser	Asp	S													

-continued

820					825					830						
Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	
835					840					845						
Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	
850					855					860						
Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Asn	Asp	Ser	Asp	Ser	
865					870					875					880	
Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ala	Gly	Lys	His	Thr	Pro	Ala	Lys	Pro	
885					890					895						
Met	Ser	Thr	Val	Lys	Asp	Gln	His	Lys	Thr	Ala	Lys	Ala	Leu	Pro	Glu	
900					905					910						
Thr	Gly	Ser	Glu	Asn	Asn	Asn	Ser	Asn	Asn	Gly	Thr	Leu	Phe	Gly	Gly	
915					920					925						
Leu	Phe															
930																

<210> SEQ ID NO 4
<211> LENGTH: 2841
<212> TYPE: DNA
<213> ORGANISM: Staphylococcus aureus

<400> SEQUENCE: 4

atgaataata	aaaagacagc	aacaaataga	aaaggcatga	taccaaatcg	attaaacaaa	60
ttttcgataa	gaaagtattc	tgtaggtact	gcttcaatth	tagtagggac	aacattgatt	120
tttggtttaa	gtggtcatga	agctaaagcg	gcagaacata	cgaatggaga	attaaatcaa	180
tcaaaaaatg	aaacgacagc	ccaagttag	aataaaacaa	ctaaaaagt	tgatagtcgt	240
caactaaaag	acaatacgca	aactgcaact	gcagatcagc	ctaaagtgac	aatgagtgat	300
agtgcacacg	ttaaagaaac	tagtagtaac	atgcaatcac	cacaaaacgc	tacagctaata	360
caatctacta	caaaaactag	caatgtaaca	acaaatgata	aatcatcaac	tacatatagt	420
aatgaaactg	ataaaagtaa	tttaacacaa	gcaaaagatg	tttcaactac	acctaaaaca	480
acgactatta	aaccaagaac	tttaaatacg	atggcagtg	atactgttgc	agctccacaa	540
caaggaacaa	atgttaatga	taaagtacat	ttttcaaata	ttgacattgc	gattgataaa	600
ggacatgtta	atcagactac	tggtaaaact	gaattttggg	caacttcaag	tgatgtttta	660
aaattaaaag	caaattacac	aatcgatgat	tctgttaaag	agggcgatac	atttactttt	720
aaatatgggc	aatatttccg	tccaggatca	gtaagattac	cttcacaaac	tcaaaattta	780
tataatgccc	aaggtaatat	tattgcaaaa	ggtatttatg	atagtacaac	aaacacaaca	840
acatatactt	ttacgaacta	tgtagatcaa	tatacaaatg	ttagaggtag	ctttgaacaa	900
gttgcatthg	cgaaacgtaa	aatgcaaca	actgataaaa	cagcttataa	aatggaagta	960
actttaggta	atgatacata	tagcgaagaa	atcattgtcg	attatggtaa	taaaaaagca	1020
caaccgctta	tttcaagtac	aaactatatt	aacaatgaag	atttatcgcg	taatattgact	1080
gcatatgtaa	atcaacctaa	aaatacatat	actaaacaaa	cgtttggttac	taattttaact	1140
ggatataaat	ttaatccaaa	tgcaaaaaac	ttcaaaatth	acgaagtgc	agatcaaaat	1200
caatttgthg	atagthttac	ccctgatact	tcaaaactta	aagatgttac	tgatcaattc	1260
gatgttatth	atagtaatga	taataaaaca	gctacagtcg	atttaattga	aggccaaaca	1320
agcagcaata	aacaatacat	cattcaacaa	gttgcttatc	cagataatag	ttcaacagat	1380

-continued

aatggaaaaa ttgattatac tttagacact gacaaaacta aatatagttg gtcaaatagt 1440
tattcaaatg tgaatggctc atcaactgct aatggcgacc aaaagaaata taatctaggt 1500
gactatgtat gggaagatac aaataaagat ggtaaacaag atgccaatga aaaagggatt 1560
aaagggtgtt atgtcattct taaagatagt aacggtaaag aattagatcg tacgacaaca 1620
gatgaaaatg gtaaatatca gttcactggg ttaagcaatg gaacttatag tgtagagttt 1680
tcaacaccag ccggttatac accgacaact gcaaatgtag gtacagatga tgctgtagat 1740
tctgatggac taactacaac aggtgtcatt aaagacgctg acaacatgac attagatagt 1800
ggattctaca aaacaccaa atatagttta ggtgattatg tttggtacga cagtaataaa 1860
gatggtaaac gagattcgac tgaaaaagga attaaagggtg ttaaagttac tttgcaaac 1920
gaaaaaggcg aagtaattgg tacaactgaa acagatgaaa atggtaaata ccgctttgat 1980
aathtagata gtggtaaata caaagttatc tttgaaaaac ctgctggctt aactcaaaca 2040
ggtacaaata caactgaaga tgataaagat gccgatggtg gcgaagttga tgtaacaatt 2100
acggatcatg atgatttcac acttgataat ggctactacg aagaagaaac atcagatagc 2160
gactcagatt ctgacagcga ttcagactca gatagcgact cagattcaga tagcgactca 2220
gattcagaca gcgattcaga cagcgactca gactcagata gcgattcaga ttcagacagc 2280
gactcagact cagacagcaa ttcagactcg gatagcgact cagactcaga tagcgactca 2340
gattcggata gcgactcaga ctcagatagc gattcagatt cagatagcga ttcggactca 2400
gacagtgatt cagattcaga ctcagatagc gactcagatt ctgacagcga ttcagactca 2460
gacagcgact cagactcaga cagtgattca gattcagaca gcgactcaga ttcagatagc 2520
gactcagact cagatagcga ctcagactca gatagcgact cagactcgga tagcgattca 2580
gattcagaca gcgactcaga ttcagatagc gattcggact cagacaacga ctcagattca 2640
gatagcgatt cagattcaga tgcaggtaaa catactccgg ctaaaccaat gagtacgggt 2700
aaagatcagc ataaaacagc taaagcatta ccagaaacag gtagtgaaaa taataattca 2760
aataatggca cattattcgg tggattattc gcggcattag gatcattatt gtcattcgg 2820
cgtcgtaaaa aacaaaataa a 2841

<210> SEQ ID NO 5
<211> LENGTH: 1315
<212> TYPE: PRT
<213> ORGANISM: Staphylococcus aureus

<400> SEQUENCE: 5

Met Leu Asn Arg Glu Asn Lys Thr Ala Ile Thr Arg Lys Gly Met Val
1 5 10 15
Ser Asn Arg Leu Asn Lys Phe Ser Ile Arg Lys Tyr Thr Val Gly Thr
20 25 30
Ala Ser Ile Leu Val Gly Thr Thr Leu Ile Phe Gly Leu Gly Asn Gln
35 40 45
Glu Ala Lys Ala Ala Glu Ser Thr Asn Lys Glu Leu Asn Glu Ala Thr
50 55 60
Thr Ser Ala Ser Asp Asn Gln Ser Ser Asp Lys Val Asp Met Gln Gln
65 70 75 80
Leu Asn Gln Glu Asp Asn Thr Lys Asn Asp Asn Gln Lys Glu Met Val
85 90 95

Ser	Ser	Gln	Gly	Asn	Glu	Thr	Thr	Ser	Asn	Gly	Asn	Lys	Leu	Ile	Glu
			100				105						110		
Lys	Glu	Ser	Val	Gln	Ser	Thr	Thr	Gly	Asn	Lys	Val	Glu	Val	Ser	Thr
		115					120					125			
Ala	Lys	Ser	Asp	Glu	Gln	Ala	Ser	Pro	Lys	Ser	Thr	Asn	Glu	Asp	Leu
		130					135					140			
Asn	Thr	Lys	Gln	Thr	Ile	Ser	Asn	Gln	Glu	Ala	Leu	Gln	Pro	Asp	Leu
		145					150					155			
Gln	Glu	Asn	Lys	Ser	Val	Val	Asn	Val	Gln	Pro	Thr	Asn	Glu	Glu	Asn
							165					170			175
Lys	Lys	Val	Asp	Ala	Lys	Thr	Glu	Ser	Thr	Thr	Leu	Asn	Val	Lys	Ser
							180							190	
Asp	Ala	Ile	Lys	Ser	Asn	Asp	Glu	Thr	Leu	Val	Asp	Asn	Asn	Ser	Asn
		195							200					205	
Ser	Asn	Asn	Glu	Asn	Asn	Ala	Asp	Ile	Ile	Leu	Pro	Lys	Ser	Thr	Ala
		210							215					220	
Pro	Lys	Arg	Leu	Asn	Thr	Arg	Met	Arg	Ile	Ala	Ala	Val	Gln	Pro	Ser
		225											235		
Ser	Thr	Glu	Ala	Lys	Asn	Val	Asn	Asp	Leu	Ile	Thr	Ser	Asn	Thr	Thr
							245								
Leu	Thr	Val	Val	Asp	Ala	Asp	Lys	Asn	Asn	Lys	Ile	Val	Pro	Ala	Gln
							260								
Asp	Tyr	Leu	Ser	Leu	Lys	Ser	Gln	Ile	Thr	Val	Asp	Asp	Lys	Val	Lys
		275							280					285	
Ser	Gly	Asp	Tyr	Phe	Thr	Ile	Lys	Tyr	Ser	Asp	Thr	Val	Gln	Val	Tyr
		290							295					300	
Gly	Leu	Asn	Pro	Glu	Asp	Ile	Lys	Asn	Ile	Gly	Asp	Ile	Lys	Asp	Pro
		305											315		
Asn	Asn	Gly	Glu	Thr	Ile	Ala	Thr	Ala	Lys	His	Asp	Thr	Ala	Asn	Asn
							325								
Leu	Ile	Thr	Tyr	Thr	Phe	Thr	Asp	Tyr	Val	Asp	Arg	Phe	Asn	Ser	Val
							340								
Gln	Met	Gly	Ile	Asn	Tyr	Ser	Ile	Tyr	Met	Asp	Ala	Asp	Thr	Ile	Pro
		355													365
Val	Ser	Lys	Asn	Asp	Val	Glu	Phe	Asn	Val	Thr	Ile	Gly	Asn	Thr	Thr
		370													380
Thr	Lys	Thr	Thr	Ala	Asn	Ile	Gln	Tyr	Pro	Asp	Tyr	Val	Val	Asn	Glu
		385													400
Lys	Asn	Ser	Ile	Gly	Ser	Ala	Phe	Thr	Glu	Thr	Val	Ser	His	Val	Gly
							405								
Asn	Lys	Glu	Asn	Pro	Gly	Tyr	Tyr	Lys	Gln	Thr	Ile	Tyr	Val	Asn	Pro
							420								
Ser	Glu	Asn	Ser	Leu	Thr	Asn	Ala	Lys	Leu	Lys	Val	Gln	Ala	Tyr	His
		435							440						
Ser	Ser	Tyr	Pro	Asn	Asn	Ile	Gly	Gln	Ile	Asn	Lys	Asp	Val	Thr	Asp
		450													460
Ile	Lys	Ile	Tyr	Gln	Val	Pro	Lys	Gly	Tyr	Thr	Leu	Asn	Lys	Gly	Tyr

Lys	Ile	Thr	Tyr	Gly	Asp	Asn	Asn	Ser	Ala	Val	Ile	Asp	Phe	Gly	Asn	
			500					505					510			
Ala	Asp	Ser	Ala	Tyr	Val	Val	Met	Val	Asn	Thr	Lys	Phe	Gln	Tyr	Thr	
		515					520					525				
Asn	Ser	Glu	Ser	Pro	Thr	Leu	Val	Gln	Met	Ala	Thr	Leu	Ser	Ser	Thr	
	530					535					540					
Gly	Asn	Lys	Ser	Val	Ser	Thr	Gly	Asn	Ala	Leu	Gly	Phe	Thr	Asn	Asn	
545					550					555					560	
Gln	Ser	Gly	Gly	Ala	Gly	Gln	Glu	Val	Tyr	Lys	Ile	Gly	Asn	Tyr	Val	
				565					570					575		
Trp	Glu	Asp	Thr	Asn	Lys	Asn	Gly	Val	Gln	Glu	Leu	Gly	Glu	Lys	Gly	
			580					585					590			
Val	Gly	Asn	Val	Thr	Val	Thr	Val	Phe	Asp	Asn	Asn	Thr	Asn	Thr	Lys	
		595					600					605				
Val	Gly	Glu	Ala	Val	Thr	Lys	Glu	Asp	Gly	Ser	Tyr	Leu	Ile	Pro	Asn	
	610					615					620					
Leu	Pro	Asn	Gly	Asp	Tyr	Arg	Val	Glu	Phe	Ser	Asn	Leu	Pro	Lys	Gly	
625					630					635					640	
Tyr	Glu	Val	Thr	Pro	Ser	Lys	Gln	Gly	Asn	Asn	Glu	Glu	Leu	Asp	Ser	
				645					650					655		
Asn	Gly	Leu	Ser	Ser	Val	Ile	Thr	Val	Asn	Gly	Lys	Asp	Asn	Leu	Ser	
			660					665					670			
Ala	Asp	Leu	Gly	Ile	Tyr	Lys	Pro	Lys	Tyr	Asn	Leu	Gly	Asp	Tyr	Val	
		675					680					685				
Trp	Glu	Asp	Thr	Asn	Lys	Asn	Gly	Ile	Gln	Asp	Gln	Asp	Glu	Lys	Gly	
	690					695					700					
Ile	Ser	Gly	Val	Thr	Val	Thr	Leu	Lys	Asp	Glu	Asn	Gly	Asn	Val	Leu	
705					710					715					720	
Lys	Thr	Val	Thr	Thr	Asp	Ala	Asp	Gly	Lys	Tyr	Lys	Phe	Thr	Asp	Leu	
				725					730					735		
Asp	Asn	Gly	Asn	Tyr	Lys	Val	Glu	Phe	Thr	Thr	Pro	Glu	Gly	Tyr	Thr	
			740					745				750				
Pro	Thr	Thr	Val	Thr	Ser	Gly	Ser	Asp	Ile	Glu	Lys	Asp	Ser	Asn	Gly	
		755					760					765				
Leu	Thr	Thr	Thr	Gly	Val	Ile	Asn	Gly	Ala	Asp	Asn	Met	Thr	Leu	Asp	
	770					775					780					
Ser	Gly	Phe	Tyr	Lys	Thr	Pro	Lys	Tyr	Asn	Leu	Gly	Asn	Tyr	Val	Trp	
785					790					795					800	
Glu	Asp	Thr	Asn	Lys	Asp	Gly	Lys	Gln	Asp	Ser	Thr	Glu	Lys	Gly	Ile	
				805					810					815		
Ser	Gly	Val	Thr	Val	Thr	Leu	Lys	Asn	Glu	Asn	Gly	Glu	Val	Leu	Gln	
			820					825				830				
Thr	Thr	Lys	Thr	Asp												

-continued

900					905					910					
Thr	Asn	Lys	Asn	Gly	Val	Gln	Asp	Lys	Asp	Glu	Lys	Gly	Ile	Ser	Gly
	915						920					925			
Val	Thr	Val	Thr	Leu	Lys	Asp	Glu	Asn	Asp	Lys	Val	Leu	Lys	Thr	Val
	930					935					940				
Thr	Thr	Asp	Glu	Asn	Gly	Lys	Tyr	Gln	Phe	Thr	Asp	Leu	Asn	Asn	Gly
945					950					955					960
Thr	Tyr	Lys	Val	Glu	Phe	Glu	Thr	Pro	Ser	Gly	Tyr	Thr	Pro	Thr	Ser
				965					970					975	
Val	Thr	Ser	Gly	Asn	Asp	Thr	Glu	Lys	Asp	Ser	Asn	Gly	Leu	Thr	Thr
			980					985					990		
Thr	Gly	Val	Ile	Lys	Asp	Ala	Asp	Asn	Met	Thr	Leu	Asp	Ser	Gly	Phe
	995						1000					1005			
Tyr	Lys	Thr	Pro	Lys	Tyr	Ser	Leu	Gly	Asp	Tyr	Val	Trp	Tyr	Asp	Ser
	1010					1015					1020				
Asn	Lys	Asp	Gly	Lys	Gln	Asp	Ser	Thr	Glu	Lys	Gly	Ile	Lys	Asp	Val
1025					1030					1035					1040
Lys	Val	Thr	Leu	Leu	Asn	Glu	Lys	Gly	Glu	Val	Ile	Gly	Thr	Thr	Lys
				1045					1050					1055	
Thr	Asp	Glu	Asn	Gly	Lys	Tyr	Cys	Phe	Asp	Asn	Leu	Asp	Ser	Gly	Lys
			1060					1065					1070		
Tyr	Lys	Val	Ile	Phe	Glu	Lys	Pro	Ala	Gly	Leu	Thr	Gln	Thr	Gly	Thr
		1075					1080					1085			
Asn	Thr	Thr	Glu	Asp	Asp	Lys	Asp	Ala	Asp	Gly	Gly	Glu	Val	Asp	Val
	1090					1095					1100				
Thr	Ile	Thr	Asp	His	Asp	Asp	Phe	Thr	Leu	Asp	Asn	Gly	Tyr	Tyr	Glu
1105					1110					1115					1120
Glu	Glu	Thr	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser
				1125					1130					1135	
Asp	Arg	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser
			1140					1145					1150		
Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Arg
	1155					1160						1165			
Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser
	1170					1175					1180				
Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser
1185				1190						1195					1200
Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser
				1205					1210					1215	
Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser
			1220					1225					1230		
Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser
		1235					1240					1245			
Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ala	Gly	Lys	His	Thr	Pro	Val	Lys	Pro
	1250					1255					1260				
Met	Ser	Thr	Thr	Lys	Asp	His	His	Asn	Lys	Ala	Lys	Ala	Leu	Pro	Glu
1265					1270					1275					1280
Thr	Gly	Asn	Glu	Asn	Ser	Gly	Ser	Asn	Asn	Ala	Thr	Leu	Phe	Gly	Gly
				1285					1290					1295	
Leu	Phe	Ala	Ala	Leu	Gly	Ser	Leu	Leu	Phe	Gly	Arg	Arg	Lys	Lys	
			1300					1305					1310		

-continued

Gln	Asn	Lys	
	1315		
<210> SEQ ID NO 6			
<211> LENGTH: 3945			
<212> TYPE: DNA			
<213> ORGANISM: Staphylococcus aureus			
<400> SEQUENCE: 6			
atgctaaaca	gagaaaataa	aacggcaata	acaaggaaag gcatggtatc caatcgatta 60
aataaat	ttt cgattagaaa	gtacacagtg	ggaacagcat caattttagt aggtacaaca 120
ttaat	tttttg gtctggggaa	ccaagaagca	aaggctgcag aaagtactaa taaagaattg 180
aacgaagcga	caacttcagc	aagtgataat	caatcgagtg ataaagttga tatgcagcaa 240
ctaaatcaag	aagacaatac	taaaaatgat	aatcaaaaag aaatggtatc atctcaaggt 300
aatgaaacga	cttcaaattg	gaataaatta	atagaaaag aaagtgtaca atctaccact 360
ggaaaataaag	ttgaagt	ttc aactgccaaa	tcagatgagc aagcttcacc aaaatctacg 420
aatgaagatt	taaacactaa	acaaactata	agtaatcaag aagcgttaca acctgatttg 480
caagagaata	aatcagtggt	aaatgttcaa	ccaactaatg aggaaaacaa aaaggtagat 540
gccaaaactg	aatcaactac	attaaatgtt	aaaagtgatg ctatcaagag taatgatgaa 600
actcttggtg	ataacaatag	taattcaa	aatgaaaata atgcagatat cat
tttgcca	aaaagtacag	cacctaaacg	tttgaataca agaatgcgta tagcagcagt acagccatca 720
tcaacagagg	ctaaaaatgt	taatgattta	atcacatcaa atacaacatt aactgtcgtt 780
gatgcagata	aaaacaataa	aatcgtacca	gcccaagatt atttatcatt aaaatcacia 840
attacagttg	atgacaaagt	taaatcaggt	gattatttca caattaaata ctcagataca 900
gtacaagtat	atggattgaa	tccggaagat	attaaaaata ttggtgatat taaagatcca 960
aataatggtg	aaacaattgc	gactgcaaaa	catgatactg caaataattt aattacatat 1020
acatttacag	attatg	ttga tcgattt	aat tctgtacaaa tgggaattaa ttattcaatt 1080
tatatggatg	ctgatacaat	tcctgttagt	aaaaacgatg ttgagtttaa tgttacgata 1140
ggtaatacta	caacaaaaac	aactgctaac	attcaatatc cagattatgt tgtaaatgag 1200
aaaaattcaa	ttggatcagc	gttcactgaa	acagtttcac atgttggaaa taaagaaaat 1260
ccagggtact	ataaacaac	gatttatgta	aatccatcgg aaaattcttt aacaaatgcc 1320
aaactaaaag	ttcaagctta	ccactcaagt	tatcctaata atatcgggca aataaataaa 1380
gatgtaacag	atataaaaat	atatcaagtt	cctaaagggt atacattaaa taaaggatac 1440
gatgtgaata	ctaaagagct	tacagatgta	acaaatcaat acttcagaa aattacatat 1500
ggcgacaaca	atagcgctgt	tattgatttt	ggaaatgcag attctgctta tg
ttgtaatg	gttaatacaa	aattccaata	tacaaatagc gaaagcccaa cacttg
tca aatggctact	ttatcttcaa	caggtaataa	atccgtttct actggcaatg ctttaggatt tactaataac 1680
caaagtggcg	gagctgg	tca agaagtatat	aaaattggta actacgtatg ggaagatact 1740
aataaaaacg	gtgttcaaga	attaggagaa	aaaggcgttg gcaatgtaac tgtaactgta 1800
tttgataata	atacaaat	ac aaaagtagga	gaagcagtta ctaaagaaga tgggtcatac 1860
ttgattccaa	acttacctaa	tggagattac	cgtgtagaat tttcaaactt accaaaaggt 1920

-continued					
tatgaagtaa	ccccttcaaa	acaaggtaat	aacgaagaat	tagattcaaa	cggcttatct 1980
tcagttatta	cagttaatgg	caaagataac	ttatctgcag	acttaggtat	ttacaaacct 2040
aaatacaact	taggtgacta	tgtctgggaa	gatacaaata	aaaatggtat	ccaagaccaa 2100
gatgaaaaag	gtatatctgg	cgtaacggta	acattaaaag	atgaaaacgg	taacgtgtta 2160
aaaacagtta	caacagacgc	tgatggcaaa	tataaattta	ctgattttaga	taatggtaat 2220
tataaagttg	aatttactac	accagaaggc	tatacacoga	ctacagtaac	atctggtagc 2280
gacattgaaa	aagactctaa	tggtttaaca	acaacaggtg	ttattaatgg	tgctgataac 2340
atgacattag	atagtggatt	ctacaaaaca	ccaaaatata	atttaggtaa	ttatgtatgg 2400
gaagatacaa	ataaagatgg	taagcaggat	tcaactgaaa	aaggtatttc	aggcgtaaca 2460
gttacattga	aaaatgaaaa	cgggtgaagtt	ttacaaacaa	ctaaaacaga	taaagatggt 2520
aaatatcaat	ttactggatt	agaaaatgga	acttataaag	ttgaattcga	aacaccatca 2580
ggttacacac	caacacaagt	aggttcagga	actgatgaag	gtatagattc	aatgggtaca 2640
tcaacaacag	gtgtcattaa	agataaagat	aacgatacta	ttgactctgg	tttctacaaa 2700
ccgacttaca	acttaggtga	ctatgtatgg	gaagatacaa	ataaaaacgg	tggtcaagat 2760
aaagatgaaa	agggcatttc	aggtgtaaca	gttacgttaa	aagatgaaaa	cgacaaagtt 2820
ttaaaaacag	ttacaacaga	tgaaaatggt	aaatatcaat	tcactgattt	aaacaatgga 2880
acttataaag	ttgaattcga	gacaccatca	ggttatacac	caacttcagt	aacttctgga 2940
aatgatactg	aaaaagattc	taatggttta	acaacaacag	gtgtcattaa	agatgcagat 3000
aacatgacat	tagacagtgg	tttctataaa	acacccaaat	atagtttagg	tgattatggt 3060
tggtacgaca	gtaataaaga	cggcaaacaa	gattcaactg	aaaaaggtat	caaagatggt 3120
aaagttactt	tattaaatga	aaaaggcgaa	gtaattggaa	caactaaaac	agatgaaaat 3180
ggtaaatact	gctttgataa	tttagatagc	ggtaaataca	aagttatttt	tgaaaagcct 3240
gctggcttaa	cacaaacagg	tacaaataca	actgaagatg	ataaagatgc	agatgggtggc 3300
gaagttgacg	taacaattac	ggatcatgat	gatttcacac	ttgataatgg	ctactacgaa 3360
gaagaaacat	cagatagcga	ctcagattcg	gacagcgact	cagattcaga	cagagactca 3420
gactcagata	gtgattcaga	ctcggatagc	gattcagatt	cagacagcga	ttcagattca 3480
gatagcgatt	cagattcaga	cagagactca	gatagtgatt	cagactcaga	tagcgactca 3540
gattcagaca	gcgactcaga	ttcagacagc	gactcagact	cagatagtga	ttcagactca 3600
gatagcgact	cagattcgga	tagcgactca	gattcagaca	gcgactcaga	ctcggatagt 3660
gattcagact	cagatagcga	ctcagactca	gatagcgatt	cagattcaga	tagcgactca 3720
gactcagaca	gcgattcaga	ctcagacagc	gactcagact	cagatgcagg	taagcacaca 3780
cctgttaaac	caatgagtac	tactaaagac	catcacaata	aagcaaaagc	attaccagaa 3840
acaggtaatg	aaaatagcgg	ctcaaataac	gcaacgttat	ttggcggatt	attcgcgaca 3900
ttaggatcat	tattgttatt	cggtcgtcgt	aaaaaacaaa	ataaa	3945

<210> SEQ ID NO 7
<211> LENGTH: 1166
<212> TYPE: PRT
<213> ORGANISM: Staphylococcus aureus

<400> SEQUENCE: 7

Met 1	Ile	Asn	Arg	Asp 5	Asn	Lys	Lys	Ala	Ile 10	Thr	Lys	Lys	Gly	Met 15	Ile
Ser	Asn	Arg	Leu 20	Asn	Lys	Phe	Ser	Ile 25	Arg	Lys	Tyr	Thr	Val 30	Gly	Thr
Ala	Ser	Ile 35	Leu	Val	Gly	Thr	Thr 40	Leu	Ile	Phe	Gly	Leu 45	Gly	Asn	Gln
Glu	Ala	Lys 50	Ala	Ala	Glu	Asn 55	Thr	Ser	Thr	Glu	Asn 60	Ala	Lys	Gln	Asp
Asp 65	Ala	Thr	Thr	Ser	Asp 70	Asn	Lys	Glu	Val	Val 75	Ser	Glu	Thr	Glu	Asn 80
Asn	Ser	Thr	Thr	Glu 85	Asn	Asn	Ser	Thr	Asn 90	Pro	Ile	Lys	Lys	Glu 95	Thr
Asn	Thr	Asp	Ser 100	Gln	Pro	Glu	Ala	Lys 105	Lys	Glu	Ser	Thr	Ser 110	Ser	Ser
Thr	Gln	Lys 115	Gln	Gln	Asn	Asn	Val 120	Thr	Ala	Thr	Thr	Glu 125	Thr	Lys	Pro
Gln	Asn	Ile 130	Glu	Lys	Glu	Asn 135	Val	Lys	Pro	Ser	Thr 140	Asp	Lys	Thr	Ala
Thr 145	Glu	Asp	Thr	Ser	Val 150	Ile	Leu	Glu	Glu	Lys 155	Lys	Ala	Pro	Asn	Asn 160
Thr	Asn	Asn	Asp	Val 165	Thr	Thr	Lys	Pro	Ser 170	Thr	Ser	Glu	Pro	Ser 175	Thr
Ser	Glu	Ile	Gln 180	Thr	Lys	Pro	Thr	Thr 185	Pro	Gln	Glu	Ser	Thr 190	Asn	Ile
Glu	Asn	Ser 195	Gln	Pro	Gln	Pro	Thr 200	Pro	Ser	Lys	Val 205	Asp	Asn	Gln	Val
Thr 210	Asp	Ala	Thr	Asn	Pro	Lys 215	Glu	Pro	Val	Asn	Val 220	Ser	Lys	Glu	Glu
Leu 225	Lys	Asn	Asn	Pro	Glu 230	Lys	Leu	Lys	Glu	Leu 235	Val	Arg	Asn	Asp	Ser 240
Asn	Thr	Asp	His 245	Ser	Thr	Lys	Pro	Val	Ala 250	Thr	Ala	Pro	Thr 255	Ser	Val
Ala	Pro	Lys	Arg 260	Val	Asn	Ala	Lys	Met 265	Arg	Phe	Ala	Val 270	Ala	Gln	Pro
Ala	Ala	Val 275	Ala	Ser	Asn	Asn	Val 280	Asn	Asp	Leu	Ile	Lys 285	Val	Thr	Lys
Gln 290	Thr	Ile	Lys	Val	Gly	Asp 295	Gly	Lys	Asp	Asn	Val 300	Ala	Ala	Ala	His
Asp 305	Gly	Lys	Asp	Ile	Glu 310	Tyr	Asp	Thr	Glu	Phe 315	Thr	Ile	Asp	Asn	Lys 320
Val	Lys	Lys	Gly	Asp 325	Thr	Met	Thr	Ile	Asn 330	Tyr	Asp	Lys	Asn	Val 335	Ile
Pro	Ser	Asp	Leu 340	Thr	Asp	Lys	Asn	Asp 345	Pro	Ile	Asp	Ile	Thr 350	Asp	Pro
Ser	Gly	Glu 355	Val	Ile	Ala	Lys	Gly 360	Thr	Phe	Asp	Lys	Ala 365	Thr	Lys	Gln
Ile 370	Thr	Tyr	Thr	Phe	Thr	Asp 375	Tyr	Val	Asp	Lys	Tyr 380	Glu	Asp	Ile	Lys
Ser 385	Arg	Leu	Thr	Leu	Tyr 390	Ser	Tyr	Ile	Asp	Lys 395	Lys	Thr	Val	Pro	Asn 400
Glu	Thr	Ser	Leu	Asn	Leu	Thr	Phe	Ala	Thr	Ala	Gly	Lys	Glu	Thr	Ser

405							410				415					
Gln	Asn	Val	Thr	Val	Asp	Tyr	Gln	Asp	Pro	Met	Val	His	Gly	Asp	Ser	
			420					425					430			
Asn	Ile	Gln	Ser	Ile	Phe	Thr	Lys	Leu	Asp	Glu	Asp	Lys	Gln	Thr	Ile	
		435				440						445				
Glu	Gln	Gln	Ile	Tyr	Val	Asn	Pro	Leu	Lys	Lys	Ser	Ala	Thr	Asn	Thr	
		450				455						460				
Lys	Val	Asp	Ile	Ala	Gly	Ser	Gln	Val	Asp	Asp	Tyr	Gly	Asn	Ile	Lys	
465				470						475						480
Leu	Gly	Asn	Gly	Ser	Thr	Ile	Ile	Asp	Gln	Asn	Thr	Glu	Ile	Lys	Val	
				485				490						495		
Tyr	Lys	Val	Asn	Ser	Asp	Gln	Gln	Leu	Pro	Gln	Ser	Asn	Arg	Ile	Tyr	
		500						505						510		
Asp	Phe	Ser	Gln	Tyr	Glu	Asp	Val	Thr	Ser	Gln	Phe	Asp	Asn	Lys	Lys	
		515				520						525				
Ser	Phe	Ser	Asn	Asn	Val	Ala	Thr	Leu	Asp	Phe	Gly	Asp	Ile	Asn	Ser	
530						535						540				
Ala	Tyr	Ile	Ile	Lys	Val	Val	Ser	Lys	Tyr	Thr	Pro	Thr	Ser	Asp	Gly	
545				550						555						560
Glu	Leu	Asp	Ile	Ala	Gln	Gly	Thr	Ser	Met	Arg	Thr	Thr	Asp	Lys	Tyr	
				565				570						575		
Gly	Tyr	Tyr	Asn	Tyr	Ala	Gly	Tyr	Ser	Asn	Phe	Ile	Val	Thr	Ser	Asn	
		580						585						590		
Asp	Thr	Gly	Gly	Gly	Asp	Gly	Thr	Val	Lys	Pro	Glu	Glu	Lys	Leu	Tyr	
		595				600						605				
Lys	Ile	Gly	Asp	Tyr	Val	Trp	Glu	Asp	Val	Asp	Lys	Asp	Gly	Val	Gln	
610						615						620				
Gly	Thr	Asp	Ser	Lys	Glu	Lys	Pro	Met	Ala	Asn	Val	Leu	Val	Thr	Leu	
625				630						635						640
Thr	Tyr	Pro	Asp	Gly	Thr	Thr	Lys	Ser	Val	Arg	Thr	Asp	Ala	Asn	Gly	
				645				650						655		
His	Tyr	Glu	Phe	Gly	Gly	Leu	Lys	Asp	Gly	Glu	Thr	Tyr	Thr	Val	Lys	
		660						665						670		
Phe	Glu	Thr	Pro	Thr	Gly	Tyr	Leu	Pro	Thr	Lys	Val	Asn	Gly	Thr	Thr	
		675				680						685				
Asp	Gly	Glu	Lys	Asp	Ser	Asn	Gly	Ser	Ser	Val	Thr	Val	Lys	Ile	Asn	
690						695						700				
Gly	Lys	Asp	Asp	Met	Ser	Leu	Asp	Thr	Gly	Phe	Tyr	Lys	Glu	Pro	Lys	
705				710						715						720
Tyr	Asn	Leu	Gly	Asp	Tyr	Val	Trp	Glu	Asp	Thr	Asn	Lys	Asp	Gly	Ile	
				725				730						735		
Gln	Asp	Ala	Asn	Glu	Pro	Gly	Ile	Lys	Asp	Val	Lys	Val	Thr	Leu	Lys	
		740						745						750		
Asp	Ser	Thr	Gly	Lys	Val	Ile	Gly	Thr	Thr	Thr	Thr	Asp	Ala	Ser	Gly	
		755				760						765				

-continued

Asp	Asn	Met	Thr	Leu	Asp	Arg	Gly	Phe	Tyr	Lys	Thr	Pro	Lys	Tyr	Ser	
			820					825					830			
Leu	Gly	Asp	Tyr	Val	Trp	Tyr	Asp	Ser	Asn	Lys	Asp	Gly	Lys	Gln	Asp	
		835					840					845				
Ser	Thr	Glu	Lys	Gly	Ile	Lys	Asp	Val	Thr	Val	Thr	Leu	Gln	Asn	Glu	
	850					855					860					
Lys	Gly	Glu	Val	Ile	Gly	Thr	Thr	Lys	Thr	Asp	Glu	Asn	Gly	Lys	Tyr	
865					870					875					880	
Arg	Phe	Asp	Asn	Leu	Asp	Ser	Gly	Lys	Tyr	Lys	Val	Ile	Phe	Glu	Lys	
			885						890					895		
Pro	Ala	Gly	Leu	Thr	Gln	Thr	Val	Thr	Asn	Thr	Thr	Glu	Asp	Asp	Lys	
			900					905					910			
Asp	Ala	Asp	Gly	Gly	Glu	Val	Asp	Val	Thr	Ile	Thr	Asp	His	Asp	Asp	
		915					920					925				
Phe	Thr	Leu	Asp	Asn	Gly	Tyr	Phe	Glu	Glu	Asp	Thr	Ser	Asp	Ser	Asp	
	930					935					940					
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	
945					950				955						960	
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	
				965				970						975		
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	
			980				985					990				
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	
		995				1000					1005					
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	
	1010				1015					1020						
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	
1025				1030					1035						1040	
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	
			1045				1050					1055				
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	
		1060				1065					1070					
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	
	1075				1080						1085					
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	
	1090				1095				1100							
Ser	Asp	Ala	Gly	Lys	His	Thr	Pro	Val	Lys	Pro	Met	Ser	Thr	Thr	Lys	
1105					1110				1115						1120	
Asp	His	His	Asn	Lys	Ala	Lys	Ala	Leu	Pro	Glu	Thr	Gly	Ser	Glu	Asn	
			1125					1130						1135		
Asn	Gly	Ser	Asn	Asn	Ala	Thr	Leu	Phe	Gly	Gly	Leu	Phe	Ala	Ala	Leu	
			1140				1145					1150				
Gly	Ser	Leu	Leu	Leu	Phe	Gly	Arg	Arg	Lys	Lys	Gln	Asn	Lys			
	1155					1160						1165				

<210> SEQ ID NO 8
<211> LENGTH: 3498
<212> TYPE: DNA
<213> ORGANISM: Staphylococcus aureus

<400> SEQUENCE: 8

atgattaaca gggataataa aaaggcaata acaaaaaagg gtatgatttc aaatcgctta 60

-continued

aacaaat	ttt	cgattagaaa	gtatactgta	ggaactgcat	cgatttttagt	aggtacgaca	120
ttgattttt	gtctagggaa	ccaagaagct	aaagctgctg	aaaacactag	tacagaaaat		180
gcaaaacaag	atgatgcaac	gactagtgat	aataaagaag	tagtgctcga	aactgaaaat		240
aattcgacaa	cagaaaataa	ttcaacaaat	ccaattaaga	aagaaacaaa	tactgattca		300
caaccagaag	ctaaaaaaga	atcaacttca	tcaagtactc	aaaaacagca	aaataacgtt		360
acagctacaa	ctgaaactaa	gcctcaaaac	attgaaaaag	aaaatgttaa	accttcaact		420
gataaaactg	cgacagaaga	tacatctgtt	attttagaag	agaagaaagc	accaaataat		480
acaaataacg	atgtaactac	aaaaccatct	acaagtgaac	catctacaag	tgaaattcaa		540
acaaaaccaa	ctacacctca	agaatctaca	aatattgaaa	attcacaacc	gcaaccaacg		600
ccttcaaaag	tagacaatca	agttacagat	gcaactaatc	caaagaacc	agtaaagtgtg		660
tcaaaagaag	aacttaaaaa	taatcctgag	aaattaaaag	aattggttag	aatgatagc		720
aatacagatc	attcaactaa	accagttgct	acagctccaa	caagtgttgc	accaaacgt		780
gtaaacgcaa	aatgcgctt	tgcagttgca	caaccagcag	cagttgcttc	aaacaatgta		840
aatgatttaa	ttaaagtga	gaagcaaaca	atcaaagttg	gcgatggtaa	agataatgtg		900
gcagcagcgc	atgacggtaa	agatattgaa	tatgatacag	agtttacaat	tgacaataaa		960
gtcaaaaaag	gcgatacaat	gacgattaat	tatgataaga	atgtaattcc	ttcggattta		1020
acagataaaa	atgatactat	cgatattact	gatccatcag	gagaggtcat	tgctaaagga		1080
acatttgata	aagcaactaa	gcaaatcaca	tatacattta	cagactatgt	agataaatat		1140
gaagatataa	aatcacgctt	aactctatat	tcgtatat	tgatattg	ataaaaaaac	agttccaaat	1200
gagacaagtt	tgaatttaac	atttgctaca	gcaggtaaag	aaacaagcca	aatgtcact		1260
gttgattatc	aagatccaat	ggtccatgg	gattcaaaca	ttcaatctat	ctttacaaaa		1320
ttagatgaag	ataagcaaac	tattgaacaa	caaatttatg	ttaaccatt	gaaaaaatca		1380
gcaaccaaca	ctaaagttga	tatagctgg	agtcaagtag	atgattatgg	aaatattaaa		1440
ctaggaaatg	gtagcaccat	tattgaccaa	aatacagaaa	taaaggttta	taaagttaac		1500
tctgatcaac	aattgcctca	aagtaataga	atctatgatt	ttagtcaata	cgaagatgta		1560
acaagtcaat	ttgataataa	aaaatcattt	agtaataatg	tagcaacatt	ggattttgg		1620
gatattaatt	cagcctatat	tatcaaagtt	gttagtaa	aatatacacctac	atcagatggc		1680
gaactagata	ttgcccaagg	tactagtatg	agaacaactg	ataaatatgg	ttattataat		1740
tatgcaggat	attcaaactt	catcgtaact	tctaatagaca	ctggcgggtg	cgacgggtact		1800
gttaaacctg	aagaaaagtt	atacaaaatt	ggtgactatg	tatgggaaga	cggttgataaa		1860
gacggtgttc	aaggtacaga	ttcaaaagaa	aaaccaatgg	caaacgtttt	agttacatta		1920
acttaccogg	acggtactac	aaaatcagta	agaacagatg	ctaaggttca	ttatgaattc		1980
ggtggtttga	aagacggaga	aacttataca	gttaaattcg	aaacgccaac	tgatattctt		2040
ccaacaaaag	taaatggaac	aactgatgg	gaaaaagact	caaatggtag	ttcgggttact		2100
gttaaaatta	atggtaaaga	tgatatgtct	ttagatactg	gttttttaca	agaacctaaa		2160
tacaacttag	gtgactatgt	atgggaagat	actaataaag	atgggtatcca	agatgcaaat		2220
gagccaggaa	tcaaagatgt	taaggttaca	ttaaaagata	gtactggaaa	agttattgg		2280
acaactacta	ctgatgcctc	gggtaaatat	aaattttacag	atttagataa	tggttaactat		2340

-continued

acagtagaat ttgaaacacc agcaggttac acgccaacgg ttaaaaatac tacagctgat	2400
gataaagatt ctaatgggtt aacaacaaca ggtgtcatta aagatgcaga taatatgaca	2460
ttagacaggg gtttctataa aacaccaaaa tacagtttag gtgattatgt ttggtacgac	2520
agtaataaag acggcaaaca agattcaact gaaaaaggta tcaaagatgt gacagttaca	2580
ttgcaaaacg aaaaaggcga agtaattgga acaactaaaa cagatgaaaa tggtaaatat	2640
cgtttcgata atttagatag cggtaaatac aaagtatttt ttgaaaagcc tgctggctta	2700
acacaaacag ttacaaatac aactgaagat gataaagatg cagatggtgg cgaagttgac	2760
gtaacaatta cggatcatga tgatttcaca cttgataacg gatacttcga agaagataca	2820
tcagacagcg attcagactc agatagtgac tcagacagcg actcagactc agacagcgac	2880
tcagactcag acagtgattc agattcagac agcgactcag attcagatag cgactcagat	2940
tcggacagcg attcagactc agatagcgac tcagattcag atagcgattc agactcagac	3000
agcgactcag attcagatag cgattcggac tcagacagcg attcagactc agatagcgac	3060
tcagactcag acagcgactc agattcagat agcgattcgg actcagatag cgactcagat	3120
tcagacagcg attcagactc agatagcgac tcagattcag acagcgattc agactcagat	3180
agcgactcag actcagacag tgattcagat tcagacagcg actcagactc agatagcgac	3240
tcagattcag acagcgactc agactcagat agcgactcag actcagacag tgattcagac	3300
agcgattcag actcggatgc aggaaaacat acacctgtta aaccaatgag tactactaaa	3360
gaccatcaca ataaagcaaa agcattacca gaaacaggta gtgaaaataa cggctcaaat	3420
aacgcaacgt tatttggtgg attatttgca gcattagggt cattattgtt attcggtcgt	3480
cgcaaaaaac aaaacaaa	3498

<210> SEQ ID NO 9
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Staphylococcus aureus
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (6)..(6)
<223> OTHER INFORMATION: n = (a or c or t or g)
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (12)..(12)
<223> OTHER INFORMATION: n = (a or c or t or g)

<400> SEQUENCE: 9

gaytcngayt cngayagy 18

<210> SEQ ID NO 10
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Staphylococcus aureus

<400> SEQUENCE: 10

Leu Pro Asp Thr Gly
1 5

<210> SEQ ID NO 11
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Staphylococcus aureus

-continued

<400> SEQUENCE: 11

Asp Tyr Ser Asn Ser
1 5

<210> SEQ ID NO 12
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Staphylococcus aureus

<400> SEQUENCE: 12

Phe Thr Asp Tyr Val Asn
1 5

<210> SEQ ID NO 13
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Staphylococcus aureus
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa = (Unspecified amino acid)
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (4)..(4)
<223> OTHER INFORMATION: Xaa = (Unspecified amino acid)

<400> SEQUENCE: 13

Asp Xaa Ser Xaa Ser
1 5

<210> SEQ ID NO 14
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Staphylococcus aureus
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (3)..(3)
<223> OTHER INFORMATION: Xaa = (Unspecified amino acid)

<400> SEQUENCE: 14

Leu Pro Xaa Thr Gly
1 5

<210> SEQ ID NO 15
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Staphylococcus aureus

<400> SEQUENCE: 15

cgaggatcct caggacaatc gaacgataca acg 33

<210> SEQ ID NO 16
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Staphylococcus aureus

<400> SEQUENCE: 16

cgaggtagca tttactgctg aatcacc 27

<210> SEQ ID NO 17
<211> LENGTH: 34
<212> TYPE: DNA
<213> ORGANISM: Staphylococcus aureus

-continued

<400> SEQUENCE: 17

cgaaagcttg tcagaacaat cgaacgatac aacg

34

<210> SEQ ID NO 18

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Staphylococcus aureus

<400> SEQUENCE: 18

Thr Tyr Thr Phe Thr Asp Tyr Val Asp

1 5

<210> SEQ ID NO 19

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Staphylococcus aureus

<400> SEQUENCE: 19

Thr Tyr Thr Phe Thr Asn Tyr Val Asp

1 5

<210> SEQ ID NO 20

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Staphylococcus aureus

<400> SEQUENCE: 20

Thr Phe Val Phe Thr Asp Tyr Val Asn

1 5

<210> SEQ ID NO 21

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Staphylococcus aureus

<400> SEQUENCE: 21

Ile Tyr Thr Phe Thr Asp Tyr Val Asn

1 5

<210> SEQ ID NO 22

<211> LENGTH: 5

<212> TYPE: PRT

<213> ORGANISM: Staphylococcus aureus

<400> SEQUENCE: 22

Leu Pro Glu Thr Gly

1 5

<210> SEQ ID NO 23

<211> LENGTH: 14

<212> TYPE: PRT

<213> ORGANISM: Staphylococcus aureus

<400> SEQUENCE: 23

Thr Ile Tyr Phe Thr Val Phe Thr Asp Asn Tyr Val Asp Asn

1 5 10

What is claimed is:

1. An isolated antibody to a nucleic acid molecule encoding a fibrinogen-binding protein that binds both the alpha and beta fibrinogen chains, wherein the fibrinogen-binding protein is isolated from *S. aureus*.

2. An isolated antibody that recognizes the sequence motif TYTFTDYVD (SEQ ID NO:18).

3. An isolated antibody to a protein that binds both the α and β chains of fibrinogen.

4. The isolated antibody of claim 3 wherein the antibody binds to an amino acid sequence comprising the sequence of SEQ ID NO: 1.

5. An isolated antibody to a protein or protein fragment that has a consensus TYTFTDYVD (SEQ ID NO:18) motif, wherein the protein is isolated from *S. aureus* and is not ClfA.

6. The isolated antibody of claim 3 wherein the protein has an amino acid sequence comprising a sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7.

7. The isolated antibody of claim 3 wherein the protein has wherein the protein or protein fragment is selected from the group consisting of ClfB, SdrC, SdrD, SdrE, and active fragments thereof.

8. The isolated antibody of claim 3 wherein the fibrinogen-binding protein is isolated from *S. aureus*.

9. The isolated antibody of claim 1 wherein the nucleic acid molecule has a sequence selected from the group

consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 and SEQ ID NO:8.

10. A diagnostic kit comprising an isolated antibody to a protein or protein fragment that binds to both the a and P chains of fibrinogen.

11. A diagnostic kit comprising the isolated antibody of claim 1.

12. A diagnostic kit comprising the isolated antibody of claim 3.

13. A diagnostic kit comprising an isolated antibody to a protein or protein fragment that has a consensus TYTFTDYVD motif, wherein the protein is isolated from *S. aureus* and is not ClfA.

14. The diagnostic kit of claim 13 wherein the protein or protein fragment is selected from the group consisting of ClfB, SdrC, SdrD, SdrE, and active fragments thereof.

15. The diagnostic kit of claim 13 wherein the protein or protein fragment has a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:5 and SEQ ID NO:7.

16. The isolated antibody of claim 1 in a pharmaceutically acceptable carrier.

17. The isolated antibody of claim 3 in a pharmaceutically acceptable carrier.

* * * * *